

# VEITH SYMPOSIUM®

Connecting The **Vascular** Community

**49<sup>th</sup>**

**Tuesday – Saturday, November 15-19, 2022**

VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS

Symposium Chairman  
**Frank J. Veith, MD**

Symposium Co-Chairmen  
**Enrico Ascher, MD**  
**Kenneth Ouriel, MD, MBA**  
**Sean P. Lyden, MD**

Sponsored by

 **Cleveland Clinic**

  
**Hilton**

[www.VEITHsymposium.org](http://www.VEITHsymposium.org)

# PROGRAM OUTLINE AT A GLANCE

## TUESDAY PROGRAMS

### Program A (Sessions 1-8)

6:45 A.M. – 6:02 P.M.

Progress In The Treatment Of Diseases Of The Coronary Arteries, Heart Valves And The Thoracic And Abdominal Aorta

**Location:** Grand Ballroom East, 3rd Floor

### Program B (Sessions 9-16)

6:44 A.M. – 6:05 P.M.

Progress In Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open And Hybrid Vascular Surgery And Treatment Of Aortic Coarctation

**Location:** Grand Ballroom West, 3rd Floor

### Program C-1 (Sessions 17-18)

7:00 A.M. – 12:00 P.M.

Management Of Pulmonary Embolism: The Ultimate Team Approach

**Location:** Trianon Ballroom, 3rd Floor

### Program C-2 (Sessions 19-22)

1:00 P.M. – 6:00 P.M.

Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments

**Location:** Trianon Ballroom, 3rd Floor

## WEDNESDAY PROGRAMS

### Program D (Sessions 23-30)

6:40 A.M. – 6:02 P.M.

Progress In Lower Extremity Occlusive Disease And Its Treatment

**Location:** Grand Ballroom East, 3rd Floor

### Program E (Sessions 31-38)

6:40 A.M. – 6:05 P.M.

New Developments In Medical Treatments And New Drugs; Progress In Anti-Atherogenic And Anti-Hypertensive Treatments; Management Of Endoleaks; Recorded Live Cases From Leading Centers In The US And EU; Issues Of Interest, Outpatient And Office Based Vascular Treatment; Topics Related To Government, Reimbursement, The SVS, VQI, FDA, Guidelines, Trials And Evidence Based Medicine

**Location:** Grand Ballroom West, 3rd Floor

### Program F (Sessions 39-46)

6:50 A.M. – 6:10 P.M.

More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, Juxta- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/ EVAR), Multilayer Bare Stents, Infraarenal AAAs And Standard EVAR, And Hot New Aortic And Carotid Topics

**Location:** Trianon Ballroom, 3rd Floor

## THURSDAY PROGRAMS

### Program G (Sessions 47-54)

6:50 A.M. – 6:07 P.M.

Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety

**Location:** Grand Ballroom East, 3rd Floor

### Program H (Sessions 55-63)

6:50 A.M. – 5:52 P.M.

New Or Improved Devices For: Standard EVAR, EVAS And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels

**Location:** Grand Ballroom West, 3rd Floor

### Program I (Sessions 64-71)

7:00 A.M. – 6:25 P.M.

Superficial Venous Disease

**Location:** Trianon Ballroom, 3rd Floor

### Program J (Sessions 72-75)

8:00 A.M. – 12:15 P.M.

Multidisciplinary Acute Stroke Management

**Location:** Murray Hill Suites, 2nd Floor

## FRIDAY PROGRAMS

### Program K (Sessions 76-83)

6:40 A.M. – 6:02 P.M.

Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care

**Location:** Grand Ballroom East, 3rd Floor

### Program L (Sessions 84-91)

7:00 A.M. – 5:42 P.M.

New Developments In The Treatment Of Popliteal Disease: Aneurysms, Entrapment And Occlusive Lesions; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma

**Location:** Grand Ballroom West, 3rd Floor

### Program M (Sessions 92-101)

6:30 A.M. – 4:57 P.M.

Deep Venous Disease

**Location:** Trianon Ballroom, 3rd Floor

## SATURDAY PROGRAMS

### Program N (Sessions 102-106)

6:55 A.M. – 1:30 P.M.

Topics Too Important To Miss In The Treatment Of Lower Extremity, Aortic Or Carotid Disease

**Location:** Grand Ballroom East, 3rd Floor

### Program O (Sessions 107-112)

8:00 A.M. – 4:05 P.M.

Improving Outcomes In Hemodialysis Access

**Location:** Grand Ballroom West, 3rd Floor



**SYMPOSIUM CHAIRMAN**

Frank J. Veith, MD

**SYMPOSIUM CO-CHAIRMAN**

Enrico Ascher, MD  
 Kenneth Ouriel, MD, MBA  
 Sean P. Lyden, MD

**SYMPOSIUM MANAGING DIRECTOR**

Jacqueline M. Simpson, BBA

**ASSOCIATE PROGRAM DIRECTORS**

Enrico Ascher, MD  
 Mark A. Adelman, MD  
 Sean P. Lyden, MD  
 Kenneth Ouriel, MD, MBA

**SYMPOSIUM ASSOCIATE DIRECTOR**

Steven J. Feld, MSW

**ADVISORY COMMITTEE**

Ali F. AbuRahma, MD  
 Mark A. Adelman, MD  
 Keith D. Calligaro, MD  
 Nicholas J.W. Cheshire, MD  
 Timur P. Sarac, MD  
 Jacqueline M. Simpson, BBA  
 Carol La Mantia Veith, RN, BA, MA

**SCIENTIFIC COMMITTEE**

Ali F. AbuRahma, MD  
 Keith D. Calligaro, MD  
 Roberto Chiesa, MD  
 Daniel G. Clair, MD  
 Sebastian E. Debus, MD, PhD  
 Ellen D. Dillavou, MD  
 Hans-Henning Eckstein, MD, PhD  
 Peter Gloviczki, MD  
 Alison Halliday, MS, FRCS  
 Krassi Ivancev, MD, PhD  
 Sriram S. Iyer, MD  
 Manju Kalra, MBBS  
 Mario L. Lachat, MD  
 Christos D. Liapis, MD  
 Evan C. Lipsitz, MD, MBA  
 Germano Melissano, MD  
 Frans L. Moll, MD, PhD  
 Samuel R. Money, MD, MBA  
 Juan C. Parodi, MD  
 Vicente Rimbau, MD, PhD  
 Caron B. Rockman, MD  
 Timur P. Sarac, MD  
 Dierk Scheinert, MD  
 Carlo Setacci, MD  
 Cynthia K. Shortell, MD  
 Sherif A.H. Sultan, MD, PhD  
 Giovanni Torsello, MD  
 Carol La Mantia Veith, RN, BA, MA  
 Eric L.G. Verhoeven, MD, PhD  
 Wayne W. Zhang, MD

**CENTER FOR CONTINUING MEDICAL EDUCATION**

Steven M. Kawczak, PhD

**CONTENTS**

Program Outline At A Glance..... Inside Front Cover  
 Acknowledgments .....4  
 Fellows Career Development Program.....6-7  
 Special Non-CME & Other Industry Events .....8-10  
 General Information .....11-13  
 Accreditation .....12  
 Faculty Disclosure .....13  
 Hotel and Travel .....13  
 Agenda .....15-120  
 Faculty Listing .....121-130  
 Registration ..... 131

## ACKNOWLEDGMENTS

The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational and in-kind grants\* in support of this activity from:

Abbott  
Artivion, Inc.  
BD  
Boston Scientific Corporation  
Cook Medical, LLC  
Cordis  
Endologix LLC  
Gore & Associates  
Inari Medical  
InspireMD  
LimFlow, Inc.  
Medtronic  
NAMSA  
Philips  
Shockwave Medical, Inc.  
Silk Road Medical  
Terumo Aortic



#### COMPONENT MEETING LEADERS

Jose I. Almeida, MD  
George L. Berdejo, BA, RVT  
Allan L. Brook, MD  
Jacob Cynamon, MD  
Steve Elias, MD  
Peter Gloviczki, MD  
Michael R. Jaff, DO  
Lowell S. Kabnick, MD  
Natalie A. Marks, MD, RPVI, RVT  
Larry A. Scher, MD  
Anton N. Sidawy, MD, MPH  
Thomas W. Wakefield, MD  
Haimanot (Monnie) Wasse, MD, MPH

#### ASSOCIATE FACULTY PODIUM PRESENTATIONS COMMITTEE

Enrico Ascher, MD  
Zach AbuRahma, MD  
Venita Chandra, MD  
Zhong Chen, MD  
Anahita Dua, MD, MS, MBA  
Maria Frankovicova, MD, PhD  
Jan M.M. Heyligers, MD, PhD  
Paulo Eduardo Ocke Reis, MD, PhD  
Rebeca Reachi Lugo, MD  
Rossi M. Silva, MD  
Jessica P. Simons, MD, MPH  
Sherif A.H. Sultan, MD, PhD  
Jorge H. Ulloa, MD  
Fuxian Zhang, MD  
Wayne W. Zhang, MD  
Yeuhong Zheng, MD




THE VASCULAR WORLD  
IS COMING TOGETHER IN NEW YORK

THIS NOVEMBER...

AND YOU'RE INVITED!

VEITH SYMPOSIUM  
Connecting The Vascular Community



## Vascular Fellows' Career Development Program

An Interactive Symposium for Vascular Surgery Fellows and Residents  
Preparing to Enter the Job Market!

Friday, November 18, 2022 • 8:00 a.m. - 5:00 p.m. • New York Hilton-Midtown, New York City  
Concourse A, Concourse Level | This is a Non-CME

**VEITHsymposium** provides vascular surgeons and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The 5-day event features rapid-fire presentations from world renowned vascular specialists with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.

Complimentary Tuition is provided through an Educational Grant by W.L. Gore & Associates, Inc. for finishing Vascular Surgery Fellows and Residents in the US and Canada. An Educational Grant from Medtronic provides travel and lodging for finishing Vascular Surgery Fellows and Residents in the US. Graduating Vascular Surgery Fellows and Residents seeking travel and/or lodging stipend must send CV and Personal Statement no later than October 4, 2022 to [admin@veithsymposium.org](mailto:admin@veithsymposium.org). Successful applicants must attend the Career Development Program in its entirety, and must be present at the end of the day reception. Travel and/or lodging must be arranged through [admin@veithsymposium.org](mailto:admin@veithsymposium.org). Lodging must be at the Symposium venue or designated hotel. Other rules apply. Stipends are limited so apply early. Please call (845-368-0069) or email [admin@veithsymposium.org](mailto:admin@veithsymposium.org) for more information.

### WHO SHOULD ATTEND:

- Graduating Fellows and Residents in Vascular Surgery
- Attending Vascular Specialists seeking new opportunity
- Potential Employers of Vascular Specialists
- Wound Care Specialists
- Vascular Career Recruiters and Potential Employer

Join us in New York City this November.  
Register online for VEITH at: [www.VEITHsymposium.org](http://www.VEITHsymposium.org)

**Program Director:**  
James F. McKinsey

## Vascular Fellows' Career Development Curriculum

<b>8:00 – 8:05</b>	<b>WELCOME</b> <i>James F. McKinsey, MD</i> <i>Venita Chandra, MD</i>	<b>11:15 - 11:25</b>	Vascular Procedure Billing and Coding <i>Sean P. Roddy, MD</i>
<b>SESSION 1</b>	<b>SELECTING YOUR FIRST JOB</b>	<b>11:25 - 11:35</b>	Balancing Your Practice with Industry Relationships - From a Physician's Viewpoint <i>Gustavo S. Oderich, MD</i>
<b>Moderator:</b>	<i>James F. McKinsey, MD</i>	<b>11:35 - 11:45</b>	What Industry Is Looking for in Collaboration with Vascular Interventionalists <i>Samuel Arbefeuill</i>
<b>8:05 – 8:15</b>	What a 21st Century Private Practice Looks Like <i>Clifford M. Sales, MD</i>	<b>11:45 - 12:00</b>	<b>Panel Discussion with Q&amp;A</b>
<b>8:15 – 8:25</b>	What a 21st Century Academic Practice Looks Like <i>James H. Black III, MD</i>	<b>12:00 - 1:00</b>	<b>Lunch Break – 2nd Floor Promenade</b>
<b>8:25 – 8:35</b>	What to Prioritize in Your First Practice? <i>Karan Garg, MD</i>	<b>SESSION 4</b>	<b>LONG-TERM PRACTICE MANAGEMENT</b>
<b>8:35 – 8:45</b>	What Should You Prioritize in Your First 5 Years in Practice? <i>Katherine A. Gallagher, MD</i>	<b>Moderator:</b>	<i>James F. McKinsey, MD</i>
<b>8:45 – 9:00</b>	<b>Panel Discussion with Q&amp;A</b>	<b>1:00 – 1:10</b>	COVID19! While We All Want to Move on from This, What Are Important Lessons We Need to Remember? <i>Thomas S. Maldonado, MD</i>
<b>SESSION 2</b>	<b>INTERVIEWING FOR YOUR FIRST JOB</b>	<b>1:10 – 1:20</b>	Resources Available to You from the Society for Vascular Surgery <i>Michael C. Dalsing, MD</i>
<b>Moderator:</b>	<i>James F. McKinsey, MD</i>	<b>1:20 – 1:30</b>	How Do You Incorporate GME and Being a Program Director into Your Practice <i>Caron B. Rockman, MD</i>
<b>9:00 – 9:10</b>	Increasing Opportunities in Vascular Surgery for the New Graduate <i>Anahita Dua, MD, MS, MBA</i>	<b>1:30 – 1:40</b>	Medical Malpractice – How to Avoid a Lawsuit <i>Christopher J. Abularrage, MD</i>
<b>9:10 – 9:20</b>	Interviewing 101: The Right Questions to Ask When Interviewing <i>Jeffrey J. Syracuse, MD</i>	<b>1:40 – 1:50</b>	Incorporating Diversity, Inclusiveness and Equality into Your Practice <i>Caitlin W. Hicks, MD, MS</i>
<b>9:20 – 9:30</b>	How to Find Out What the Practice Is Really Like <i>Luis A. Sanchez, MD</i>	<b>1:50 – 2:00</b>	How to Incorporate Clinical Innovation and Change into Your Practice <i>Christopher J. Kwolek, MD, MBA</i>
<b>9:30 – 9:40</b>	Do I Need to Hire a Lawyer to Review My Employment Contract? <i>Ellen D. Dillavou, MD</i>	<b>2:00 – 2:10</b>	Long-Term Career Planning: What Are Your Long-Term Goals? <i>Timur P. Sarac, MD</i>
<b>9:40 – 9:50</b>	How to Negotiate Your First Contract <i>James F. McKinsey, MD</i>	<b>2:10 – 2:20</b>	Resources Available to You from Your Regional Vascular Societies <i>Peter L. Faries, MD</i>
<b>9:50-10:00</b>	Healthcare Delivery in the US and Vascular Surgery - You Made the Right Choice <i>Mark A. Adelman, MD</i>	<b>2:20 – 2:30</b>	Tips/Tricks to Manage Malignant Settings, Toxic Leadership, Difficult Partners And Turf Wars <i>Shang Loh, MD</i>
<b>10:00-10:15</b>	<b>Panel Discussion with Q&amp;A</b>	<b>2:30 – 2:40</b>	Career Options throughout Your Career <i>Kenneth J. Cherry, MD</i>
<b>10:15-10:25</b>	<b>Break</b>	<b>2:40 – 3:00</b>	<b>Panel Discussion with Q&amp;A</b>
<b>SESSION 3</b>	<b>FIRST YEAR IN PRACTICE</b>	<b>3:00 – 5:00</b>	<b>Interactive Cocktail Reception with Faculty, Fellows/Residents, Potential Employers and Industry</b>
<b>Moderator:</b>	<i>James F. McKinsey, MD</i>		
<b>10:25-10:35</b>	Keys to Building a Successful Practice <i>Venita Chandra, MD</i>		
<b>10:35-10:45</b>	Building Your Practice: Clinical Practice <i>Joann Lohr, MD</i>		
<b>10:45-10:55</b>	Building Your Practice: Research Programs <i>Wei Zhou, MD</i>		
<b>10:55-11:05</b>	Building Your Practice: Outcomes Research <i>Marc L. Schermerhorn, MD</i>		
<b>11:05-11:15</b>	Things I Wish I Had Known When I Was Selecting My First Job <i>Jason T. Lee, MD</i>		

# SPECIAL NON-CME AND OTHER INDUSTRY SPONSORED EVENTS

(PLEASE VISIT [WWW.VEITHSYMPOSIUM.ORG](http://WWW.VEITHSYMPOSIUM.ORG) FOR A FULL AND UPDATED LISTING OF THESE ACTIVITIES.)

## TUESDAY, NOVEMBER 15, 2022

### **ABBOTT**

Lunch Symposium

**Time:** 12:00 PM - 1:00 PM

**Location:** Americas Hall 1, 3rd Floor

### **GORE & ASSOCIATES**

Hot topics spanning 25 years of EVAR experience: What can we learn from past and present challenges to better inform EVAR device selection in the future?

**Time:** 12:00 PM – 1:00 PM

**Location:** Mercury Rotunda & Ballroom, 3rd Floor

### **PENUMBRA, INC.**

Lunch Symposium

**Time:** 12:00 PM - 1:30 PM

**Location:** Gramercy Suite East, 2nd Floor

## WEDNESDAY, NOVEMBER 16, 2022

### **CAGENT VASCULAR**

Lunch Symposium: Serration Angioplasty - The Complete Lower Extremity Solution

**Time:** 12:00 PM - 1:00 PM

**Location:** Gramercy Suite East, 2nd Floor

### **CONCEPT MEDICAL**

Lunch Symposium

**Time:** 12:00 PM - 1:00 PM

**Location:** Sutton Parlor Center, 2nd Floor

### **GORE & ASSOCIATES**

Compelling insights from long-term follow-up of the GORE® VIABAHN® Device family of covered stents

**Time:** 12:00 PM – 1:00 PM

**Location:** Mercury Rotunda & Ballroom, 3rd Floor

### **JANSSEN PHARMACEUTICALS, INC.**

Luncheon: Clinical Insights in CAD and/or PAD: Reducing the Risk of Major Cardiovascular and Major Thrombotic Vascular Events

**Time:** 11:45 AM – 1:00 PM

**Location:** Madison Suite, 2nd Floor

### **MEDTRONIC**

Vessel Preparation and Treatment Algorithms for Complex Peripheral Artery Disease

**Time:** 12:00 PM – 1:00 PM

**Location:** Medtronic Pavilion – Beekman Parlor, 2nd Floor

### **VENOUS VENOUS VENOUS® WORKSHOPS at**

#### **VEITHsymposium**

Workshops will include Video Case Presentations, Lectures and Demonstration on vein management by experts, plus Hands-On opportunities where participants can rotate through multiple training stations staffed by professionals to assist with your experience.

**Time:** 1:00 PM – 6:00 PM

**Location:** Americas Hall 2, 3rd Floor



# SPECIAL NON-CME AND OTHER INDUSTRY SPONSORED EVENTS

THURSDAY, NOVEMBER 17, 2022

## **EnVveno Medical Corporation (NVNO)**

Lunch and Learn on New Modalities for Treatment of Chronic Venous Disease (3-Year Data on VenoValve Implant in Colombia - Introduction and Early Results of the Percutaneous enVVE Valve for CVI).

**Time:** 12:00 PM - 1:30 PM

**Location:** Madison Suite, 2nd Floor

## **GORE & ASSOCIATES**

Innovations for the Thoracic Aorta: 1st to market TEVAR solutions for complex anatomies

**Time:** 12:00 PM - 1:00 PM

**Location:** Mercury Rotunda & Ballroom, 3rd Floor

## **MEDTRONIC**

Redefining EVAR Success: A Global Perspectives Discussion

**Time:** 12:00 PM - 1:00 PM

**Location:** Medtronic Pavilion - Beekman Parlor, 2nd Floor

## **MIMEDX**

Lunch Symposium: Introducing the AMNIOEFFECT and AXIOFILL PURION® Processed Placental-Based Allografts in Vascular Surgery

**Time:** 12:00 PM - 1:30 PM

**Location:** Gramercy Suite East, 2nd Floor

FRIDAY, NOVEMBER 18, 2022

## **Vascular Fellows' Career Development Program**

**Time:** 8:00 AM - 5:00 PM

**Location:** Concourse A, Course Level

## **LATIN AMERICAN SESSION at VEITHsymposium**



**Course Leaders:** Enrico Ascher, MD (USA), Jorge H. Ulloa, MD (COL), Rebeca Reachi, MD (MEX), Tulio P. Navarro, MD, PhD (BRA) and Frank J. Veith, MD (USA).

Five-minute presentations in English, Spanish, or Portuguese. Submit abstracts to [easchermd@gmail.com](mailto: easchermd@gmail.com) no later than October 15, 2022.

Best Presentation Award will be given.

**Time:** 7:30AM - 10:30AM

**Location:** Sutton Parlor Center, 2nd Floor

## **THE BEST CLI TRIAL: A REVIEW AND DISCUSSION OF PRIMARY OUTCOMES**

Moderators: Alik Farber, MD, MBA, Matthew T. Menard, MD and Kenneth Rosenfield, MD

**Time:** 1:00 PM - 2:30 PM

**Location:** Sutton Parlor Center, 2nd Floor

## SPECIAL NON-CME AND OTHER INDUSTRY SPONSORED EVENTS

### WORLD FEDERATION OF VASCULAR SURGERY at VEITHsymposium



**Moderators:** Palma M. Shaw, MD, MBA, RVPI & Enrico Ascher, MD

The World Federation of Vascular Societies (WFVS) exists to improve the quality of care of vascular patients worldwide, by providing a forum for the international exchange of scientific and educational knowledge related to the diagnosis, treatment and prevention of vascular diseases. The WFVS is composed of member societies consisting of federated, national and affiliate vascular societies.

**Time:** 5:00 PM - 6:30 PM

**Location:** Trianon Ballroom, 3rd Floor

SATURDAY, NOVEMBER 19, 2022

#### GORE & ASSOCIATES

Updates to KDOQI guidelines and their influence on my patient algorithm

**Time:** 12:00 PM – 1:00 PM

**Location:** Mercury Rotunda & Ballroom, 3rd Floor

## NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data, and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered at the meeting and for further reference in the web-based library, a long-term permanent resource.

In addition, by having numerous short (4.5-7 minutes) talks followed by panel discussions and capturing the entire meeting on the web-based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

## FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 900 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

## OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors

# GENERAL INFORMATION

## TARGET AUDIENCE

Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists, Cardiac Surgeons and all others interested in the management of vascular disease.

## ASSOCIATE FACULTY GLOBAL PODIUM PRESENTATIONS

Wednesday – Thursday, November 16-18, 2022

**Location:** Concourse A, Concourse Level

In order to have more younger and less familiar vascular surgeons and vascular specialists play an active role as Associate Faculty at our meeting, we have initiated programs whereby they can present their scientific work at the podium. Vascular surgeons and vascular specialists participating in these programs will have submitted abstracts for a podium presentation, and these abstracts will be posted on our website. The best three abstracts will receive cash prizes of \$1,000 (1st place), \$500 (2nd place) and \$250 (3rd place). Please visit [www.veithsymposium.org](http://www.veithsymposium.org) for additional information about the Associate Faculty Global Podium Presentations component of VEITHsymposium.

## COMPONENT SESSIONS WILL BE HELD AS FOLLOWS:

### Multidisciplinary Acute Stroke Management

Thursday, November 17, 2022

**Location:** Murray Hill Suites East and West, 2nd Floor

### Hemodialysis Access

Saturday, November 19, 2022

**Location:** Grand Ballroom West, 3rd Floor

## ACCREDITATION STATEMENT

In support of improving patient care, Cleveland Clinic Center for Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Credit Designation

#### American Medical Association (AMA)

Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 48.5 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

#### American Nurses Credentialing Center (ANCC)

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 48.5 ANCC contact hours.

### Certificate of Participation

A certificate of participation will be provided to other healthcare professionals for requesting credits in accordance with their professional boards and/or associations.

## ABS CONTINUOUS CERTIFICATION

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner

## GENERAL INFORMATION

completion information to the ACCME for the purpose of granting ABS credit.

### ETHICAL MEDTECH COMPLIANCE

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.

### CME CERTIFICATES AND COURSE EVALUATION FORMS

Your CME certificate will be available online within two weeks after the meeting. An e-mail with instructions on how to obtain the certificate and complete a brief, optional course evaluation will be sent to all registered attendees. The e-mail will be sent to the e-mail address that was used to register the attendee. Please note that CME Certificates must be claimed by **February 28, 2023**.

### FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Integrity and Independence requiring mitigation of all faculty conflicts of interest. Faculty declaring a relevant financial relationship will be identified in the activity syllabus.

### ADA STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request to VEITHsymposium by e-mail to [admin@veithsymposium.org](mailto:admin@veithsymposium.org) at least one month prior to the activity.

### ONLINE CONFERENCE LIBRARY

The entire program with almost all the talks, slides, audio and videos - fully synchronized - and the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please visit [www.veithondemand.com](http://www.veithondemand.com) or call (800) 987-9314, ext. 300.

### ONLINE ACCESS TO ABSTRACTS

Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium website at [www.veithsymposium.org](http://www.veithsymposium.org) after the meeting. Abstracts will be available on the website for one full year.

## HOTEL AND TRAVEL

A block of rooms has been reserved at the conference rate of \$349 plus taxes per night. This rate is available until the block is filled or until October 10, 2022. *Please request the VEITH rate when reserving your accommodations.*

### **New York Hilton-Midtown (Symposium Site)**

1335 Avenue of the Americas

New York, NY 10019

(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)

### **American Express Global Business Travel at The Cleveland Clinic**

Phone: (216) 444-2564, Extension 62134971

E-mail: [diane.m.geneva@amexgbt.com](mailto:diane.m.geneva@amexgbt.com)

**VEITH** SYMPOSIUM<sup>®</sup>

Connecting The **Vascular** Community

**SAVE THE DATE**

**Tuesday - Saturday, November 14-18, 2023**

VEITH  
VASCULAR ENDOVASCULAR ISSUES TECHNIQUES HORIZONS

Symposium Chairman

**Frank J. Veith**

Symposium Co-Chairmen

**Enrico Ascher**

**Kenneth Ouriel**

**Sean P. Lyden**

Sponsored by



**Cleveland Clinic**



**Hilton**

[www.VEITHsymposium.org](http://www.VEITHsymposium.org)

**TUESDAY, NOVEMBER 15, 2022**

- 6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor  
 6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor  
 6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

**CONCURRENT TUESDAY PROGRAMS**

PROGRAM A: (SESSIONS 1-8)

**Progress In The Treatment Of Diseases Of The Coronary Arteries, Heart Valves And The Thoracic And Abdominal Aorta**  
 6:45 A.M. – 6:02 P.M.  
 Grand Ballroom East, 3rd Floor

PROGRAM B: (SESSIONS 9-16)

**Progress In Vascular Robotics, Guidance Systems, Laparoscopy, Simulation And COVID; New Developments In Carotid Disease And Acute Stroke Treatment; Abdominal Aortic Branch Treatment; New Technology Concepts And Artificial Intelligence (AI); Vascular Surgery Identity, Training, Manpower And Mentorship; Updates On Open And Hybrid Vascular Surgery And Treatment Of Aortic Coarctation**  
 6:44 A.M. – 6:05 P.M.  
 Grand Ballroom West, 3rd Floor

PROGRAM C-1: (SESSIONS 17-18)

**Management Of Pulmonary Embolism: The Ultimate Team Approach**  
 7:00 A.M. – 12:00 P.M.  
 Trianon Ballroom, 3rd Floor

Course Leader: **Michael R. Jaff**

PROGRAM C-2: (SESSIONS 19-22)

**Interesting Topics Related To Lower Extremity Occlusive Disease And Its Treatments**  
 1:00 P.M. – 6:00 P.M.  
 Trianon Ballroom, 3rd Floor

PROGRAM A (SESSIONS 1-8)

**PROGRESS IN THE TREATMENT OF DISEASES OF THE CORONARY ARTERIES, HEART VALVES AND THE THORACIC AND ABDOMINAL AORTA**  
 Grand Ballroom East, 3rd Floor

**6:45 – 6:50** Opening Remarks  
*Frank J. Veith*

SESSION 1 (Grand Ballroom East, 3rd Floor)

**PROGRESS IN CORONARY ARTERY STENTING, TRANSCATHETER VALVE REPLACEMENT, AND TREATMENT OF ASCENDING AORTIC DISEASE**

**Moderators:** *Hazim J. Safi*  
*Roxana Mehran*

**CORONARY STENTS**

**6:50 – 6:55** What Is New In Coronary Artery Stenting: How Good Are New Drug Eluting Stents: Is There A Role For Bare Metal Stents  
*Martin B. Leon*

**6:56 – 7:01** Left Main PCI With Drug-Eluting Stents Versus CABG: Clinical Trial Synthesis And Take-Home Messages  
*Gregg W. Stone*

**TRANSCATHETER HEART VALVES**

- 7:02 – 7:07** Update On Status Of Transcatheter Mitral Valve Replacement/Repair (TMVR)  
*Juan F. Granada*
- 7:08 – 7:13** **DEBATE:** Update On Transcatheter Aortic Valve Replacement (TAVR): A Cardiologist's View  
*Martin B. Leon*
- 7:14 – 7:19** **DEBATE:** Update On Current State Of TAVR: A Cardiac Surgeon's View: What Is The Role Of Surgery In Aortic Valve Disease Treatment And How To Avoid The Need For Alternative Access Sites  
*Ali Khoynezhad*

**THE ASCENDING AORTA**

- 7:20 – 7:25** Progress In Endovascular Graft Treatment Of Ascending Aortic Lesions: What Is The Status Of IDEs And Industry Made Graft  
*Rodney A. White*
- 7:26 – 7:31** Progress In Endovascular Combined Devices For Repairing Lesions Of The Ascending Aorta And The Aortic Valve: The Endo-Bentall Concept  
*Ali Khoynezhad*
- 7:32 – 7:37** Endo-Bentall Using A Rendezvous-Access: Why A Combined Transfemoral/Transapical Access Is The Way To Go: How To Do It And Results  
*Tilo Kölbel*
- 7:38 – 7:43** Endovascular Treatment Of Type A Aortic Dissections (TAADs) In 2022: What Is Here And What Is Coming  
*Ali Azizzadeh*
- 7:44 – 7:50** **Panel Discussion**

SESSION 2 (Grand Ballroom East, 3rd Floor)

**PROGRESS IN THE TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS**

**Moderators:** *Alan B. Lumsden*  
*Anthony L. Estrera*

- 7:50 – 7:55** Hybrid Repair Of Aortic Arch And Thoracic Aortic Aneurysms Using ThoraFlex (Hybrid) And Relay Devices For Frozen Elephant Trunk (FET) And TEVAR: Indications And Results  
*Joseph S. Coselli*  
*Ourania Preventza*
- 7:56 – 8:01** Current Status Of Hybrid Arch Repair With Elephant Trunk And FET: What Does The Future Hold And How Often Are Secondary Procedures Required  
*Anthony L. Estrera*
- 8:02 – 8:07** Update On Endovascular Arch Repair With Cook 2- Or 3-Branched Device For Lesions Involving The Entire Aortic Arch: Indications, Results And Can It Be Combined With An Endo-Bentall: When Is Open Repair The Best Treatment  
*Stephan Haulon*
- 8:08 – 8:13** Comparison Of Early And Mid-Term Results With 2-Branched Endograft (Relay – Terumo Aortic) And Single Branched Device (Nexus – Endospan) For Treatment Of Zone 0 Arch Lesions  
*Toru Kuratani*



- 8:14 – 8:19** Update On Relay Branch For Arch Lesion Endovascular Repairs: Advantages, Limitations And Results  
*Vicente Riambau*  
*Ciro Ferrer*  
*Martin Czerny*
- 8:20 – 8:25** Direction-Turnover Technique For Endovascular Repair Of Aortic Arch Lesions With Branched Or In Vitro Fenestrated Endografts  
*Qingsheng Lu (PowerPoint Presentation With Synched Audio)*  
*Zaiping Jing*
- 8:26 – 8:31** Total And Partial Aortic Arch Lesion Repairs With The Gore TAG Single Branch Endograft: An Off-The-Shelf (OTS) Device For Revascularizing Arch Branches: Experience To Date, Advantages And Limitations  
*Michael D. Dake*  
*Himanshu Patel*
- 8:32 – 8:37** How Best To Treat TBADs Extending Into The Arch Or Ascending Aorta; When Open, When Endo, When Hybrid  
*I-Hui Wu*
- 8:38 – 8:43** How To Prevent Complications During Partial Or Total Endovascular Aortic Arch Repairs: Value Of Special Radiopaque Markers  
*Chang Shu (PowerPoint Presentation With Synched Audio)*
- 8:44 – 8:49** How Best To Treat Aortic Arch Lesions: Customized Versus Chimney Versus Physician Modified Endografts: When Open: Role Of Each  
*Nicola Mangialardi*
- 8:50 – 8:55** Value Of Ascending Aortic Banding As Primary Or Adjunctive Treatment For Aortic Arch Lesions  
*Chun Che Shih*
- 8:56 – 9:02** **Panel Discussion**

SESSION 3 (Grand Ballroom East, 3rd Floor)

**PROGRESS IN THE ENDOVASCULAR TREATMENT OF AORTIC DISSECTIONS: REPORTING STANDARDS, CLASSIFICATION SYSTEMS, STABILISE, AND MORE**

**Moderators:** *Michael D. Dake*  
*Joseph V. Lombardi*

- 9:02 – 9:07** New SVS-STs Aortic Dissection Reporting Standards And Classification System: How Do They Help In Determining Precisely High Risk TBAD Patients  
*Joseph V. Lombardi*
- 9:08 – 9:13** The TEM Aortic Dissection Classification System: What Is It And How Does It Improve Clinical Practice  
*Martin Czerny*
- 9:14 – 9:19** Current Advances And Trends In TEVAR Treatment For Type B Aortic Dissection In China: More Or Less Liberal Use; More Or Less Aortic Coverage; What Adjunctive Procedures Are Used More  
*Weiguo Fu (PowerPoint Presentation With Synched Audio)*
- 9:20 – 9:25** Update On The STABILISE Concept For Treating Acute And Chronic TBADs By Disrupting The Intimal Flap By Overdilating The Distal Bare Stent: How It Works, Precautions, And Should It Be The Treatment Of Choice  
*Jean-Marc Alsac*

- 9:26 – 9:31** Considerations For Parallel Endografts In The Management Of Arch Vessels In Very Proximal Type B Aortic Dissections  
*David J. Minion*
- 9:32 – 9:37** Dual Lumen Interventions To Promote False Lumen Thrombosis In Chronic Aortic Dissections: The FLIRT Procedure: Indications, Technique And Results  
*Christoph A. Nienaber*
- 9:38 – 9:43** There Will Always Be A Need For Open Repair For Post-Dissection TAAAs: In What Circumstances  
*Hazim J. Safi*  
*Anthony L. Estrera*
- 9:44 – 9:49** Distal Stent-Graft Induced New Re-Entry Tears (SINeS) With TEVAR Treatment Of TBADs: Prevention By Avoiding Oversizing And Ballooning And Using Tapered Endografts  
*Ludovic Canaud*
- 9:50 – 9:55** The Impact Of Distal Stent-Graft Induced New Entry Tears On Aortic Remodeling Of Chronic TBADs: How To Prevent And Treat Them  
*Chun Che Shih*
- 9:56 – 10:01** Highlights From The New AHA, ACC, AATS, SVS, ACR, STS, SVM, SCAI, SCA Aortic Disease Guidelines  
*James H. Black, III*
- 10:02–10:07** The Global Experience With Endovascular Aortic Repair In >200 Patients With Connective Tissue Disease: Is There A Role  
*Anders Wanhainen*
- 10:08–10:14** **Panel Discussion**
- 10:14–10:24** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 4 (Grand Ballroom East, 3rd Floor)

**MORE NEW DEVELOPMENTS IN THE TREATMENT OF TBADs, THORACIC AORTIC DISEASE AND THORACOABDOMINAL ANEURYSMS (TAAAs)**

**Moderators:** *Hazim J. Safi*  
*Ali Khojnejhad*

- 10:24–10:29** Long-Term Durability Of Open Repair Of Type I-IV TAAAs Remains Excellent: When Should It Be The First Line Treatment And When Should A Hybrid (Endo + Open) Down-Staging Approach Be Used To Improve Outcomes: How To Do The Latter  
*Mark Conrad*  
*Richard P. Cambria*
- 10:30–10:35** New Strategies And Indications For Open TAAA Repair Including Failed EVAR And F/B/EVAR: Technical Tips And Results  
*Andrea Kahlberg*  
*Roberto Chiesa*  
*Germano Melissano*
- 10:36–10:41** Aortic Arch Repairs With Frozen Elephant Trunk (FET) Followed By Open Or Endo Extensions For TAAA Repairs: Techniques And Outcomes; Importance Of Staging  
*Michael J. Jacobs*
- 10:42–10:47** Lessons Learned From The STABLE I And II Trials: What Are The Short And Long-Term Benefits And Limitations Of A Distal Bare Stent Combined With A Proximal Covered Stent: The Petticoat Procedure  
*Joseph V. Lombardi*

- 10:48–10:53** Changing Current Trends In Management And Outcomes With Acute TBADs: Based On 3000 Patients In The IRAD Registry Over 25 Years: What Is Helping And What Is Not  
*Santi Trimarchi*
- 10:54–10:59** Why Is F/B/EVAR The Best Treatment For Post TBAD TAAAs: Challenges And Results From A 10-Year Experience  
*Eric L.G. Verhoeven*  
*Athanasios Katsargyris*
- 11:00–11:05** Roles Of Inner And Outer Branched Endografts And The t-Branch OTS Device (Cook) To Treat TAAAs After TBADs: Technical Tips And Results  
*Marcelo Ferreira*
- 11:06–11:12** **Panel Discussion**
- 11:12–11:17** Gore TAMBE Endovascular Graft Device For TAAA Repair: How Does It Work: Advantages And Limitations  
*Michel S. Makaroun*  
*Mark A. Farber*
- 11:18–11:23** Unitary Manifold Endograft System For Complex Type 4 TAAAs, Aneurysms With Chronic TBADs, Ruptured Complex AAAs And Failed Prior EVAR Repairs: How Does It Work And Up To 9-Year Results  
*Patrick W. Kelly*
- 11:24–11:29** Type A Aortic Dissection With Malperfusion: When Should TEVAR Be The First Order Of Business Before Fixing The Ascending Aorta: Where Should The TEVAR Be Placed And What Are The Advantages And Dangers  
*Firas F. Mussa*
- 11:30–11:35** Improved Aortic Remodeling With TEVAR And A Distal Bare Metal Stent In Acute Complicated TBAD  
*Christoph A. Nienaber*
- 11:36–11:41** Embolization And Other Strategies To Achieve Complete False Lumen Exclusion With Endovascular Repair Of Dissecting Aneurysms With TAAAs  
*Carlos H. Timaran*
- 11:42–11:47** Varying Solutions To Treat Type 1 Endoleaks After TEVAR And EVAR  
*Nicola Mangialardi*
- 11:48–11:53** High Failure Rate Of Best Medical Treatment For Intramural Hematoma Mandates Increased Use Of TEVAR: Does This Help Outcomes  
*Jean M. Panneton*
- 11:54–12:00** **Panel Discussion**  
**Publisher**
- 12:00– 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 5 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN ABDOMINAL AORTIC ANEURYSM (AAA) ETIOLOGY AND TREATMENT, EVAR AND EVAS (ENDOVASCULAR ANEURYSM SEALING) (5 AND 4 ¾-MINUTE [SS] TALKS)**

**Moderators: Ronald L. Dalman**  
**Grace J. Wang**

- 1:00 – 1:05** Current Pros And Cons Of The Nellix EVAS Endograft For AAA Repair: Latest Update Of The EVAS 2 IDE Trial Of The Modified Improved Nellix Endograft With 2-Year Results: Why Is Mid-Term Mortality Better With EVAS Than EVAR  
*Marc L. Schermerhorn*  
*Jeffrey P. Carpenter*
- 1:06 – 1:11** What Is The Best Type Of Evidence To Evaluate The Relative Value Of EVAR Versus Open Repair: RCTs May Not Reflect Reality As Well As Other Methods: The NICE Guidelines Prove It  
*Matt M. Thompson*
- 1:12 – 1:17** Failing EVARs Are An Enlarging Epidemic: Etiology And How Best To Avoid And Treat The Problem  
*Murray L. Shames*
- 1:18 – 1:23** Diabetes And AAAs: Facts, Clues And Potential Treatment Opportunities  
*Ronald L. Dalman*
- 1:24 – 1:29** [SS] Further Thoughts About The Odd Relationship Between Diabetes And AAA Disease: How Should It Influence Treatment  
*Christos D. Liapis*
- 1:29 – 1:34** [SS] How Does Metformin Work To Slow AAA Growth At The Cellular Level: Could It Be Effective Treatment For Small AAAs: Is It The Reason For Decreased AAA Incidence In Diabetics  
*Kak Khee Yeung*
- 1:34 – 1:39** [SS] The Metformin For AAA Growth Inhibition (MAAGI) Multicenter Trial: Design And 3-Year Results  
*Anders Wanhainen*
- 1:39 – 1:46** **Panel Discussion**  
*Moderators: Michel S. Makaroun*  
*Caron B. Rockman*
- 1:46 – 1:51** Evolved Treatment Algorithm For Aortic Graft Infections Endo And Open: Lessons Learned From A Large Tertiary Experience  
*Martin R. Back*
- 1:52 – 1:57** Decreased AAA Sac Diameter After EVAR Is Associated With Good Outcomes While Sac Stability Is Not  
*Andres Schanzer*
- 1:57 – 2:02** Sac Dynamics After EVAR Influence Long-Term Survival: What Can Be Done To Improve AAA Sac Shrinkage: Can Filling The Sac With Polymer Plugs From Shape Memory Medical Promote Shrinkage: The AAA-SHAPE-NLD Study  
*Michel M.P. Reijnen*  
*Andrew Holden*
- 2:03 – 2:08** In Patients Suitable For EVAR Or Open Repair, Adverse Neck Anatomy (Short, Wide, Angulated) Is Associated With Increased Reintervention And Mortality Rates Equally After Open And Endo Repairs: From The DREAM RCT: How Should This Influence Treatment  
*Jan B. Blankensteijn*
- 2:09 – 2:14** How Best To Treat Iliac Aneurysms In 2022: When Endo; Open Repair Is Sometimes Essential: Technical Tips  
*Heron E. Rodriguez*

- 2:15 – 2:20** EVAR Surveillance Models Have Failed: How They Should Be Changed  
*Ian Loftus*  
*Pete Holt*
- 2:21 – 2:26** Which AAA Patients Should Get Open Repair (OR) In 2022: Young Healthy Patients With Large AAAs Do Better With OR: But EVAR Outcomes Are Improving While OR Outcomes Are Not  
*Marc L. Schermerhorn*
- 2:27 – 2:40** **Panel Discussion And Break**  
**Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 6 (Grand Ballroom East, 3rd Floor)

**MORE ABOUT AAAs AND EVAR: UPDATES ON THE UK NICE AAA GUIDELINES AND SACCULAR AAAs**

**Moderators:** *Matt M. Thompson*  
*Bhama Ramkhelawon*  
*Maarit Venermo*

- 2:40 – 2:45** Are Key Points In The NICE Guidelines For Treatment Of AAAs Still Valid And Should They Be Applied And Used More Widely Or Less Widely  
*Nicholas J.W. Cheshire*
- 2:46 – 2:51** Review Of All AAA Guidelines: Do They Support Or Refute The NICE AAA Guidelines  
*Alun H. Davies*
- 2:52 – 2:57** Why Are The NICE AAA Guidelines So Flawed: Has Bias Played A Role  
*Frans L. Moll (PowerPoint Presentation With Synched Audio)*
- 2:58 – 3:03** Are The NICE AAA Guidelines The End Of EVAR In The UK: Why The Guidelines Are Wrong And Can They Be Fixed  
*Michael P. Jenkins, BSc*
- 3:04 – 3:09** Impact Of NICE AAA Draft And Final Guidelines On Complex AAA Endovascular Repair: Will They Be Good For Patients  
*Tara M. Mastracci*
- 3:10 – 3:15** What Has Been The Impact Of The UK NICE AAA Guidelines In Germany And Elsewhere – Despite Their Flaws  
*Dittmar Böckler*
- 3:16 – 3:21** Long-Term Results Of The OVER RCT: Pertinence To NICE AAA Guidelines: How Operator Training And Experience Influence EVAR Outcomes  
*Jon S. Matsumura*
- 3:22 – 3:27** Why EVAR Is Not The Best Treatment For All AAAs – Especially In Young Patients (<70) With A Long Life Expectancy  
*Fabio Verzini*
- 3:28 – 3:33** Spontaneous Infrarenal Acute Aortic Syndrome: What Is It And How Should It Be Treated  
*Felice Pecoraro*
- 3:34 – 3:39** Should Saccular AAAs Be Fixed At A Smaller Diameter Than Fusiform AAAs: How Should Saccular AAA Diameter Be Measured: To Include The Normal Aorta Or Not  
*Frans L. Moll (PowerPoint Presentation With Synched Audio)*
- 3:40 – 3:45** With Failed EVAR, When Is F/EVAR The Best Treatment: Tips And Tricks For Performing It Successfully  
*Andres Schanzer*
- 3:46 – 3:56** **Panel Discussion**

SESSION 7 (Grand Ballroom East, 3rd Floor)

**MORE NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC DISSECTIONS AND THORACIC PATHOLOGY; STROKE PREVENTION WITH TEVAR**

**Moderators:** *Mark A. Farber*  
*Manju Kalra*

**3:56 – 4:01** Update On Prevention Of Gas Emboli And Stroke With TEVAR And Other Cardiovascular Interventions: Why It's Such A Big Deal: What Is The STEP 2 Study Telling Us

*Tilo Kölbel*  
*Stephan Haulon*

**4:02 – 4:07** How Well Do Young/Old Patients Recover Mentally And Physically After Treatment For Type A And Type B Aortic Dissections: What Can Be Done To Improve This Recovery

*Richard G.J. Gibbs*

**4:08 – 4:13** Update On Value Of Embolic Brain Protection Devices For Proximal TEVAR And TAVR Procedures: When Are They Indicated And When Not

*Joseph V. Lombardi*  
*Jeffrey P. Carpenter*

**4:14 – 4:19** Physician Modified Double Fenestrated Stent-Grafts For Total Aortic Arch Repair: Results In 100 Patients: Advantages And Limitations

*Ludovic Canaud*

**4:20 – 4:25** Will More Oversizing Of Thoracic Endografts Prevent Bird Beaking And Type I Endoleaks With TEVAR In The Aortic Arch: Will Oversizing Cause Other Problems: What Is The Optimal Sizing In This Location

*Thomas L. Forbes*

**4:26 – 4:31** Natural History Of Aortic Intramural Hematomas (IMHs) And Predictors Of Need For TEVAR Treatment: Which IMH Patients Do Not Need TEVAR

*I-Hui Wu*

**4:32 – 4:37** How To Deal With An Uncontrolled And Enlarging False Lumen After TEVAR For TBADs

*Cherrie Z. Abraham*

**4:38 – 4:43** Long-Term (>5 Years) Good Results Of Valiant Captiva Endografts For TEVAR In TBAD Patients: Advantages And Disadvantages

*Joseph E. Bavaria*

**4:44 – 4:49** How To Treat Aortic Dissections With An Entry Tear In The Aortic Arch

*Santi Trimarchi*

**4:50 – 4:56** **Panel Discussion**

SESSION 8 (Grand Ballroom East, 3rd Floor)

**MORE NEW DEVELOPMENTS REGARDING TBADs AND TEVAR: NATURAL HISTORY; NEED FOR AND TIMING OF TEVAR FOR ACUTE UNCOMPLICATED TBADs**

**Moderators:** *Joseph E. Bavaria*  
*Thomas L. Forbes*

**4:56 – 5:01** Long-Term Outcomes Of Medically Managed Acute TBADs: How Were Patients Selected For This Treatment

*Thomas C. Bower*

**MEGA DEBATE ON TREATMENT OF  
ACUTE UNCOMPLICATED TBADs**

- 5:02 – 5:07** **DEBATE:** Many Uncomplicated Acute TBADs Never Need Invasive Interventions And Are Better Treated Medically; How To Select Such Patients  
*Rachel E. Clough*
- 5:08 – 5:13** **DEBATE:** With Uncomplicated Acute TBADs, The Case For Waiting 2-6 Weeks From Onset And Then Limiting Aortic Coverage With TEVAR  
*Mark A. Farber*
- 5:14 – 5:19** **DEBATE:** With Uncomplicated TBADs, The Case For Early TEVAR With Extensive Aortic Coverage In Most Patients  
*William D. Jordan, Jr.*  
*Brad Leshnower*
- 5:20 – 5:25** **DEBATE:** Early Intervention For Acute TBADs (7-30 Days After Onset) With TEVAR For Acute TBADs Prevents Abdominal Extension Of False Lumen And TAAA Formation  
*Rodney A. White*
- 5:26 – 5:31** Impact Of Timing On Outcomes After TEVAR For Acute Uncomplicated TBAD Patients: When Is Medical Treatment Indicated  
*Ali Azizzadeh*
- 5:32 – 5:37** Incidence And Importance Of Reinterventions Following F/B/EVAR: Are They A Marker Of Bad Care Or Good Care: From The Aortic Research Consortium (ARC)  
*Sara L. Zettervall*  
*Benjamin W. Starnes*  
*Andres Schanzer*
- 5:38 – 5:43** With TBADs Distal Fenestrations Are As Important As The Primary Tear: What Can And Should Be Done About Them  
*Frank R. Arko*
- 5:44 – 5:49** Techniques For And Advantages Of Rerouting A Misplaced TEVAR Which Is Leading To A Growing False Lumen And Malperfusion In Acute TBAD Patients  
*David M. Williams*
- 5:50 – 5:55** Re-Entry Specific Endovascular Therapy (RESET), i.e., TEVAR Plus Dealing With Re-Entry Tears Improves Outcomes: How To Do It  
*Jean M. Panneton*
- 5:56 – 6:02** **Panel Discussion**  
**End of Program A**

**PROGRAM B (SESSIONS 9-16)**

**PROGRESS IN VASCULAR ROBOTICS, GUIDANCE SYSTEMS, LAPAROSCOPY, SIMULATION AND COVID; NEW DEVELOPMENTS IN CAROTID DISEASE AND ACUTE STROKE TREATMENT; ABDOMINAL AORTIC BRANCH TREATMENT; NEW TECHNOLOGY CONCEPTS AND ARTIFICIAL INTELLIGENCE (AI); VASCULAR SURGERY IDENTITY, TRAINING, MANPOWER AND MENTORSHIP; UPDATES ON OPEN AND HYBRID VASCULAR SURGERY AND TREATMENT OF AORTIC COARCTATION**

Grand Ballroom West, 3rd Floor

**6:44 – 6:49** Opening Remarks  
*Enrico Ascher*

SESSION 9 (Grand Ballroom West, 3rd Floor)  
**PROGRESS IN VASCULAR ROBOTICS,  
LAPAROSCOPY, GUIDANCE SYSTEMS AND  
SIMULATION**

**Moderators:** *Willem Wisselink*  
*Celia Riga*

**6:50 – 6:55** Update On Endovascular Robotics: They Have A Promising Future  
*Joseph J. Ricotta II*

**6:56 – 7:01** Laparoscopic Assisted Aortofemoral Bypasses For Juxtarenal Aortic Occlusions: Why It Is The Best Treatment Method As Indicated By Long And Short Term Outcomes: What Are The Risks  
*Joseph S. Giglia*

**7:02 – 7:07** Laparoscopic Robotic Assisted Aortic Surgery: Is It Worthwhile And Cost Effective In The Endovascular Era: Based On A 7-Year Experience In 87 Patients  
*Pierre-Olivier Thiney*

**7:08 – 7:13** Laparoscopic Aortic Surgery: How I Did It Routinely And Why I Stopped After More Than 150 Cases  
*Laurent Chiche*

**7:14 – 7:19** Present Status And Future Potential Of Radiation Free Guidewire And Catheter Guidance: The Fiber Optic RealShape (FORS) From Philips: What Are Microbots And How Do They Work  
*Barry T. Katzen*

**7:20 – 7:25** Updated Experience With The Fiberoptic 3D Endovascular Guidance With The FORS System (Philips): How Does It Work, Advantages And Limitations  
*Joost A. van Herwaarden*

**7:26 – 7:31** Update On The 3D Radiation Free Intraoperative Positioning System (IOPS) From Centerline For Endovascular Guidance: How Does It Work, Advantages And Limitations  
*Matthew J. Eagleton*

**7:32 – 7:37** The MAZE BOX: A Simple Table Top Endovascular Simulator For Training In Endovascular Tasks And Procedures  
*Barend M.E. Mees*

**7:38 – 7:44** **Panel Discussion**

SESSION 10 (Grand Ballroom West, 3rd Floor)  
**NEW DEVELOPMENTS IN CAROTID DISEASE  
AND ITS TREATMENT; DIFFERING VIEWS ON  
TREATMENT OF ASYMPTOMATIC CAROTID  
STENOSIS (ACS) AND CAROTID SCREENING**

**Moderators:** *Ali F. AbuRahma*  
*Anne L. Abbott*  
*Adnan H. Siddiqui*

**7:44 – 7:49** International Variations In Carotid Stenosis Treatment Within Countries And Between Countries Is Huge Despite All The RCTs On Which They Are Based Being The Same: What Are The Implications  
*Maarit Venermo*



**7:50 – 7:55** Current Optimal Treatment For Carotid Artery Dissection: When Best Medical Therapy (BMT), When Open Surgery, When Carotid Stenting (CAS) With Proximal Embolic Protection

*Felice Pecoraro*

**7:56 – 8:01** What Vascular Surgeons And Vascular Specialists Need To Know About What Can Be Learned From MRI And MRA Studies Of The Head And Neck

*Allan L. Brook*

**8:02 – 8:07** Update On Near Total Occlusions And String Signs Of The Internal Carotid Artery (ICA): How Are They Best Treated: When Conservatively; When Invasively By CEA; By CAS: How Does Newer Imaging Help

*Christos D. Liapis*

**8:08 – 8:13** Update On Isolated Carotid Webs As A Cause Of Cryptogenic Stroke: How Best To Diagnose And Treat: How Should Asymptomatic Webs Be Treated

*Evan C. Lipsitz*

**8:14 – 8:20** **Panel Discussion**

**DIFFERING VIEWS ON TREATMENT OF ACS**

**8:20 – 8:25** **DEBATE:** ALL Asymptomatic Carotid Stenosis (ACS) Patients Are Best Treated Medically: Invasive Treatment Causes More Harm Than Good

*Anne L. Abbott*

**8:26 – 8:31** **DEBATE:** Not So: About 25% Of ACS Patients Can Benefit From CEA Or CAS And Should Be So Treated

*Bruce A. Perler*

**8:32 – 8:37** **DEBATE:** Both Views Are Wrong: Severe Carotid Stenosis Has Declined As A Cause Of Ischemic Stroke To <1% Per Year: So <5% Of ACS Patients Should Be Treated Invasively

*Robert W. Chang*

**8:38 – 8:43** With ACS: When Not To Treat Invasively And When To Treat Invasively: A Balanced Logical View – But No One Knows Which View Is Right Or Best

*Martin Storck*

**DIFFERING VIEWS ON CAROTID SCREENING**

**8:44 – 8:49** **DEBATE:** The Case For Widespread Carotid Screening

*George S. Lavenson*

**8:50 – 8:55** **DEBATE:** The Case Against Carotid Screening: It Leads To Unneeded And Possibly Harmful Treatment

*Anne L. Abbott*

**8:56 – 9:01** What Are The Effects Of A Minor Stroke With Apparent Full Recovery: Minor Strokes Are By No Means Minor: Why Is This Important In Evaluating The Conclusions Of The CREST Trial

*Emmanuel M. Houdart*

**9:02 – 9:07** Screening For ACS And Common Femoral Artery Disease: How Can It Guide Lipid Treatment: How Low Should LDL-Cholesterol (LDL-C) Be Pushed And What Will It Do To Carotid Plaques

*Stavros Kakkos*

*Andrew N. Nicolaidis*

**9:08 – 9:15** **Panel Discussion**

**9:15 – 9:30** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 11 (Grand Ballroom West, 3rd Floor)

**MORE ABOUT CAROTID AND VERTEBRAL DISEASE:  
UPDATE ON INVASIVE TREATMENT FOR ACUTE  
STROKES**

**Moderators:** *Allan L. Brook*  
*Klaus D. Mathias*  
*Thomas G. Brott*

- 9:30 – 9:35** Carotid Artery Aneurysms: What Etiologies Cause Them; When Is Endovascular Treatment Best And Technical Tips For Doing So Successfully  
*Klaus D. Mathias*
- 9:36 – 9:41** When After Thrombolysis Treatment For A Stroke Should Carotid Endarterectomy (CEA) Be Performed And What Is The Best Timing For Those CEAs: Delay Has Consequences: But CEA Within 48 Hours Of Symptom Onset Has A Higher Complication Rate  
*Maarit Venermo*
- 9:42 – 9:47** Why Vascular Surgeons Should Become Involved In Intracranial Endovascular Treatments For Acute Strokes: How To Learn These Procedures And Benefit Patients  
*Laura Capoccia*
- 9:48 – 9:53** With Acute Strokes What Is New With Endovascular Intracranial Techniques For Arterial Clot Removal: How Can Artificial Intelligence (AI) And Intraarterial Thrombolysis With Alteplase (Genentech) Help – From The CHOICE RCT  
*Adnan H. Siddiqui*  
*L. Nelson Hopkins*
- 9:54 – 9:59** How Can Intolerance To Carotid Clamping Be Predicted Before CEA: It Is An Indication For CAS  
*Piotr Myrcha*
- 10:00–10:05** Acute Stroke Interventions: What Is New: Who Should Do Them And Lessons Learned  
*Horst Sievert*
- 10:06–10:11** How Best To Treat An ICA Occlusion With Distal Embolization: Sequence And Timing Of Treatment: Site Of Treatment (OR Versus Angio Suite Versus Hybrid Room): Technical Tips  
*Adnan H. Siddiqui*  
*L. Nelson Hopkins*
- 10:12–10:17** Differences In Outcomes Of Carotid Interventions (CEA And CAS) In Women And Younger Patients: What Is The Impact Of These Differences On Patient Management  
*Caron B. Rockman*
- 10:18–10:23** Endovascular Interventions In The Vertebro-Basilar System For Acute Strokes: A New Horizon, What Is Involved And Results  
*Ivo Petrov*
- 10:24–10:30** **Panel Discussion**

SESSION 12 (Grand Ballroom West, 3rd Floor)

**PROGRESS IN THE TREATMENT OF AORTIC AND  
AORTO-ILIAC OCCLUSIVE DISEASE**

**Moderators:** *Daniel G. Clair*  
*Wayne W. Zhang*

- 10:30-10:35** Current Concepts And Techniques For Treating External Iliac Artery Endofibrosis In Committed Athletes: What Works And Doesn't Work: Is There A Role For Endovascular Treatment  
*Kenneth J. Cherry*
- 10:36-10:41** Iliac Stenosis In Professional Cyclists: How To Diagnose And Treat: ABIs Don't Help  
*Gabriel Szendro*
- 10:42-10:47** Value Of VBX Balloon Expandable Covered Stents In Treating Complex Aorto-Iliac Occlusive Disease: Advantages And Limitations  
*Palma Shaw*
- COVERED ENDOVASCULAR RECONSTRUCTION OF THE AORTIC BIFURCATION (CERAB) PROCEDURE**
- 10:48-10:53** Long-Term Outcomes Of The CERAB Procedure With Covered Stents For Complex Aorto-Iliac Occlusive Disease: Why It's Better Than Kissing Stents And Which Covered Stent Works Best  
*Michel M.P. Reijnen*  
*Peter C.J. session*
- 10:54-10:59** The CERAB Technique: From A Niche Procedure To A Worldwide Solution For Complex Aorto-Iliac Occlusive Disease  
*Maria A. Ruffino*
- 11:00-11:05** Covered Endovascular Reconstruction Of The Aortic Bifurcation (CERAB) Technique: Multicenter UK Experience  
*Hany Zayed*
- 11:06-11:11** Value Of Shockwave Intravascular Lithotripsy (IVL) For Calcified Aorto-Iliac Occlusive Disease Treatment And Other Lower Extremity Arterial Lesions: The DISRUPT PAD III RCT  
*Andrew Holden*  
*Gunnar Tepe*  
*William A. Gray*
- 11:12-11:18** **Panel Discussion**
- 11:18-11:23** Treatment Of Infrarenal And Pararenal Aortic Stenosis: When Stents; When Stent-Grafts; When Open Bypass Or Endarterectomy  
*Sigrid Nikol*
- 11:24-11:29** Endovascular Treatment Of Difficult Aorto-Iliac Occlusions: Technical Tips And Late Results: Is Open Repair Ever Needed  
*Sonia Ronchey*
- 11:30-11:35** **DEBATE:** How To Treat Chronic Flush Juxtarenal Aortic Occlusions Endovascularly With Safety: Endo Is The Way To Go  
*David J. Minion*
- 11:36-11:41** **DEBATE:** Not So: Open Surgery Is The Best Way To Treat Flush Juxtarenal Aortic Occlusions Safely: Technical Tips On How To Do It Transperitoneally And Retroperitoneally  
*Thomas C. Bower*
- 11:42-11:47** **DEBATE:** Both Wrong: Hybrid Repairs Are Best For Complex Aorto-Iliac Occlusive Disease: Technical Tips On How To Do It  
*Yamume Tshomba*

- 11:48–11:53** Impact Of Female Gender On Outcomes Of Endovascular Treatment Of Aorto-Iliac Occlusive Disease: When Is Open Repair Indicated  
*Franco Grego*
- 11:54–12:00** **Panel Discussion**
- 12:00 – 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 13 (Grand Ballroom West, 3rd Floor)

**NEW CONCEPTS, MACHINE LEARNING AND ARTIFICIAL INTELLIGENCE (AI)**  
(SEE ALSO SESSION 87)

**Moderators:** *Barry T. Katzen*  
*Lindsay Machan*  
*Frank J. Veith*

- 1:00 – 1:05** What Is Big Data In Vascular Surgery: How Can It Be Used With Artificial Intelligence (AI) In Evidence Based Medicine: Could It Replace Randomized Controlled Trials (RCTs)  
*Jean-Baptiste Ricco (PowerPoint Presentation With Synched Audio)*
- 1:06 – 1:11** What Is The Bright Future Of AI And Robotic Technology In Vascular Surgery  
*Willem Wisselink*
- 1:12 – 1:17** How AI Will Change The Way We Practice Medicine  
*Lindsay Machan*
- 1:18 – 1:23** Update On How Vascular Treatment Will Intersect With Other New Technologies: Wearable Trackers, AI, And Using CT Scans To Predict Plaque Histology (ElucidVivo)  
*David H. Deaton*
- 1:24 – 1:29** How 3D And 4D Machine Learning Is Changing Vascular Surgery  
*Matthew T. Menard*
- 1:30 – 1:35** Is Image Fusion Guidance For Complex And Simple Aortic Procedures Really Worthwhile And Cost Effective: Why Is It A Question  
*Rachel E. Clough*
- 1:36 – 1:41** How Can AI Facilitate AAA Monitoring And Volume Measurement Before And After EVAR  
*Stephan Haulon*
- 1:42 – 1:47** High Fidelity Computer Modeling: How Can It Help In Graft Selection And Procedural Performance With TEVAR And EVAR  
*Santi Trimarchi*
- 1:48 – 1:53** Siemens I-Flow: A New Intelligent Technology To Improve The Endo Treatment Of Lower Extremity Occlusive Disease  
*Ravi K. Veeraswamy*
- 1:54 – 1:59** Dual Fluoroscopy With Digital Zooming And Other Strategies To Decrease Radiation During Complex AAA Repairs  
*Carlos H. Timaran*
- 2:00 – 2:05** How Can AI Be Used To Predict Endoleaks And AAA Growth: Will It Have Clinical Value  
*Kak Khee Yeung*
- 2:06 – 2:12** **Panel Discussion**

SESSION 14 (Grand Ballroom West, 3rd Floor)

PART 1: VASCULAR SURGERY'S NUMBERS AND IDENTITY AND HOW TO MEET THE SPECIALTY'S NEEDS FOR ITS SERVICES; THE IMPORTANCE OF MENTORSHIP IN VASCULAR SURGERY

PART 2: LATE BREAKING DEVELOPMENTS IN COVID RELATED VASCULAR DISEASE ISSUES

PART 1 – VASCULAR SURGERY'S NUMBERS AND IDENTITY AND HOW TO MEET THE SPECIALTY'S NEEDS FOR ITS SERVICES; THE IMPORTANCE OF MENTORSHIP IN VASCULAR SURGERY

*Moderators: Samuel R. Money  
Jerry Goldstone*

- 2:12 – 2:17** What Makes Vascular Surgery Different, Why Are There Insufficient Numbers Of Vascular Surgeons: How Can We Expand Our Numbers  
*Evan C. Lipsitz*
- 2:18 – 2:23** Update On Applicants For 0+5 And 5+2 Vascular Surgery Training Programs: The Number Of Applicants Is Up: What About Their Quality: Do We Need More Programs  
*Peter L. Faries  
Murray L. Shames*
- 2:24 – 2:29** Increased Diversity In Vascular Surgery And Will It Improve The Shortage Of Vascular Surgeons  
*Dawn M. Coleman*
- 2:30 – 2:35** Why US News & World Report Cannot And Does Not Rank Vascular Surgery Programs: Vascular Surgery Needs To Be An Independent ABMS Approved Specialty: Why Isn't It  
*James H. Black, III*
- 2:36 – 2:41** The Key To More Vascular Surgeons Is Better Exposure To Medical Students: We Are A Hidden Specialty Because Of Our Subordinate Specialty Status Which Also Limits Our Training Programs  
*Jerry Goldstone*
- 2:42 – 2:47** The Importance Of Mentorship In Vascular Surgery: How Best To Achieve It  
*Audra Duncan*
- 2:48 – 2:53** **Panel Discussion**

PART 2 – LATE BREAKING DEVELOPMENTS IN COVID RELATED VASCULAR DISEASE ISSUES

*Moderators: Michel S. Makaroun  
Ronald L. Dalman*

- 2:54 – 2:59** The COVID Pandemic And Its Effects On The Staffing And Economics Of A Hospital System: How Best To Deal With These Effects  
*Samuel R. Money*
- 3:00 – 3:05** Late Breaking Factual Developments In The Prophylaxis And Treatment Of COVID-19: Update On The Real Value Of Vaccines, Boosters And Antivirals  
*Clayton J. Brinster*
- 3:06 – 3:11** Impact Of COVID-19 On The Extra- And Intracranial Circulation: How Effective Are Endovascular Treatments  
*Allan L. Brook*

**3:12 – 3:17** How Does COVID Influence The Occurrence Of Luminal Thrombus During CEA And CEA Timing; What Should Be Done During Invasive Treatment  
*Domenico Valenti*

**3:18 – 3:23** **Panel Discussion**

**3:24 – 3:36** **Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 15 (Grand Ballroom West, 3rd Floor)

## PROGRESS IN THE TREATMENT OF VISCERAL AND RENAL ARTERY DISEASE

**Moderators:** *James C. Stanley*  
*Michael C. Dalsing*

**3:36 – 3:41** **DEBATE:** All Visceral And Renal Artery Aneurysms Can Be Treated Endovascularly  
*Robert A. Lookstein*

**3:42 – 3:47** **DEBATE:** Open Treatment Of Visceral And Renal Artery Aneurysms Is Sometimes Best: When Is This  
*Timur P. Sarac*

**3:48 – 3:53** Open Retrograde SMA Stenting: When Is It Indicated And How To Do It  
*Richard J. Powell*

**3:54 – 3:59** With Acute Mesenteric Ischemia With Peritoneal Signs, Laparotomy And Retrograde SMA Stenting Is The Best Treatment: Technical Tips To Do It Safely And Quickly  
*Markus K. Furrer*

**4:00 – 4:05** Technical Tips For Recanalizing Long Complex Visceral Artery (SMA) Occlusions  
*Armando Mansilha*

**4:06 – 4:11** Renal And Visceral Arterial Interventions: How To Get Into Trouble And How To Get Out Of Trouble  
*Benjamin M. Jackson*  
*Ronald M. Fairman*

**4:12 – 4:17** Update On New SVS Practice Guidelines For Treating Visceral Artery Aneurysms; When Endo; When Open  
*Rabih A. Chaer*

**4:18 – 4:23** The Vascular Low Frequency Consortium: What Is It And What Does It Tell Us About The Size When Renal Artery Aneurysms Become Dangerous: It Is >3 cm In Diameter  
*Peter F. Lawrence*

**4:24 – 4:29** Optimal Current Treatment Of Renal Artery Aneurysms: When Endo; When Open; Technical Tips  
*Fred A. Weaver*

**4:30 – 4:36** **Panel Discussion**

SESSION 16 (Grand Ballroom West, 3rd Floor)

## UPDATE ON OPEN VASCULAR SURGICAL AND HYBRID PROCEDURES; PROGRESS IN THE TREATMENT OF AORTIC COARCTATIONS

**Moderators:** *Linda M. Harris*  
*Jerry Goldstone*

### OPEN AND HYBRID VASCULAR SURGERY

**4:36 – 4:41** Coral Reef Atherosclerotic Lesions Of The Aorta And Common Femoral Artery Are Best Treated By Open Repair  
*Laurent Chiche*

**4:42 – 4:47** Technical Tips For Performing Retroperitoneal Aorto-Bifemoral Bypass (Video Presentation)  
*William J. Quinones-Baldrich*

- 4:48 – 4:53** Tips And Tricks For Open Retroperitoneal Exposure Of The Aorta And All Its Abdominal Branches  
*Kamphol Laohapensang (PowerPoint Presentation With Synched Audio)*
- 4:54 – 4:59** Update On Minimal Incision For Retroperitoneal Aorto-Bifemoral Bypass And Other Procedures: Technical Tips And Limitations  
*Robert M. Proczka*
- 5:00 – 5:05** Duplex Surveillance Should Be Used After All Open Aorto-Bifemoral Bypasses: It Improves Outcomes  
*Keith D. Calligaro*
- 5:06 – 5:11** Thoraco-Bifemoral Bypass: A Good Option After All Endo And Open Standard Approaches Have Failed: Technical Tips  
*Manju Kalra*
- 5:12 – 5:17** Update On Renal Consequences Of Left Renal Vein Division During Open AAA Repair: It Is Not Always Benign  
*Kimihiko Komori (PowerPoint Presentation With Synched Audio)*
- 5:18 – 5:23** **Panel Discussion**
- UPDATE ON COARCTATION TREATMENT**
- 5:23 – 5:28** The Importance Of Microanatomy In Endovascular And Open Surgical Treatment Of Abdominal Aortic Coarctations  
*James C. Stanley*
- 5:29 – 5:34** **DEBATE:** Endovascular Techniques Are The Best Treatment For Aortic Coarctations: When Bare Stents; When Covered Stents; Precautions  
*Zvonimir Krajcer*
- 5:35 – 5:40** **DEBATE:** Not So: Open Surgery Is Sometimes Needed: What Are The Indications  
*Michael J. Jacobs*
- 5:41 – 5:46** Value Of BeGraft (From Bentley), A Balloon Expandable Covered Stent In Treating Aortic Coarctations: Can It Treat All Cases  
*Elchanan Bruckheimer*
- 5:47 – 5:52** Positive Aortic Remodeling In Aortic Coarctations Following TEVAR From The Ascending Aorta As Well As Distally  
*Frank R. Arko*
- 5:53 – 5:58** Axillo-Unifemoral And Axillo-Bifemoral Bypasses Have Equal Patency For More Than A Year: Why The Bilateral Procedure Should Only Be Used When Bilateral Ischemia Exists  
*Jeffrey J. Siracuse*
- 5:59 – 6:05** **Panel Discussion**  
**End of Program B**

PROGRAM C-1 (SESSIONS 17-18)

MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE TEAM APPROACH

Trianon Ballroom, 3rd Floor

Course Leader: **Michael R. Jaff**

SESSION 17 (Trianon Ballroom, 3rd Floor)

MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 1

Moderator: **Michael R. Jaff**

- 7:00 – 7:05** Introduction To The Symposium  
*Frank J. Veith*
- 7:05 – 7:15** Welcome And Introduction  
*Michael R. Jaff*
- 7:15 – 7:25** The Basics Of Pulmonary Embolism Diagnosis: What Is The Role Of The History, Exam, Biomarkers  
*Raghu Kolluri*
- 7:25 – 7:35** Do We Need An Echocardiogram To Manage Acute Submassive PE  
*David M. Dudzinski*
- 7:35 – 7:45** Advanced Imaging For PE: What Is The Optimal Strategy For The Diagnosis Of Acute And Chronic PE  
*Brian B. Ghoshhajra*
- 7:45 – 7:55** Testing For Cancer And Other Hypercoagulable States In PE  
*Rachel Rosovsky*
- 7:55 – 8:05** The First Opportunity – The Emergency Physician Algorithm For Acute PE Management  
*D. Mark Courtney*
- 8:05 – 8:20** Medical Treatment Of PE: When, Why, For How Long, And How Can I Remember  
*Geno J. Merli*
- 8:20 – 8:30** Intravenous Thrombolytic Therapy For PE: No Need For Catheter-Based Intervention  
*Jay Giri*
- 8:30 – 8:45** An Overview Of Technologies For Management Of High-Risk PE  
*Eric A. Secemsky*
- 8:45 – 8:55** Ultrasound-Assisted Pharmacomechanical Thrombectomy: Does This Really Work  
*Linda Le*
- 8:55 – 9:05** Percutaneous Mechanical Thrombectomy Without Lytics: The Indigo System  
*Robert A. Lookstein*
- 9:05 – 9:15** Percutaneous Mechanical Thrombectomy Without Lytics: The FlowTriever System  
*Mitchell D. Weinberg*
- 9:15 – 9:25** Step-By-Step Technical Tips For Pharmacomechanical Intervention For PE  
*Gary M. Ansel*
- 9:25 – 9:40** **Panel Discussion**  
**Moderator:** *Michael R. Jaff*  
Panelists: *Gary M. Ansel*  
*D. Mark Courtney*  
*David M. Dudzinski*  
*Brian B. Ghoshhajra*  
*Jay Giri*  
*Raghu Kolluri*  
*Linda Le*  
*Robert A. Lookstein*  
*Geno J. Merli*  
*Rachel Rosovsky*  
*Eric A. Secemsky*  
*Mitchell D. Weinberg*
- 9:40 – 10:10** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**



SESSION 18 (Trianon Ballroom, 3rd Floor)

**MANAGEMENT OF PULMONARY EMBOLISM: THE ULTIMATE APPROACH – PART 2**

**Moderator:** *Michael R. Jaff*

**10:10–10:20** Large Bore Aspiration Thrombectomy: Tips, Tricks And Pearls

*Ripal T. Gandhi*

**10:20–10:30** Vortex Strategy For Massive PE

*Christopher J. Kwolek*

**10:30–10:40** ECMO And Surgical Thromboembolectomy For Massive PE: When, How, And Why

*Mark G. Davies*

**10:40–10:55** What Algorithm Is Best For Acute PE Intervention

*Keith M. Sterling*

**10:55–11:10** Vena Cava Filters In PE Treatment: Do We Need To Do This, And If So, When

*John A. Kaufman*

**11:10–11:25** Balloon Pulmonary Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Has This Become Mainstream

*Kenneth Rosenfield*

**11:25–11:35** The Team Approach To PE Management: The National PERT Consortium

*William B. Keeling*

**11:35–12:00** Challenging Cases And “PERT” Decisions

**Moderator:** *Michael R. Jaff*

Panelists: *Mark G. Davies*

*John A. Kaufman*

*William B. Keeling*

*Christopher J. Kwolek*

*Kenneth Rosenfield*

*Keith M. Sterling*

*Ido Weinberg*

**12:00 – 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

**End of Program C-1**

PROGRAM C-2 (SESSIONS 19-22)

**INTERESTING TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS**

Trianon Ballroom, 3rd Floor

SESSION 19 (Trianon Ballroom, 3rd Floor)

**HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENTS**

**Moderators:** *Cynthia K. Shortell*

*Iris Baumgartner*

**1:00 – 1:05** Key Points From The SVS Appropriate Use Criteria For Management Of Intermittent Claudication

*Karen Woo*

*Jessica P. Simons*

- 1:06 – 1:11** Endovascular Treatments Including Atherectomy For Lower Extremity Occlusive Disease Are Associated With Poorer Long-Term Patient Survival: How Is It Related To Their Endovascular Treatments And/Or Their Underlying Atherosclerosis: Based On A VQI Study  
*Dipankar Mukherjee*
- 1:12 – 1:17** Real Five-Year Single Center Results With Atherectomy For De Novo Lower Extremity Lesions And In Stent Restenosis: How Good Or Bad Are They  
*Russell H. Samson*
- 1:18 – 1:23** Intravascular Lithotripsy For Peripheral Arterial Occlusive Lesions: Theory, Data, And What We Don't Know  
*Scott L. Stevens*
- 1:24 – 1:29** How Do SoundBite Wires (From SoundBite Medical) Help To Cross Calcified Lesions, Especially BTK  
*Marianne Brodmann (PowerPoint Presentation With Synched Audio)*
- 1:30 – 1:35** Alternate Approaches To Lower Extremity Arteries When Standard Approaches Are Prevented By Scarring Or Infection  
*Ramesh K. Tripathi*
- 1:36 – 1:41** Current Status And Prospects For Sirolimus Coated Devices And Bioresorbable Stents ATK And BTK  
*Marianne Brodmann (PowerPoint Presentation With Synched Audio)*
- 1:42 – 1:47** Natural Progression Of High-Risk Chronic Limb Threatening Ischemia (CLTI): The CLariTI Study: How Can Deep Vein Arterialization (DVA) And Pedal Loop Revascularization Alter This Progression  
*Anahita Dua*
- 1:48 – 2:04** **Panel Discussion**

SESSION 20 (Trianon Ballroom, 3rd Floor)

## MORE HOT NEW TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT

**Moderators:** *Vincent I. Rowe*  
*Patrick J. Geraghty*

- 2:04 – 2:09** Ten Golden Rules To Train Vascular Surgeons In Distal Bypass Procedures In 2022  
*Francesco Spinelli*
- 2:10 – 2:15** Free Tissue Flap Transfer For CLTI With Deep Venous Arterialization: Indications, Precautions And Results  
*John M. Felder*  
*Patrick J. Geraghty*
- 2:16 – 2:21** New Developments In How To Determine High Risk Stents And Bypass Grafts For Post Procedural Thrombosis: Selective Anticoagulation To Prevent Such Thrombosis  
*Anahita Dua*
- 2:22 – 2:27** Near Infrared Spectroscopy (NIRS) For Real-Time Monitoring Of Deep Tissue Oxygenation During Peripheral Angioplasty For CLTI Treatment: Intra-Procedural Value And Follow-Up Results  
*Konstantinos Katsanos*
- 2:28 – 2:33** Feasibility And Utility Of Pedal Acceleration Time (PAT) As A Novel Assessment Tool For Limb Ischemia And Adequacy Of Revascularization Procedures  
*Vincent I. Rowe*

**2:34 – 2:39** What Are The Best Ways To Evaluate CLTI Treatment Outcomes: Physiology, Wound Healing, Anatomy (Angiography Or Ultrasound), MACE Or MALE: Why It Matters

*Ido Weinberg*

*Mitchell D. Weinberg*

**2:40 – 2:45** Head To Head Comparison Of The SUPERA Interwoven Stent And Drug Eluting Stents For The Treatment Of Femoropopliteal Lesions: Advantages, Disadvantages And Specific Indications For Each

*Iris Baumgartner*

**2:46 – 2:52** **Panel Discussion**

**2:52 – 3:00** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 21 (Trianon Ballroom, 3rd Floor)

**HOT NEW SHORT SUMMARY TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE (ALL TALKS ARE 4 ¾ MINUTES)**

**Moderators:** *Neal S. Cayne*

*Gary M. Ansel*

**3:00 – 3:05** Key Steps For Success With Radial Artery Access For Remote Visceral, Renal Or Lower Extremity Lesion Treatment

*Marcelo Guimaraes*

**3:05 – 3:10** Value And Technical Tips To Make The Supera Stent Work In Curved And Angulated Non-SFA Lesion Locations

*Rajiv Parakh*

**3:10 – 3:15** Why And When Angiographic Final Evaluation Of Interventional Treatment Is Inadequate: What Else Is Needed And When

*Gary M. Ansel*

**3:15 – 3:20** How Should COVID-19 Change The Approach To Managing Acute Limb Ischemia

*Palma M. Shaw*

**3:20 – 3:25** Patient Reported Outcomes For Treatments For Intermittent Claudication: What Are They And Why Are They Important

*Jessica P. Simons*

**3:25 – 3:30** 12 Commandments For A Successful BTK Intervention In Patients With CLTI Including How To Perform An Antegrade Femoral Artery Puncture And Easily Pass The Guidewire Into The SFA

*Ali Amin*

**3:30 – 3:35** Importance Of Technical Factors In Use Of Drug Coated Balloons (DCBs): Value Of IVUS And DCB Undersizing: Are There Differences With Chronic Total Occlusions (CTOs)

*Eric A. Secemsky*

*Jihad A. Mustapha*

**3:35 – 3:40** Local Anesthetic Injection Into Lesion Site Facilitates PTA And Stent Placement: How To Do It (Video Presentation)

*Andrej Schmidt*

**3:40 – 3:45** **Panel Discussion**

**3:45 – 3:50** Value Of Tack Optimized Balloon Angioplasty In Lower Extremity Interventions: When Should They Be Used And When Not (Tacks From Intact Vascular)

*Lawrence A. Garcia*

- 3:50 – 3:55** Three-Year Results Of The Lutonix DCB BTK Trial: Final Results Of This Landmark Trial Missed Its Primary Endpoint: Among Lessons Learned Is That Duplex Lacks Sensitivity For Critical Findings: How To Improve BTK IDE Trial Design  
*Patrick J. Geraghty*
- 3:55 – 4:00** The Optimal Stent And Techniques For Treating Occlusive Lesions In Heavily Calcified Superficial Femoral Arteries  
*Hany Zayed*
- 4:00 – 4:05** How Best To Use DCBs To Treat Femoro-Popliteal Lesions  
*Fabrizio Fanelli*
- 4:05 – 4:10** What Is Small Artery Disease (SAD) Below The Ankle: With CLTI How Should This Be Treated: With Or Without DEBs  
*Marianne Brodmann* (PowerPoint Presentation With Synched Audio)
- 4:10 – 4:15** Heel Ulceration And Ischemic Gangrene Involving The Achilles Tendon Should Not Be An Indication For A BTK Amputation: How To Save Such A Limb  
*Mark G. Davies*
- 4:15 – 4:20** Popliteal Artery-To-Distal Bypass For Limb Salvage: Current Status, Technical Tips And Value: When Is It Better Than Endovascular Treatments  
*Francesco Spinelli*
- 4:20 – 4:25** Hybrid Lower Extremity Revascularizations: When And Why Are They Better Than Endo Approaches  
*Joseph S. Giglia*
- 4:25 – 4:30** **Panel Discussion**
- SESSION 22 (Trianon Ballroom, 3rd Floor)  
MORE HOT NEW SHORT SUMMARY TOPICS RELATED TO LOWER EXTREMITY OCCLUSIVE DISEASE AND CHRONIC LIMB THREATENING ISCHEMIA (CLTI) [ALL TALKS ARE 4 ¾ MINUTES]  
**Moderators:** *Brian G. DeRubertis*  
*Lawrence Garcia*
- 4:30 – 4:35** CLTI Is A Global Epidemic; How Can A CLTI Program Decrease Its Morbidity  
*Barry T. Katzen*
- 4:35 – 4:40** Technical Tips For Open Tibial And Pedal Artery Exposures And Open Venous Exposures For Deep Venous Arterialization  
*William P. Robinson*
- 4:40 – 4:45** Bare Metal Stents (BMSs) Still Have A Role In The Superficial Femoral Artery (SFA): In Precisely What Circumstances  
*Lawrence A. Garcia*
- 4:45 – 4:50** Intravascular Lithotripsy And DCB Versus DCB Alone In The Treatment Of Infrapopliteal Lesions In Diabetics: The Rationale And Design Of The DEBATE-BTK SHOCK RCT  
*Francesco Liistro*
- 4:50 – 4:55** How To Size Lower Extremity Target Arteries For Endo Treatments Accurately Using Intravascular Ultrasound (IVUS): Why It Is Important  
*Jos C. van den Berg*
- 4:55 – 5:00** Lower Extremity Interventions (PTA, Stents, Atherectomy) Under IVUS Guidance: Its Costs, Value And Limitations  
*Ignacio Escotto*

- 5:00 – 5:05** **Panel Discussion**
- 5:05 – 5:10** Best Treatment For Heavily Calcified Occlusive Lesions And When Are Re-Entry Devices Needed With Retrograde Recanalizations: Tips On How To Use Them  
*Erwin Blessing*
- 5:10 – 5:15** Knowing When Not To Do A Major Amputation After All Possibilities Are Exhausted: Understanding How Bias Affects Your Professional Decision-Making  
*Robert B. McLafferty*
- 5:15 – 5:20** How To Do Bypass Surgery To Heavily Non-Compressible Calcified Target Arteries  
*Enrico Ascher*  
*Frank J. Veith*
- 5:20 – 5:25** Early Failure Of Endovascular Treatment Of Tibial Disease With CLTI Is Associated With Increased Amputation Rates: How Can It Be Predicted And Is A Primary Open Bypass A Solution  
*Mark G. Davies*
- 5:25 – 5:30** 2-Year Results With Sirolimus Coated Drug Eluting Stents (DESs) For Fempop Lesions: The ILLUMINA Trial  
*Andrea Kahlberg*
- 5:30 – 5:35** Contemporary Comparative Results Of BTK Open Bypass Revascularization: Heparin Bonded PTFE Grafts Versus In Situ Or Reversed Vein Grafts: When Are PTFE Grafts To Tibial/Peroneal Arteries Worthwhile  
*Carlo Pratesi*  
*Giovanni Pratesi*
- 5:35 – 5:40** Distal Bypasses Under Nerve Block Without General Anesthesia Improves Results Of Bypasses For CLTI  
*Nobuyoshi Azuma*
- 5:40 – 5:45** Techniques For Overcoming Problems With Subintimal Angioplasty For Chronic Total Occlusions (CTOs): Like Inability To Re-Enter The True Lumen: Fancy Gadgets (Outback, Pioneer, Enteer, OffRoad) Are Almost Never Needed  
*Ali Amin*

## WEDNESDAY, NOVEMBER 16, 2022

- 6:00 A.M.** General Registration – Rhinelander Gallery, 2nd Floor  
*Michael S. Conte*
- 6:00 A.M. – 6:05 A.M.** Faculty Registration – Pharmacy Suite West, 2nd Floor
- 6:15 A.M.** Continental Breakfast – Rhinelander Gallery, 2nd Floor  
End of Program C

### CONCURRENT WEDNESDAY PROGRAMS

PROGRAM D: (SESSIONS 23-30)

**Progress In Lower Extremity Occlusive Disease And Its Treatments**

6:40 A.M. – 6:02 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM E: (SESSIONS 31-38)

**New Developments In Medical Treatments And New Drugs;**

**Progress In Anti-Atherogenic And Anti-Hypertensive**

**Treatments; Management Of Endoleaks; Recorded Live Cases**

**From Leading Centers In The US And EU; Issues Of Interest;**

**Outpatient And Office Based Vascular Treatment; Topics**

**Related To Government, Reimbursement, The SVS, VQI, FDA,**

**Guidelines, Trials And Evidence Based Medicine**

6:40 A.M. – 6:05 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM F: (SESSIONS 39-46)

**More New Developments In Thoracic Aortic Disease, TEVAR, Aortic Dissections, TAAAs, Juxta- And Pararenal AAAs, Parallel Grafts, Fenestrated And Branched EVAR (F/B/EVAR), Multilayer Bare Stents, Infrarenal AAAs And Standard EVAR, And Hot New Aortic And Carotid Topics**

6:50 A.M. – 6:10 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM D (SESSIONS 23-30)

**PROGRESS IN LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT**

Grand Ballroom East, 3rd Floor

SESSION 23 (Grand Ballroom East, 3rd Floor)

**GENERALITIES IN THE ENDOVASCULAR AND OPEN TREATMENT OF LOWER EXTREMITY OCCLUSIVE DISEASE AND CLTI (5 AND 4¾-MINUTE SHORT SUMMARY [SS] TALKS)**

**Moderators:** *Enrico Ascher*  
*Andrej Schmidt*

- 6:40 – 6:45** How Do Prior Endovascular Interventions Affect Future Lower Extremity Bypass Outcomes For CLTI  
*Ramesh K. Tripathi*
- 6:46 – 6:51** Do Diabetic Patients With CLTI And Substantial Foot Necrosis Have Time For An Endovascular First Strategy: Why Primary Open Bypass Treatment Is Better  
*Katariina M. Noronen*
- 6:52 – 6:57** Presenting Symptoms Of Lower Extremity Occlusive Disease And Intermittent Claudication In Women: How Do They Differ From Those In Men  
*Linda M. Harris*
- 6:58 – 7:03** Selective Coronary Revascularization Based On Preop CT Fractional Flow Reserve (FFR<sub>CT</sub>) Improves 3-Year Survival Of CLTI Patients After Revascularization: Are Current Cardiac Evaluation Guidelines Out Of Date  
*Christopher K. Zarins*  
*Dainis K. Krievins*
- 7:04 – 7:09** Small Artery Disease (SAD), Medial Artery Calcification (MAC) And Below The Ankle (BTA) Disease: Major Causes Of CLTI With A Poor Prognosis: How Are They Best Treated Endovascularly  
*Roberto Ferraresi*

**OPTIMAL TECHNIQUES FOR VESSEL PREP FOR ENDOVASCULAR TREATMENTS**

- 7:10 – 7:15** [SS] Optimal Different Techniques Of Vessel Prep For Plain Old Balloon Angioplasty (POBA), Drug Coated Balloon (DCB) Treatment And Drug Eluting Stent (DES) Treatment  
*Fabrizio Fanelli*
- 7:15 – 7:20** [SS] Technical Tips For Vessel Prep Before DCBs And DESs: It Is Different And Not Simple  
*Erwin Blessing*
- 7:20 – 7:25** Tips And What Is New For Safe Radial Access For Renal/Visceral And Lower Extremity Interventions: How Far Distally In The Leg Can Lesions Be Treated  
*Craig M. Walker*

**7:26 – 7:31** What Are The Downsides To Trans-Radial Or Pedal Access  
*Gary M. Ansel*

**TECHNICAL TIPS ON GUIDEWIRE CHOICE AND USAGE**

**7:32 – 7:37** [SS] Tips For Treating Difficult BTK/BTA Lesions: How To Get A Guidewire Across A Long Calcified Occlusion And Getting A Resistant Balloon To Go Over The Wire  
*Marco G. Manzi*

**7:37 – 7:42** [SS] Guidewire Tips For Treating BTK And Crural Artery Lesions  
*Craig M. Walker*

**7:42 – 7:47** [SS] Guidewire Tips For Treating Lesions Below The Ankle (BTA): Sliding, Piercing, Dissecting, Retrograde Maneuvers  
*Roberto Ferraresi*

**7:47 – 7:53** **Panel Discussion**

SESSION 24 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN ATHERECTOMY, STENTS (UNCOATED, COATED AND BIORESORBABLE) [ALL TALKS ARE 5 MINUTES]**

**Moderators:** *Craig M. Walker*  
*Iris Baumgartner*

**PROGRESS IN ATHERECTOMY**

**7:53 – 7:58** New Developments In Laser Atherectomy: What Makes It Different: When Is It Beneficial With Certainty  
*George L. Adams*

**7:59 – 8:04** Index Atherectomy Interventions For Intermittent Claudication Are Associated With Higher Reintervention Rates Than Other Endovascular Treatments: Is This Device Specific  
*Caitlin W. Hicks*

**8:05 – 8:10** Update On Optical Coherence Tomography (OCT) Guided Atherectomy (Pantheris) For In Stent Restenosis (ISR): Why It Is More Effective Treatment: From The INSIGHT Trial  
*Todd R. Vogel*

**8:11 – 8:16** Current Role Of Atherectomy In Treating Lower Extremity CLTI: A Vascular Surgeon's View  
*James F. McKinsey*

**UPDATE ON THE SUPERA STENT**

**8:17 – 8:22** Update On The Advantages Of The Supera Vasculomimetic (VMI) Stent For Treating Long Complex Fempop Occlusive Lesions: Is There Value To DCB Vessel Prep First  
*Peter C.J. Goverde (PowerPoint Presentation With Synched Audio)*

**8:23 – 8:28** The Supera Interwoven Stent: When Is It The Best Treatment And How To Optimally Deploy This Unique Stent  
*D. Christopher Metzger*  
*Craig M. Walker*

**DRUG ELUTING STENTS (DESs) FOR BTK LESIONS**

**8:29 – 8:34** Updated 10-Year Experience With Everolimus DESs To Treat Long Infrapopliteal Lesions Causing CLTI: Indications, Results, Value And Limitations  
*Robert A. Lookstein*

- 8:35 – 8:40** Bioresorbable Everolimus DESs To Treat BTK Lesions Causing CLTI: Promising Results Up To 5-7 Years: From The DISAPEAR Registry And A Meta-Analysis Of The Absorb Stent From Abbott  
*Steven Kum*  
*Ramon L. Varcoe*
- 8:41 – 8:46** An Update Of Long-Term Outcomes For Drug-Eluting Resorbable Scaffolds Below-The-Knee (BTK) And Progress Of The LIFE-BTK Trial With The Esprit Stent From Abbott  
*Ramon L. Varcoe*  
*Sahil A. Parikh*  
*Brian G. DeRubertis*
- 8:47 – 8:52** Update On A 3-French Compatible Microstent (From Micro Medical) For Antegrade Or Retrograde Insertion To Treat Tibial Artery Lesions: The STAND And HEAL Trials  
*Robert E. Beasley*
- 8:53 – 9:00** **Panel Discussion**

SESSION 25 (Grand Ballroom East, 3rd Floor)

LOWER EXTREMITY TOPICS RELATED TO THE DRUG COATED DEVICES CAUSING INCREASED MORTALITY CONTROVERSY: DO PACLITAXEL COATED DEVICES CAUSE INCREASED MORTALITY: DEB AND DES ALTERNATIVES TO PACLITAXEL AND RELATED ISSUES

**Moderators:** *Kenneth Ouriel*  
*Sahil A. Parikh*

- 9:00 – 9:05** Older And More Recent Meta-Analyses Still Reveal An Increased Mortality Signal In Patients Receiving Paclitaxel Coated Devices Compared To Uncoated Devices: The More Recent Study Of DCBs In BTK Arteries Showed Increased Mortality And Amputation Rates After Only 1 Year  
*Konstantinos Katsanos*
- 9:06 – 9:11** An Update Of The Real-World Evidence Evaluating Paclitaxel Coated Device Safety In Treating Fempop And Crural Artery Lesions: The SAFE-PAD Study  
*Eric A. Secemsky*
- 9:12 – 9:17** The Paclitaxel Increased Mortality Effect Reported By Dr. Katsanos et al. Seems Not To Be Confirmed By Added Data: Let's Put 4 Years Of Frenetic Activity Into Perspective  
*Peter A. Schneider*
- 9:18 – 9:23** Large Population Based German Multicenter Study Of Paclitaxel Coated BTK DCBs And DESs Indicates Decreased Mortality And Amputation Rates Compared To Uncoated Devices  
*Christian A. Behrendt* (PowerPoint Presentation With Synched Audio)
- 9:24 – 9:29** The SWING Study: First In Human Use Of A Sirolimus DCB In Arteries Below-The-Knee  
*Ramon L. Varcoe*  
*Andrew Holden*  
*Peter A. Schneider*
- 9:30 – 9:35** Alternatives To Paclitaxel Coated Devices For Limiting Intimal Hyperplasia After Treatment: Sirolimus Coating, Bioresorbables And Adventitial Drug Delivery With The Bullfrog Device: How Do Paclitaxel And Limus Drugs Work And How Do They Differ  
*William A. Gray*



- 9:36 – 9:41** Progress And Problems With A Sustained Release Limus DCB: 3-Year Results With The Magic Touch DCB: From The SIRONA Study  
*Dierk Scheinert*  
*Thomas Zeller*
- 9:42 – 9:47** The Light And Darkness Of Fluoropolymer-Based Limus DESs In The Treatment Of Femoropopliteal Lesions  
*Marianne Brodmann* (PowerPoint Presentation With Synched Audio)
- 9:48 – 9:53** Key New Developments In Endovascular Treatments For CLTI  
*Sahil A. Parikh*
- 9:54 – 9:59** Are DESs Ever Associated With Aneurysmal Degeneration: Is It Related To The Drug (Paclitaxel Or Limus) Or To The Fluoropolymer Excipient To Which The Drug Is Attached  
*Theodosios Bisdas*
- 10:00–10:08** **Panel Discussion**
- 10:08–10:18** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 26 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN DRUG COATED BALLOONS (DCBs) AND DRUG ELUTING STENTS (DESs): UPDATES ON RANDOMIZED CONTROLLED TRIALS (RCTs) AND BTK LESION TREATMENTS WITH DCBs AND DESs

*Moderators: Joseph L. Mills*  
*John R. Laird*

*NEW INFORMATION ON DCBs AND DESs FOR FEMPOP LESIONS: UPDATES ON RCTs*

- 10:18–10:23** Cost Effectiveness Analysis Of Drug Eluting Technologies For Femoropopliteal Lesions Show That They Are Worth The Increased Device Costs  
*Stefan Müller-Hülsbeck*
- 10:24–10:29** Stellarex (Philips) DCBs With Low Dose Paclitaxel Is Safe And Has Higher Patency Rates Than POBA With Fempop Lesions At 5 Years In The ILLUMENATE US And European RCTs: There Was No Paclitaxel Mortality Signal  
*Sean P. Lyden*  
*Marianne Brodmann*  
*Sahil A. Parikh*  
*William A. Gray*
- 10:30–10:35** Pooled Data From The In.Pact RCT And Real World DCB Trials For SFA-Pop Lesions Show Safety And Efficacy For 5 Years Compared To POBA: Will The Advantage Of DCBs Diminish With Time  
*Peter A. Schneider*  
*John R. Laird*  
*Thomas Zeller*
- 10:36–10:41** New Findings From The DRASTICO Study Comparing DESs To DCBs For Fempop Lesions: 5-Year Results With TASC A/B Lesions Versus TASC C/D Lesions  
*Francesco Liistro*
- 10:42–10:47** Value Of In.Pact DCBs For Long Complex SFA-Pop Lesions Including ISR And CTOs: Technical Tips And Contraindications: From The Global Registry: What Is The Best Endo Treatment For These Lesions  
*Gunnar Tepe*  
*Marianne Brodmann*

- 10:48-10:53** Update On The Randomized Head To Head Comparison Of In.Pact (Medtronic) And Ranger (Boston Scientific) DCBs For Complex SFA Lesions: 2-Year Results Of The COMPARE RCT: Similar Results With Different Paclitaxel Dosages  
*Dierk Scheinert*  
*Sabine Steiner*
- 10:54-10:59** Update On The Global RANGER II RCT Comparing Ranger DCBs With POBA: How Does It Help Us Determine The Best Treatment For Long Complex ATK Lesions  
*Marianne Brodmann* (PowerPoint Presentation With Synched Audio)
- 11:00-11:05** New Information On The Safety And Effectiveness Of The Cook Zilver PTX DES Based On Global Trials Including A RCT: When Is It The Best Treatment  
*Michael D. Dake*
- 11:06-11:11** 2-Year Results Of The IMPERIAL RCT Head To Head Comparison Of The Zilver PTX DES (Cook) With The Eluvia DES (Boston Scientific): Both Are Safe And Effective: Is There A Difference  
*Stefan Müller-Hülsbeck*  
*William A. Gray*  
*Thomas Zeller*
- 11:12-11:18** **Panel Discussion**  
  
**NEW INFORMATION ON BTK DCBs AND DESs**
- 11:18-11:23** Advances In BTK Drug Delivery Technology And DCBs: What Have We Learned From The In.Pact Deep BTK DCB Trial And New Challenges With Treating CLTI Patients  
*Thomas Zeller*
- 11:24-11:29** The Sirolimus DCB BTK Era Begins – Current Experience With The SolutioN DEB And Design Of The SELUTION SLR .014 BTK IDE Trial: Early Results From Singapore And Europe  
*Patrick J. Geraghty*
- 11:30-11:35** Orbital Vessel Preparation To Maximize DCB Efficacy In Calcified BTK Lesions: OPTIMIZE BTK RCT 1-Year Results  
*Thomas Zeller*
- 11:36-11:41** 3-Year Results From The AcoArt II BTK DCB RCT Show Safety With No Increased Mortality And Improved Patency Versus POBA  
*Wei GUO* (PowerPoint Presentation With Synched Audio)  
*Francesco Liistro*
- 11:42-11:47** Why Some BTK DCB Trials Have Not Shown Uniformly Better Results: Technical And Balloon Factors Matter  
*Francesco Liistro*
- 11:48-11:53** Update On The SAVAL Trial With A Self-Expanding DES (From Boston Scientific) For BTK Occlusive Lesions  
*Miguel F. Montero*  
*Jihad A. Mustapha*
- 11:54-12:00** **Panel Discussion**
- 12:00- 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 27 (Grand Ballroom East, 3rd Floor)

PROGRESS IN EXOTIC AND EXTREME NEW TREATMENTS FOR VERY DISTAL LOWER EXTREMITY DISEASE CAUSING ADVANCED CLTI: HOW TO SAVE THE “NO OPTION FOR TREATMENT” LIMB OR THE “DESERT FOOT” WITH NO PATENT TARGET ARTERIES

**Moderators:** *Joseph L. Mills*  
*Marco G. Manzi*  
*Hasan H. Dosluoglu*

**1:00 – 1:05** No Option CLTI: What Is It: What Are The Actual Options For Treatment  
*Hisham Rashid*

**1:06 – 1:11** Contemporary Survival After Below-Knee Amputation (BKA), Above-Knee Amputation (AKA), Bilateral Amputations For Trauma; For Vascular Disease: It Is Definitely Worthwhile Saving Limbs Especially In Vascular Patients  
*Philip P. Goodney*

**VALUE OF PROSTHETIC (PTFE) TIBIAL BYPASSES**

**1:12 – 1:17** Value Of Spliced Vein Grafts Versus PTFE Grafts For Bypasses When A Single Autologous Vein Is Inadequate  
*Joseph L. Mills*

**1:18 – 1:23** PTFE Tibial And Peroneal Artery Bypasses Can Save No Option Limbs Which Would Otherwise Require Amputation: They Have Worthwhile Long-Term Patency Rates And Limb Salvage Rates  
*Hasan H. Dosluoglu*  
*Gregg S. Landis*  
*Richard F. Neville*  
*Enrico Ascher*  
*Frank J. Veith*

**1:24 – 1:29** PTFE Tibial And Peroneal Bypasses: Cases With Ultra-Long-Term Patency And Limb Salvage Prove Their Value When There Are No Other Options: Why Do They Work For Some Surgeons But Not Others  
*Gregg S. Landis*  
*Richard F. Neville*  
*Hasan H. Dosluoglu*  
*Frank J. Veith*

**1:30 – 1:35** For Patients Facing Amputation With No Endo Options Or Useable Vein, PTFE Tibial Bypasses Are A Worthwhile Option That Yields Acceptable Mid-Term Patency And Long-Term Limb Salvage Rates  
*R. Clement Darling III*

**1:36 – 1:41** Current Outcomes With PTFE Bypasses To Infrapopliteal (Tibial) Targets: Is There Variability Between Surgeons And Institutions  
*Matthew T. Menard*

**UPDATE ON FOOT VEIN ARTERIALIZATION FOR CLTI**

**1:42 – 1:47** Role And Value Of Vein ArterIALIZATION: Best Way To Do It And Long-Term Results: From The Pioneer  
*Pramook Mutirangura*

**1:48 – 1:53** Pathophysiology Of Venous ArterIALIZATION And Neo Angiogenesis For No Option CLTI: How To Predict When It Will Work And When It Won't: What Is The Medial Arterial Calcification (MAC) Score And Its Significance  
*Roberto Ferraresi*

- 1:54 – 1:59** Pivotal US Trial (PROMISE II), US Feasibility Study (PROMISE I) And European 2-Year Registry Results With Deep Vein Arterialization With The LimFlow Device For CLTI With Gangrene Shows Reasonable Limb Salvage And Wound Healing  
*Daniel G. Clair*  
*Andrej Schmidt*  
*Daniela Branzan*
- 2:00 – 2:05** How To Perform The LimFlow Procedure: Equipment Required And Technical Tips  
*Miguel F. Montero*
- 2:06 – 2:11** Deep Vein Arterialization And Valve Lysis By Surgical Means For No Option Desert Feet With Gangrene: How To Do It And Results  
*Richard F. Neville*
- 2:12 – 2:18** **Panel Discussion**

SESSION 28 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN STENTS; PROSTHETIC GRAFTS; ENDOVASCULAR BYPASSES; STENT GRAFTS AND TREATMENT OF IN STENT RESTENOSIS (ISR)**

**Moderators:** *Linda M. Harris*  
*Mark A. Adelman*

- 2:18 – 2:23** Why The BioMimics 3D Stent Should Be The Treatment Of Choice In Complex Patients And Lesions  
*Peter A. Gaines*  
*Michael K. W. Lichtenberg*

**ARTERIAL PTFE BYPASSES**

- 2:24 – 2:29** RCT Comparing Heparin Bonded PTFE (Propaten) Grafts With Plain PTFE Grafts For BTK CLTI Bypasses: Is Heparin Bonding Helpful  
*Yann Gouëffic*
- 2:30 – 2:35** Hybrid Fluoroscopically Guided Improved Method For Restoring Patency To Occluded PTFE Bypasses: It's Less Invasive And More Effective  
*Neal S. Cayne*  
*Frank J. Veith*

**PERCUTANEOUS BYPASSES**

- 2:36 – 2:41** Percutaneous (PQ) Transvenous Fempop PTFE Bypasses With The Torus 2 Device (Now From Endologix): How It Works And Status Of The DETOUR And TORUS Trials In The US: 1-Year Results  
*Sean P. Lyden*  
*Daniel G. Clair*  
*Peter A. Schneider*
- 2:42 – 2:47** 4-Year Results Of The Detour PQ Fempop Arterial Bypass Routed Through The Femoral Vein: Will It Make Open Bypass Obsolete  
*Dainis K. Krievins*
- 2:48 – 2:53** A Novel Technique For Percutaneous Extravascular Fempop Bypass - Routing A PTFE Graft Through The Soft Tissue Of The Thigh: It Is A Transcatheter Technique That Is Clampless, Sutureless And Without External Exposure: How Does It Work And Results  
*Pierre G. Sarradon*  
*Jean-Pierre Becquemin*
- 2:54 – 2:58** **Panel Discussion**

NEW INFORMATION ON STENT-GRAFTS

- 2:58 – 3:03** Can Viabahn Stent-Grafts Be Used Safely And Effectively In The SFA For CLTI: From Pooled Multicenter Data: What Are The Limitations Of These Devices  
*Michel M.P. Reijnen*
- 3:04 – 3:09** How Can IVUS Improve Outcomes When Self-Expanding Stent-Grafts (Viabahn) Are Used To Treat SFA Occlusive Lesions  
*Eric A. Secemsky*
- 3:10 – 3:15** Advantages, Limitations And Results Of Gore VBX BE Stent-Graft For Occlusive Disease In Various Vascular Beds And For F/B/EVAR Branches  
*Rocco Giudice*  
*Ciro Ferrer*

TREATMENT OF IN STENT RESTENOSIS (ISR)

- 3:16 – 3:21** Laser Atherectomy May Facilitate Endovascular Treatment Of ISR But Does Not Provide Long-Term Benefit: How Should ISR Be Treated  
*Russell H. Samson*
- 3:22 – 3:27** The Excimer Laser For Treating ISR: It Has A Role In Crossing And Debulking Difficult Lesions: Technical Tips  
*Craig M. Walker*
- 3:28 – 3:33** How Best To Treat Long Difficult Complex SFA Lesions Including Those From ISR  
*Sonia Ronchey*
- 3:34 – 3:46** **Panel Discussion And Break**  
**(Visit Exhibits And Pavilions – 2nd and 3rd Floors)**

SESSION 29 (Grand Ballroom East, 3rd Floor)

LOWER EXTREMITY TRIALS; GUIDELINES; FOOT PERFUSION EVALUATION METHODS AND VALUE OF ANGIOSOMES

Moderators: *Mark K. Eskandari*  
*Jacques Busquet*  
*Frank J. Veith*

- 3:46 – 3:51** The Japanese SPINACH Registry Shows Why WifI Wound Severity Helps To Select Open Versus Endovascular Treatment And Predicts Patient Survival  
*Nobuyoshi Azuma*
- 3:52 – 3:57** The New Global Vascular Guidelines And WifI Staging For CLTI Are Better Than Obsolete TASC Guidelines Because Treatment Recommendations, Revascularization Strategies And Needs For The Future Are Not Based On Lesion Anatomy But Are Nuanced By Other Factors: What Are They  
*Michael S. Conte*
- 3:58 – 4:03** The Main Outcomes Of The BEST-CLI RCT Comparing Endovascular And Open Treatment Of Lower Extremity Ischemia: Limitations And What Will Be Its Value  
*Alik Farber*  
*Matthew T. Menard*  
*Kenneth Rosenfield*

**4:04 – 4:13 Panel Discussion On Meaning And Significance Of Best-CLI Results**

Panelists: *Marianne Brodmann*  
*Michael S. Conte*  
*Matthew T. Menard*  
*Kenneth Rosenfield*

**METHODS FOR EVALUATING FOOT PERFUSION**

**4:13 – 4:18** Value Of Perfusion Assessment Of The CLTI Foot Before Treatment And For Quality Control After Revascularization: How Best To Do It  
*Maarit Venermo*

**4:19 – 4:24** How And Why To Measure Foot Perfusion During Endo Treatments: Hyperspectral Imaging, O2 Sensors, etc: When Is The Angiosome Concept Helpful; When Not  
*Marianne Brodmann* (PowerPoint Presentation With Synched Audio)

**4:25– 4:30** New Methods For Evaluating Lower Extremity Arterial Lesions And Foot Perfusion Using Fractional Flow (FFR) And MRI; How They Work And Their Value In Assessing Therapeutic Success  
*Bijan Modarai*

**4:31 – 4:36** Pedal Arch Patency Is Key To Predicting Limb Salvage With Endovascular Treatment For CLTI With Tissue Necrosis: How Is It Best Evaluated  
*Hasan H. Dosluoglu*  
*Linda M. Harris*

**4:37 – 4:42** Foot Perfusion Measurements Are Invaluable In CLTI And Predicting Amputation Healing: They Also Show Why Open Bypasses Are Often Better Than Endovascular Treatments  
*Werner Lang*

**4:43 – 4:48 Panel Discussion**

SESSION 30 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND ACUTE LIMB ISCHEMIA**

Moderators: *Michael S. Conte*  
*Matthew T. Menard*

**INTERMITTENT CLAUDICATION (IC)**

**4:48 – 4:53** **DEBATE:** A RCT After 2 Years Shows That Stent Treatment For Intermittent Claudication (IC) Improves Quality Of Life More Than Medical Treatment And Exercise And Is Cost Effective  
*Hans Lindgren*

**4:54 – 4:59** **DEBATE:** Interventions For IC Are Safe But Lead To Greater Decreased Function And Increased Limb Loss  
*Jeffrey J. Siracuse*

**5:00 – 5:05** Overuse Of Vascular Interventions For IC Is A Measure Of Poor Care: How Is This Determined  
*Caitlin W. Hicks*  
*James H. Black, III*

**5:06 – 5:11** Endovascular Interventions For IC: At 2 Years Only 32% Are Free From IC Recurrence: What Factors Decrease This Recurrence Rate: From A VQI Study  
*Karen Woo*  
*Peter F. Lawrence*  
*Michael S. Conte*  
*Adam Beck*  
*Mark L. Schermerhorn*

- 5:12 – 5:16** **Panel Discussion**  
*ACUTE LIMB ISCHEMIA (ALI) (See Also Session 63)*
- 5:16 – 5:21** Key Points From The 2020 New European Guidelines For Diagnosis And Treatment Of ALI In The Upper And Lower Limbs: When To Use Which Treatments: How Have These Guidelines Been Modified Recently  
*Martin Björck*
- 5:22 – 5:27** Update On Thrombosuction Devices For Treating ALI: Which Device In Which Circumstance: Advantages And Limitations  
*Athanasios Katsargyris*  
*Eric L.G. Verhoeven*
- 5:28 – 5:33** Endovascular Mechanical Thrombectomy Is Obviating The Need For Thrombolytics In ALI: Which Device Is Best – When And Why  
*Patrick E. Muck*
- 5:34 – 5:39** Percutaneous Vacuum Thrombectomy For ALI: Devices And Techniques: In 2022 What Is The Residual Role For Thrombolytics And Open Balloon Catheter Thrombectomy  
*Scott L. Stevens*
- 5:40 – 5:45** Penumbra Indigo Clot Aspiration System: What Makes It Different: Indications And Contraindications: What Is New In 2022  
*James F. Benenati*
- 5:46 – 5:51** Value And Technical Tips For Using The Indigo Clot Removal System Before And After Treating ISR And Other Lesions With Balloon And Stents  
*Frank R. Arko*
- 5:52 – 5:57** How To Treat ALI Under Duplex Ultrasound Guidance: Advantages And Limitations  
*Natalie A. Marks*  
*Enrico Ascher*
- 5:58 – 6:02** **Panel Discussion**  
**End of Program D**

PROGRAM E (SESSIONS 31-38)

NEW DEVELOPMENTS IN MEDICAL TREATMENTS AND NEW DRUGS; PROGRESS IN ANTI-ATHEROGENIC AND ANTI-HYPERTENSIVE TREATMENTS; MANAGEMENT OF ENDOLEAKS; RECORDED LIVE CASES FROM LEADING CENTERS IN THE US AND EU; ISSUES OF INTEREST; OUTPATIENT AND OFFICE BASED VASCULAR TREATMENT; TOPICS RELATED TO GOVERNMENT, REIMBURSEMENT, THE SVS, VQI, FDA, GUIDELINES, TRIALS AND EVIDENCE BASED MEDICINE

Grand Ballroom West, 3rd Floor

SESSION 31 (Grand Ballroom West, 3rd Floor)

ADVANCES IN MEDICAL TREATMENTS, NEW ANTI-ATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIs IN VASCULAR SURGERY PATIENTS

**Moderators:** *Caron B. Rockman*  
*Ido Weinberg*

- 6:46 – 6:51** New Information From The VOYAGER And COMPASS Trials With Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin: How Does It Help In The Management Of Patients With Arterial And Venous Disease: With And Without Kidney Disease And With And Without Statins  
*Marianne Brodmann (PowerPoint Presentation With Synched Audio)*
- 6:52 – 6:57** New Strategies On How To Avoid And Treat Perioperative Myocardial Infarctions (MIs) In Open Vascular Surgery Patients  
*Peter Henke*
- 6:58 – 7:03** Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins  
*J. David Spence (PowerPoint Presentation With Synched Audio)*
- 7:04 – 7:09** **DEBATE:** LDL-C Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show  
*Sherif A.H. Sultan*
- 7:10 – 7:15** **DEBATE:** Not So: Update On LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients' Risk Of MI And Death  
*Ron Waksman*
- 7:16 – 7:21** Low Dose Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin Improve Survival And Decrease Major Adverse Limb Events (MALE) After Endo And Open Treatments For PAD/CLTI: From The VOYAGER RCT: What Does The XATOA Prospective Registry Add  
*Sebastian E. Debus*  
*Marianne Brodmann*
- 7:22 – 7:27** How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials  
*Anthony J. Comerota (PowerPoint Presentation With Synched Audio)*
- 7:28 – 7:33** New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimibe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For  
*Richard Bulbulia*
- 7:34 – 7:42** **Panel Discussion**

SESSION 32 (Grand Ballroom West, 3rd Floor)

CATHETER BASED TREATMENTS OF RESISTANT HYPERTENSION; MANAGEMENT OF CARDIAC PROBLEMS, SMOKING AND TRANSFUSION IN VASCULAR SURGERY PATIENTS; MORTALITY RISK IN STROKE PATIENTS; VASCULAR AND CARDIAC COMPLICATIONS OF COVID-19

**Moderators:** *Ron Waksman*  
*Michael R. Jaff*



UPDATE ON RENAL DENERVATION FOR  
HYPERTENSION

- 7:42 – 7:47** Current Status Of Renal Denervation For Drug Resistant Hypertension: Why The Simplicity Spyral Radiofrequency Denervation System Is Different: Status Of The SPYRAL HTN-OFF MED RCT (Versus Sham)  
*Sahil A. Parikh*
- 7:48 – 7:53** Updates On Other Methods Of Renal Denervation: Chemical (Alcohol) Infusion Via The Peregrine Catheter (Ablative Solutions) And Ultrasound Via The Paradise Catheter (ReCor Medical)  
*Horst Sievert*
- 7:54 – 7:59** Update On The Status Of Renal Denervation For Hypertension: Is It Here To Stay: Where Is It Going  
*Eric A. Secemsky*

OTHER TOPICS RELATED TO VASCULAR DISEASE AND  
ITS TREATMENT

- 8:00 – 8:05** How Does The Female Sex Impact The Occurrence Of Lower Extremity Atherosclerosis, Its Treatment And Results Of Treatment  
*Katherine A. Gallagher*
- 8:06 – 8:11** How And Why Do Thoracic Stent-Grafts For TEVAR Negatively Affect The Heart  
*Frans L. Moll (PowerPoint Presentation With Synched Audio)*
- 8:12 – 8:17** When Should Smoking Be Stopped Before AAA Repair; Before Lower Extremity Bypass: At Least 4 Weeks Because Duration Of Cessation Matters  
*Jeffrey J. Siracuse*
- 8:18 – 8:23** Limiting Transfusion And Permitting Anemia After Major Vascular Operations Increases Mortality And Serious Adverse Events Especially In Patients With Cardiac Co-Morbidities  
*Panos Kougiass*
- 8:24 – 8:29** How To Quantitate Late Mortality Risk In Asymptomatic Carotid Stenosis (ACS) Patients: Why It's Important In Decision Making And What To Do About It Other Than Treating ACS Patients Non-Invasively  
*Stavros Kakkos*  
*Andrew N. Nicolaides*
- 8:30 – 8:35** Update On Vascular Complications Of COVID-19 Infections: What Is Known And Unknown: How To Diagnose And Treat: Endo Versus Open  
*Michael E. Barfield*
- 8:36 – 8:41** Update On Cardiac Complications Of COVID-19 Infections: What Is Their Genesis: Diagnosis And Treatment  
*Roxana Mehran*
- 8:42 – 8:50** **Panel Discussion**
- 8:50 – 9:06** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 33 (Grand Ballroom West, 3rd Floor)

PROGRESS IN MANAGING ENDOLEAKS:  
UNDERSTANDING THEIR CONSEQUENCES AND  
PREDICTING, PREVENTING AND TREATING THEM

Moderators: *Timur P. Sarac*  
*Peter L. Faries*

TO TREAT OR NOT TO TREAT TYPE 2 ENDOLEAKS

- 9:06 – 9:11 Most Type 2 Endoleaks Are Benign: The Case Can Be Made That By Treating Type 2 Endoleaks The Harm And Cost Of Such Treatment Outweighs The Benefits: When If Ever Should They Be Treated: Is There A Relationship With AAA Remodeling  
*Michel M.P. Reijnen*

TREATING TYPE 1 ENDOLEAKS

- 9:12 – 9:17 Type 1A Endoleaks After EVAR: Predictability Does Not Equate To Preventability: How Are They Best Treated  
*Michael J. Singh*
- 9:18 – 9:23 When And How To Treat Type 1 Endoleaks With Embolization: Technical Tips  
*Robert A. Morgan*
- 9:24 – 9:29 When And How To Use Embolization Coils To Treat Type 1A Endoleaks Successfully: When Won't Coils Work: How To Diagnose Type 1A Endoleaks Accurately  
*Sigrid Nikol*
- 9:30 – 9:35 How To Minimize Gutter Type 1A Endoleaks With Chimney EVAR (Ch/EVAR): A Standard Protocol Helps  
*David J. Minion*
- 9:36 – 9:41 Fibrin Glue Sac Filling Technique During EVAR To Prevent All Endoleaks: It Should Be Routine And Is A Game Changer Based On A Multicenter Trial: How To Do It  
*Qingsheng Lu (PowerPoint Presentation With Synched Audio)*
- 9:42 – 9:48 **Panel Discussion**

PREVENTION OF TYPE 2 ENDOLEAKS AFTER EVAR

- 9:49 – 9:54 A RCT Shows The Advantages Of Inferior Mesenteric Artery (IMA) And Lumbar Embolization: The Next Generation Of EVAR Endografts Must Prevent Endoleaks: How Can It Be Done  
*Dominique Fabre*  
*Stephan Haulon*
- 9:55-10:00 Preventing Threatening Type 2 Endoleaks By IMA Embolization When AAA Sac And IMA Are Large: Indications And Technical Tips And Evidence  
*Toru Kuratani*
- 10:01-10:06 With A Large IMA (>3 mm), When Should It Be Embolized; When Should It Be Revascularized And Why  
*Piotr M. Kasprzak*
- 10:07-10:12 Selective Coiling Of IMA And Lumbar Arteries Decrease Harmful Type 2 Endoleaks After EVAR: When And How To Do It  
*Götz M. Richter*
- 10:13-10:19 **Panel Discussion**

TREATMENT OF TYPE 2 ENDOLEAKS AND ENDOTENSION AFTER EVAR

- 10:20-10:25 How Duplex Ultrasound Velocities In Type 2 Endoleaks Determine Behavior And Help In Treatment: Technical Tips  
*Ross Milner*

- 10:26–10:31** Glue Embolization Is Effective Treatment For Most Threatening Type 2 Endoleaks: When And How Best To Do It  
*Neal S. Cayne*
- 10:32–10:37** New Concepts In Post EVAR Endoleaks And Endotension: The Role Of Fabric Fatigue, Concealed Endoleaks And AAA Sac Hygromas: How Can These Be Detected And Best Treated  
*Sherif A.H. Sultan*
- 10:38–10:43** How To Best Leverage 3D Fusion Software (GE) To Get Into The Nidus And Treat Type 2 Endoleaks: Best Embolic Agent And Value Of Transcaval Access For Type 1 And 2 Endoleaks  
*Mark W. Mewissen*
- 10:44–10:49** Transgraft Approach To Treat Type 2 Endoleaks: Indications, Equipment, Advantages And Precautions  
*James F. McKinsey*
- 10:50–10:55** Laser Assisted Transgraft Onyx Embolization Of Type 2 Endoleaks: Indications, Equipment And Technique  
*Zvonimir Krajcer*
- 10:56–11:01** With Type 2 Endoleaks And Sac Expansion Open Sacotomy And Branch Ligation Is The Best Treatment: Why And What Precautions Are Needed To Be Sure There Is No Occult Type 1 Leak  
*Zachary M. Arthurs*
- 11:02–11:11** **Panel Discussion**

SESSION 34 (Grand Ballroom West, 3rd Floor)

**TCT AND PLINIO ROSSI RECORDED LIVE COMPLEX AND CHALLENGING ENDOVASCULAR CASES**

**TCT RECORDED LIVE CHALLENGING ENDOVASCULAR CASES**

**Moderators:** *Juan F. Granada*  
*Sahil A. Parikh*

**11:12–11:36** **PROGRAM TO BE DETERMINED**

**PLINIO ROSSI RECORDED LIVE COMPLEX AND CHALLENGING ENDOVASCULAR CASES**

**Moderators:** *Fabrizio Fanelli*  
*Andrew Holden*  
*Carlo Setacci*

- 11:36–11:48** Reconstruction Of Symptomatic And Chronically Occluded Iliac Veins And IVC (Video Presentation And Discussion)  
*Marcelo Guimaraes*

- 11:48–12:00** A Complex Below-The-Knee Occlusive Case And Management Of Multiple Complications (Video Presentation And Discussion)  
*Marco G. Manzi*

- 12:00– 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 35 (Grand Ballroom West, 3rd Floor)

**RECORDED LIVE CHALLENGING CASES AND INNOVATIVE TECHNIQUES FROM THE LINC GROUP**

**Moderators:** *Dierk Scheinert*  
*Andrej Schmidt*  
*Daniela Branzan*

**1:00 – 1:32** **PROGRAM TO BE DETERMINED**

SESSION 36 (Grand Ballroom West, 3rd Floor)

**ISSUES IMPORTANT IN VASCULAR SURGERY:  
LEADERSHIP, HISTORY, EFFICIENCY, MALPRACTICE,  
SCIENCE, TRAINING AND HUMAN BEHAVIOR**

**Moderators:** *Kim J. Hodgson*

*Dawn M. Coleman*

- 1:33 – 1:38** How To Succeed In Academic Vascular Surgery: Don't Be A Revolutionary  
*Ronald L. Dalman*
- 1:39 – 1:44** Surgeons In The Time Of Pandemics: How Does Our Current COVID Crisis For Surgeons Compare To The Plague And Guy de Chauillac In 14th Century France  
*Cynthia K. Shortell*
- 1:45 – 1:50** How To Improve Operating Room Efficiency For Vascular Surgical Operations: Why Is Inefficiency In This Setting So Widespread And Hard To Fix  
*Panos Kougias*
- 1:51 – 1:56** Patient Reported Outcomes (PROs): What Are They: Importance And Pitfalls: How Do They Differ From Patient Satisfaction  
*Christopher J. Smolock*
- 1:57 – 2:02** In A Malpractice Proceeding Or Trial What Recourse Does A Physician-Defendant Have When An Expert Witness Provides Inaccurate Or False Testimony  
*O. William Brown*
- 2:03 – 2:08** RCTs And Meta-Analyses Can Be Flawed And Biased: They Should Only Be Viewed With Other Evidence And Common Sense  
*George S. Lavenson*
- 2:09 – 2:14** Why Systematic Reviews And Meta-Analyses Can Be Misleading: What To Do About It  
*Janet T. Powell*

**ISSUES IN VASCULAR TRAINING**

- 2:15 -2:20** Optimal New Training Paradigm For Vascular Surgeons: 0+5 Vascular Surgery Residency Followed By 2 Years Of Cardiac Surgery Residency Training: Why Is It Better Than 2 Extra Years Of Laboratory Research  
*Alan B. Lumsden*
- 2:21 – 2:26** Coming Crisis In Vascular Surgical Training – In Both 5+2 And 0+5 Programs: What Can Be Done About It  
*Michael B. Silva, Jr.*
- 2:27 – 2:32** How To Remedy The Deficiency Vascular Fellows And Residents Have In Their Numbers Of Open Vascular Surgical Operations  
*Malachi Sheahan*
- 2:33 – 2:38** Negative Impact Of The COVID Pandemic On Vascular Surgical Training: How Long Will They Last  
*Jason T. Lee*
- 2:39 – 2:44** How Human Behavior Is Controlled By Biases And Rationalizations: How To Overcome These And Perform Better  
*Scott L. Stevens*
- 2:45 – 2:58** **Panel Discussion And Break**  
**Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 37 (Grand Ballroom West, 3rd Floor)

MORE ISSUE-RELATED TOPICS IMPORTANT  
TO VASCULAR SURGEONS AND VASCULAR  
SPECIALISTS; ISSUES RELATED TO OUTPATIENT  
CENTERS OR OFFICE BASED LABS (OBLs)

Moderators: Anton N. Sidawy  
Krishna Jain

- 2:58 – 3:03** The Wellness Of Vascular Surgeons: Physical And Mental: How To Monitor And Promote It: The Importance Of Intraoperative Posture  
*Samuel R. Money*
- 3:04 – 3:09** Unfilled Promises With Devices, Drugs And Treatments: Initial Hype That Is Not Fulfilled: It Is Often Hidden: More Transparency Is Needed: A Few Examples  
*Sherif A.H. Sultan*
- 3:10 – 3:15** Heart And Vascular Centers Are Artificial Entities That Disadvantage Vascular Surgeons  
*Malachi Sheahan*
- 3:16 – 3:21** Effect Of Increased Hydration And Protein Intake On Lower Extremity Arteriosclerotic Ischemia With IC And CLTI: What Is The Evidence And The Mechanism: Will It Change The Game And Decrease The Need For Stents And Bypasses  
*Juan C. Parodi (PowerPoint Presentation With Synched Audio)*
- 3:22 – 3:27** Vascular Spinoff Revenue In Tertiary Healthcare Systems: More Downstream Benefits From Vascular Surgeons: How To Make Hospital Administrators Appreciate The Value Of Vascular Surgeons  
*Joseph V. Lombardi*
- 3:28 – 3:33** The Ever Changing Reimbursement For Lower Extremity Endovascular Therapies In Hospitals And OBLs: Why It's Happening And Where Is It Going  
*Sean P. Roddy*  
*Robert M. Zwolak*
- 3:34 – 3:39** **Panel Discussion**  
**ISSUES RELATED TO OUTPATIENT CENTERS AND OBLs**
- 3:39 – 3:44** A Balanced View Of Atherectomy In Ambulatory Surgicenters (ASCs) And OBLs In 2022: Are There Differences And Is The Procedure Overused  
*Krishna Jain*
- 3:45 – 3:50** Why And How Do Outpatient Angio Suites And OBLs Fail  
*Sam S. Ahn*
- 3:51 – 3:56** How Can OBLs Provide Good Vascular Care With Excellent Results, Be Profitable And Still Allow Vascular Surgeons To Only Work From 8 AM to 5 PM  
*Mark A. Mattos*
- 3:57 – 4:02** Tips And Tricks For Performing High-Risk Lower Extremity Endovascular Procedures Safely And Successfully In An Outpatient Setting  
*Anil P. Hingorani*  
*Enrico Ascher*
- 4:03 – 4:08** OBL Audits: What Are They Looking For And How To Avoid Civil And Criminal Penalties  
*O. William Brown*
- 4:09 – 4:13** **Panel Discussion**

SESSION 38 (Grand Ballroom West, 3rd Floor)

UPDATES AND ISSUES IMPORTANT TO ALL VASCULAR SURGEONS AND SPECIALISTS: FUTURE REIMBURSEMENT; ETHICS OF FDA ACCESS; VASCULAR REGISTRIES AND THE VQI, VALUE OF GUIDELINES, ENDPOINTS; INDUSTRY RELATIONS; IMPACT OF GOVERNMENT (ACA) AND REGULATORY AGENCIES (FDA)

*Moderators: Robert M. Zwolak*

*Sean P. Roddy*

**4:13 – 4:18** What Obstacles And Blows Are Vascular Surgeons And Other Vascular Specialists Facing In 2022: Will Planned Increased Reimbursement For Office And Hospital Visits Cause Decreases In Procedural Reimbursements

*Sean P. Roddy*

**4:19 – 4:24** How Can Vascular Surgeons Identify High Risk, High-Cost Patients And Help Health Care Systems Control Costs: How To Prevent Inappropriate Treatments In These Patients

*Lee Kirksey (PowerPoint Presentation With Synched Audio)*

**4:25 – 4:30** International Consortium of Vascular Registries (ICVR) And The Use Of Real World Evidence To Evaluate Aortic Endograft Performance In Ruptured Aneurysms

*Adam Beck*

**4:31 – 4:36** The Role And Value Of Guidelines In Vascular Practice; Why Guidelines Can Be Misleading; How Should They Be Written To Not Be

*Anders Wanhainen*

**4:37 – 4:42** Non-Compliance With The SVS AAA Practice Guidelines Is Common: How Does It Impact Outcomes

*Elliot L. Chaikof*

**4:43 – 4:48** Ethics Of Limiting Access To Potentially Promising Technology: At What Point Is It Ethical To Use And Evaluate An Innovative Technology In A Patient/ Clinical Study

*Valerie M. Merkle*

**4:49 – 4:54** Managing Various Specialties And Generations Of Specialists In A Multi-Specialty Vascular Institute Or Center: How To Optimize Patient Outcomes

*Gary M. Ansel*

**4:55 – 5:00** Despite What The New York Times And Others Say, Close Relationships Of Vascular Surgeons With Industry Are Mostly Ethical And Beneficial To Patients And Society: Pitfalls To Avoid

*Bruce A. Perler*

**5:01 – 5:06** How Do Surgeons Drive Vascular Innovation: What Are The Critical Steps Leading To Success

*Jeffrey H. Lawson*

**5:07 – 5:14** **Panel Discussion**

*Moderators: Jack L. Cronenwett*

*Sean P. Roddy*

**EVIDENCE BASED MEDICINE ISSUES**

**5:14 – 5:19** Propensity Score Matching Studies: How Do They Work And What Are Their Strengths And Weaknesses

*Charles C. Miller*

- 5:20 – 5:25** Registry Based RCTs: What Are They And Why Are They Better Than Other Evidence Based Techniques  
*Jens Eldrup Jorgensen*  
*Jack L. Cronenwett*

**REGULATORY ISSUES**

- 5:26 – 5:31** Historical Perspective Over The Last 25 Years On FDA Approvals Of EVAR Devices Submitted By Investigators And Industry: Lessons Learned To Guide Future Applications  
*Dorothy B. Abel*

**JOURNAL ISSUES**

- 5:32 – 5:37** How To Get A Paper Accepted In A High Impact Journal Like The JVS: Does Bias Ever Matter  
*Peter Gloviczki*  
*Peter F. Lawrence*

**SVS, GOVERNMENT AND MEDICAL INSURANCE TOPICS**

- 5:38 – 5:43** The SVS Foundation: How Does It Serve Vascular Surgeons And Their Patients  
*Peter F. Lawrence*
- 5:44 – 5:49** Effects Of The Affordable Care Act (ACA) On Vascular Surgical Outcomes: Does The Medicaid Expansion Of The ACA Improve Outcomes Or Not  
*Mohammad H. Eslami*
- 5:50 – 5:55** If You Want Medicare For All Look At The NHS First  
*Firas F. Mussa*
- 5:56 – 6:05** **Panel Discussion**  
**End of Program E**

**PROGRAM F (SESSIONS 39-46)**

**MORE NEW DEVELOPMENTS IN THORACIC AORTIC DISEASE, TEVAR, AORTIC DISSECTIONS, TAAAs, JUXTA- AND PARARENAL AAAs, PARALLEL GRAFTS, FENESTRATED AND BRANCHED EVAR (F/B/EVAR), MULTILAYER BARE STENTS, INFRARENAL AAAs AND STANDARD EVAR, AND HOT NEW AORTIC AND CAROTID TOPICS**

Trianon Ballroom, 3rd Floor

SESSION 39 (Trianon Ballroom, 3rd Floor)

**MORE TOPICS RELATED TO THE THORACIC AORTA, AORTIC DISSECTIONS, INTRAMURAL HEMATOMAS (IMHs), PENETRATING AORTIC ULCERS (PAUs) AND THEIR TREATMENT**

**Moderators:** *Ramon Berguer*  
*Paulo E. Ocke-Reis*

- 6:50 – 6:55** False Lumen Thrombosis Is An Overused And Meaningless Endpoint In The Treatment Of Uncomplicated TBAD  
*Firas F. Mussa*
- 6:56 – 7:01** Acute Aortic Dissection (Type A And B) Is More Common Than We Think: From A Swedish Population Based Study: Why Are We Missing Cases And What Can Be Done About It  
*Johnny Steuer*
- 7:02 – 7:07** Value Of Stent-Grafts In Genetically Triggered Aortopathy  
*Cherrie Z. Abraham*

- 7:08 – 7:13** What Is Best Medical Treatment For TBAD Patients: How Best To Control Blood Pressure And To Get Patients To Comply: They Don't  
*Colin D. Bicknell*
- 7:14 – 7:19** Multimodular Approach To Treating Chronic TBADs With TAAAs: Who Needs A F/B/EVAR; Who Needs A Candy-Plug  
*Tilo Kölbel*  
*Fiona Rohlfjs*
- 7:20 – 7:25** **Panel Discussion**
- 7:25 – 7:30** Comparison Of The STABILISE And Petticoat Techniques For Treatment Of Acute And Subacute TBADs: Preliminary Results Suggest STABILISE Achieves Better False Lumen Obliteration  
*Igor A. Laskowski*  
*Josh B. Goldberg*  
*Heepeel Chang*
- 7:31 – 7:36** Reinterventions After TEVAR For TBADs: How To Plan For The Future At The Index Procedure And Strategies For Successful Repair In The Chronic Phase  
*Bijan Modarai*
- 7:37 – 7:42** Requirement For Adjunctive Branch Stents After TEVAR For Complicated TBADs Is An Indicator Of Poor Prognosis: What Can Be Done To Offset It  
*Mark K. Eskandari*
- 7:43 – 7:48** Update On Intramural Hematoma (IMH): The Majority Can Be Managed With Medical Treatment And Close Observation, But Some Require Urgent Intervention: Which Ones  
*Frank J. Criado*
- 7:49 – 7:54** Natural History And Optimal Treatment For Penetrating Aortic Ulcers (PAUs): When To Observe And When To Treat With TEVAR  
*Colin D. Bicknell*
- 7:55 – 8:00** **Panel Discussion**

SESSION 40 (Trianon Ballroom, 3rd Floor)

**MORE ADVANCES RELATED TO TREATING PATHOLOGY INVOLVING THE ASCENDING AORTA AND THE AORTIC ARCH; AORTIC DISSECTIONS AND THEIR TREATMENT**

**Moderators:** *Rodney A. White*  
*Joseph E. Bavaria*

- 8:00 – 8:05** The Majority Of TBAD Patients – Complicated And Uncomplicated – Require Secondary Endovascular Procedures After TEVAR: What Secondary Procedures And When  
*Götz M. Richter*
- 8:06 – 8:11** Antegrade Stent-Graft Delivery For Treating Acute Type A Dissections: When Is It Advantageous And How To Do It  
*Ourania Preventza*  
*Joseph S. Coselli*
- 8:12 – 8:17** Status Of A Catheter Aortic Septotomy Device For Treating Aortic Dissections: Why And How Should It Work As A Treatment  
*Ramon Berguer*  
*Juan C. Parodi*



- 8:18 – 8:23** Caval Balloon Occlusion: A Better Way Than Rapid Pacing To Permit Precise Stent-Graft Placement In The Proximal Aorta: How To Do It And Is It Better For The Heart  
*Nuno V. Dias*  
*Björn Sonesson*
- 8:24 – 8:29** Updated Experience For Precise TEVAR Placement In Or Near The Arch By Valsalva And PEEP: It Is Safe And Effective: Adenosine, Rapid Pacing And Caval Occlusion Are NOT Needed: How To Do It And How To Do It With A Prosthetic Aortic Valve  
*Nikolaos Tsilimparis*
- 8:30 – 8:35** **Panel Discussion**
- 8:35 – 8:40** Arch Lesion Repair With Single, Double Or 3-Branched Devices: When Is Each Best And Why: How To Do It From A Totally Femoral Approach  
*Gustavo S. Oderich* (PowerPoint Presentation With Synched Audio)
- 8:41 – 8:46** Chimney Technique For Dealing With Total Arch Lesions And Dissections: How To Make It Work, Limitations And Results  
*Ivo Petrov*
- 8:47 – 8:52** Laser Fenestrations And Total Percutaneous Techniques For Endovascular Arch Repair  
*Timothy A. Resch*
- 8:53 – 8:58** In Situ Fenestration With Life Tech Technology For Aortic Arch Aneurysms: An Alternative To Branched Graft Devices And Parallel Grafts: Results In >50 Cases And How Does The New Technology Work  
*Ralf R. Kolvenbach* (PowerPoint Presentation With Synched Audio)
- 8:59 – 9:04** Multicenter International Study On Preloaded Fenestrated Endografts With A Modified Biport Handle (Cook): A Way To Make F/EVAR Easy: How Does The System Work  
*Nikolaos Tsilimparis*
- 9:05 – 9:11** **Panel Discussion**
- 9:11 – 9:24** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 41 (Trianon Ballroom, 3rd Floor)

## OPEN AND ENDO TREATMENT OF COMPLEX AAAs (JUXTA, PARA- AND SUPRA-RENAL) AND TAAAs; NEW DEVICES FOR THEIR TREATMENT

**Moderators:** *Nuno V. Dias*  
*Tara M. Mastracci*

### COMPLEX AAAs AND TAAAs

- 9:24 – 9:29** Lower Extremity Ischemic Complications After F/B/ EVAR: Etiology And How To Avoid Them  
*Thomas S. Maldonado*
- 9:30 – 9:35** Long-Term Survival Results After Type II TAAA Endovascular Repair: When Is The Procedure Contraindicated  
*Matthew J. Eagleton*
- 9:36 – 9:41** How To Make 3 Chimney EVAR With Involvement Of The SMA Safe And Effective  
*Manish Mehta*
- 9:42 – 9:47** Value Of Ch/EVAR For Juxtarenal AAAs: They Are As Safe And Effective As Any Other Procedure And Simpler: Based On A Meta-Analysis Of Mid-Term Outcomes  
*Joost A. van Herwaarden*

**9:48 – 9:53** Risk Factors Associated With Long-Term Mortality And Complications After Open And Endovascular TAAA Repair: What Is The Role Of Open Repair In 2022

*Thomas F. Lindsay*

**9:54 – 9:59** Comparison Of Endo And Open Repair Of Post Dissection TAAAs: Which Procedure Is Best And When

*Fabio Verzini*

**10:00-10:05** Comparative Morbidity And Mortality Outcomes Of Open, Hybrid And F/B/EVAR For Type II And III TAAAs Justify Greater Use Of F/B/EVAR For These Complex Lesions

*Gilbert R. Upchurch*

*Salvatore T. Scali*

*Dean Arnaoutakis*

**10:06-10:12** **Panel Discussion**

**TOPICS RELATED TO INTERESTING NEW DEVICES**

**10:12-10:17** Update Of A New Hybrid Device (Thoracoflo From Terumo Aortic) For TAAA Repair: How It Works, Clinical Experience And Advantages

*Sebastian E. Debus*

**10:18-10:23** How To Prevent Patch Aneurysms After Open TAAA Repair With Long Antegrade Grafts: How To Treat Them When They Occur

*Thomas C. Bower*

*Manju Kalra*

**10:24-10:29** Update On The Role Of Device Engineering And Components On Sac Regression: Failed Regression After EVAR Are Device Related Not Patient Related

*Michael C. Stoner*

**10:30-10:35** WeFlow Device For Juxtarenal AAA, TAAA And Arch Repairs: A New Inner Branch And Outer Branch Approach: How Does It Work And Early Results

*Wei Guo (PowerPoint Presentation With Synched Audio)*

**10:36-10:40** **Panel Discussion**

SESSION 42 (Trianon Ballroom, 3rd Floor)

**PROGRESS IN TREATING ILIAC ANEURYSMS; ILIAC BRANCHED DEVICES (IBDs); UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS FOR TREATING ANEURYSMS AND DISSECTIONS**

**Moderators:** *Thomas S. Maldonado*

*Nicholas J.W. Cheshire*

**TREATMENT OF ILIAC ANEURYSMS AND IBDs**

**10:40-10:45** Surprisingly, Occlusion Of 1 Or Both Hypogastric Arteries During EVAR Does NOT Result In Serious Adverse Events: From A Large VQI Study

*Heepeel Chang*

**10:46-10:51** Update On The Gore IBD Excluder For Treating Iliac Aneurysms And Preserving Hypogastric Artery Flow: Advantages And Limitations: From The European ICEBERG Registry

*Michel M.P. Reijnen*

**10:52-10:57** Experience With Cook IBD For The Treatment Of Common Iliac Aneurysms: Including After Previous EVAR And In Octogenarians

*Giovanni B. Torsello*

- 10:58–11:03** Long-Term Comparison Of The Cook Zenith And Gore Excluder IBDs: Advantages And Limitations Of Both: What Is The Best Bridging Stent  
*Giovanni Pratesi*
- 11:04–11:09** An Iliac Customized Fenestrated Device (From Terumo Aortic): When And How Can It Work In Anatomies Unsuitable For Branched Endografts: Advantages And Limitations  
*Fadi Taher*  
*Afshin Assadian*
- 11:10–11:15** Advantages Of The Artivion (Formerly CryoLife/Jotec) IBD Device Now From Artivion For Treating Common And Internal Iliac Artery Aneurysms: When Bell Bottom Technique; When IBD  
*Lee Bouwman*
- 11:16–11:22** **Panel Discussion**  
**UPDATE ON MULTILAYER FLOW MODULATING (MLFM) AND OTHER BARE STENTS**
- 11:22–11:27** Systematic Review And Meta-Analysis Of The Multilayer Flow Modulating Bare Stent (From Cardiatis) For Complex Aortic Lesions: Early And Mid-Term Results Are Still Interesting: Does This Technology Have A Future  
*George Geroulakos*
- 11:28–11:33** Resurgence Of Interest In Uncovered Bare Stents As A Promising Treatment For Acute Aortic Dissections: What Is Their Future  
*Rodney A. White*
- 11:34–11:39** Role Of Bare Metal AMDS Stents From Artivion (Formerly CryoLife/Jotec) For Repair Of Acute Type A Dissections: Indications And Results  
*Wilson Y. Szeto*  
*Grayson H. Wheatley*
- 11:40–11:45** MLFM Bare Stents Will Be Effective Treatment For Aortic Dissections: How Extensive A Portion Of The Aorta Needs To Be Treated  
*Claude A. Vaislic*
- 11:46–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 43 (Trianon Ballroom, 3rd Floor)

MORE NEW DEVELOPMENTS IN AAA TREATMENT AND STANDARD EVAR: A NEW DEVICE TO SLOW AAA GROWTH; AAA NECK DILATATION AFTER EVAR; VALUE OF LOW PROFILE AAA ENDOGRAFTS; LINK TO CANCER; IMPROVED ULTRASOUND SURVEILLANCE AND ALL AAAs ARE NOT TIME BOMBS WAITING TO EXPLODE

**Moderators:** *Thomas S. Maldonado*  
*Claude Mialhe*

- 1:00 – 1:05** Update On A Novel New Technology (Nectero) To Slow AAA Growth; How Does It Work And Early Clinical Results  
*Venkatesh G. Ramaiah*  
**AAA NECK BEHAVIOR AFTER EVAR**
- 1:06 – 1:11** Optimal Stent Design And Optimal Degree Of Oversizing To Avoid Neck Dilatation And Why It Matters  
*Carlos Bechara*

- 1:12 – 1:17** Aortic Neck Dilatation Is Different After F/EVAR And EVAR: What Is The Reason And Why Is It Important For Outcomes  
*Thomas S. Maldonado*
- 1:18 – 1:23** Major Aortic Neck Dilatation Occurs Equally After EVAR And Open Repair: From The DREAM RCT: This ONLY Occurs After EVAR With Self-Expanding Endografts  
*Jan D. Blankensteijn*
- 1:24 – 1:29** Do AAA Necks And Sacs Dilate After F/EVAR For Juxtarenal AAAs At 1 And 5 Years: What Are The Good Or Bad Consequences Of Neck And Sac Enlargement: What Can Be Done To Improve Results  
*Benjamin W. Starnes*
- 1:30 – 1:35** **DEBATE:** Low Profile Devices For EVAR Are Failing: Their Future Is Questionable  
*Hence J.M. Verhagen*
- 1:36 – 1:41** **DEBATE:** Not So: Ovation Stent-Grafts (From Endologix) Have Good 5-Year Results With No Neck Dilatation Or Migration Even With Challenging Neck Anatomy: Based On A Multicenter International Study Of A Low Profile Endograft  
*Mahmoud B. Malas*
- 1:42 – 1:47** Why We Need A New RCT Comparing EVAR With Watchful Surveillance In Women With Small AAAs  
*Janet T. Powell*
- 1:48 – 1:53** Causes And Treatment Of Ureter-To-Iliac Artery Fistula: When Open, When Endo Treatment And Results  
*Piotr M. Kasprzak*
- 1:54 – 1:59** Presenting Small AAAs As Ticking Time Bombs Or Unexploded Grenades Is Wrong-Headed And Harmful: Diameter-Based Indications For AAA Repair May Lead To Unnecessary Procedures  
*Frank J. Criado*
- 2:00 – 2:06** **Panel Discussion**

SESSION 44 (Trianon Ballroom, 3rd Floor)

## MORE NEW DEVELOPMENTS IN AAAs: HOW DOES THROMBUS LOAD EFFECT PROGNOSIS AFTER EVAR AND EVAS; OTHER RELATED AAA TOPICS

**Moderators:** *Ali F. AbuRahma*  
*Janet T. Powell*

### AAA SAC THROMBUS LOAD

- 2:06 – 2:11** Impact Of Thrombus In AAA Sac And Neck On AAA Behavior And EVAR Outcomes: How To Quantitate Thrombus Load And Distribution  
*Nicos Labropoulos*
- 2:12 – 2:17** **DEBATE:** Large Amount Of AAA Sac Thrombus Promotes Morbidity Without Rupture And With Rupture: By What Mechanisms Is Thrombus Harmful And How Can Thrombus Load Be Quantitated  
*David H. Deaton*
- 2:18 – 2:23** **DEBATE:** Large Flow Luminal Space In An AAA Sac With Minimal Mural Thrombus Is Associated With Adverse Events After EVAR: It Is More Important Than AAA Sac Size: Thrombus May Be Protective  
*Hence J.M. Verhagen*

OTHER AAA RELATED TOPICS

- 2:24 – 2:29** Graft Infolding: A Unique EVAR Complication: How To Prevent It And How To Treat It  
*Ashraf Mansour*
- 2:30 – 2:35** Perioperative Mortality With F/EVAR And B/EVAR Is Inversely Related To Hospital Volume For These Procedures: What About Surgeon Volume From A National Audit Database  
*Hence J.M. Verhagen*
- 2:36 – 2:41** Favorable Anatomy For Endovascular Repair Is Preserved During Two Years Of Observation Of Small AAAs  
*Jon S. Matsumura*
- 2:42 – 2:47** 1-Year Sac Dynamics Predict Survival, Rupture And Need For Re-Intervention Long-Term After EVAR: Shrinkage Is Better Than Stable: Stable Is Better Than Expansion In Population Based Studies  
*Marc L. Schermerhorn*
- 2:48 – 2:53** Technical Tips To Perform SAFE Large Sheath Percutaneous Femoral Access For Complex AAA EVAR In Obese Or Scarred Groins – Even With Calcified Arteries  
*Barend M.E. Mees*
- 2:54 – 2:59** 4X Increased 18F FDG Uptake On PET CT In Female AAA Patients Compared To Males Indicates Increased Aortic Wall Inflammations: Does This Explain Increased Rupture Risk In Females: Implications For Treatment  
*Natzi Sakalihan*
- 3:00 – 3:06** **Panel Discussion**
- 3:06 – 3:15** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 45 (Trianon Ballroom, 3rd Floor)

SHORT HOT AORTIC TOPICS (4 ¾-MINUTE FAST PACED TALKS)

**Moderators:** *Timothy A.M. Chuter*  
*Luis A. Sanchez*

- 3:15 – 3:20** Large Diameter AAA Necks (>34 mm) Negatively Impact Patient Survival After EVAR: Is Inflammation Involved: How Should Such Patients Be Treated  
*Matt M. Thompson*
- 3:20 – 3:25** A Large Proportion Of EVARs Are Performed On AAAs Smaller Than The SVS Guideline: What Is The Long-Term Effect And What Should Be Done About It  
*Salvatore T. Scali*
- 3:25 – 3:30** Late Delayed Renal Artery Revascularization After Inadvertent Occlusion For Many Days Is Worthwhile: Collaterals Keep The Kidney Viable Although No Urine Is Produced  
*Nikolaos Tsilimparis*
- 3:30 – 3:35** Giant Hypogastric Artery Aneurysms: Strategies And Techniques For Treating Them Endovascularly  
*Jacques Busquet*
- 3:35 – 3:40** Impact Of COVID, The NICE Guidelines And Changing Disease Patterns On AAA Practice In The UK  
*Ian Loftus*  
*Pete Holt*

- 3:40 – 3:45** TEVAR For Acute Complicated TBAD: Improved Outcomes When The Endograft Is Extended To Zone 2 Versus Zone 3: Why Is This So  
*Jean M. Panneton*
- 3:45 – 3:50** Long-Term Propensity Matched Comparison Of Open Repair And F/B/EVAR For Pararenal And Paravisceral AAAs  
*Giovanni G.T. Tinelli*  
*Yamume Tshomba*
- 3:50 – 4:00** **Panel Discussion**
- 4:00 – 4:05** Visceral Debranching With A Simple Aortic Endograft Is The Best Way To Treat TAAAs In Good Risk Patients: How To Do It Safely  
*Guillermo A. Escobar*
- 4:05 – 4:10** Shaggy Aortic Score: What Is It: How Is It Associated With Postoperative Lower Extremity Weakness After F/B/EVAR  
*Jade S. Hiramoto*
- 4:10 – 4:15** Laser In Situ F/EVAR As An Off-The-Shelf Option For Ruptured Complex Or Short Necked AAAs And Failed EVAR: Experience And Technical Tips  
*Timothy A. Resch*
- 4:15 – 4:20** Advantages And Disadvantages Of The BeGraft, BeGraft Plus (Bentley) And Advanta (iCAST™ – Getinge) Bridging Stents For F/B/EVAR: Experience With >2000 Target Vessels  
*Eric L.G. Verhoeven*  
*Athanasios Katsargyris*
- 4:20 – 4:25** Update On Performing EVAR With Only IVUS Guidance To Decrease Radiation: Technical Tips And 4-Year Results  
*Jörg Tessarek*
- 4:25 – 4:30** Risk Factors And Late Clinical Consequences Of AAA Neck Dilatation After EVAR With Self-Expanding Endografts: What Are The Differences In Neck Behavior After Excluder And Endurant Endografts  
*Hence J.M. Verhagen*
- 4:30 – 4:35** **Panel Discussion**
- SESSION 46 (Trianon Ballroom, 3rd Floor)  
MORE SHORT HOT NEW TOPICS RELATED TO AORTO-ILIAC AND CAROTID DISEASE AND THEIR TREATMENTS (4 ¾-MINUTE FAST PACED TALKS)  
**Moderators:** *Fred A. Weaver*  
*Michael L. Marin*
- 4:35 – 4:40** Are Low Profile Devices For EVAR And TEVAR Improving Or Worsening Outcomes  
*Naoki Fujimura*
- 4:40 – 4:45** Endovascular Repair Of Thoracic Aneurysms With TEVAR Outside IFUs: Value And Limitations: From A Multicenter Study  
*Fabio Verzini*
- 4:45 – 4:50** How To Avoid ‘Lost To Follow Up’ After Invasive Treatment Of AAAs And Why Is It Important  
*Matthew W. Mell*
- 4:50 – 4:55** The VORTEC Technique For Revascularizing Hypogastric Arteries Without Clamping Or Suturing: How Does It Work And Advantages  
*Zoran Rancic*  
*Mario L. Lachat*

- 4:55 – 5:00** Impact Of Iliac Aneurysms On The Treatment Of Complex AAAs  
*Matthew J. Eagleton*
- 5:00 – 5:05** Isolated Iliac Artery Aneurysms Do NOT Need To Be Treated Until They Are At Least 4 Centimeters In Diameter  
*Christopher J. Smolock*
- 5:05 – 5:10** How To Safely Stent The Large Fenestration Of A ZFEN Endograft When It Is Crossed By Struts: Indications For Doing So And Late Results  
*Luis A. Sanchez*
- 5:10 – 5:15** 3-Stage Concept For Treating Mega-Aortic Syndrome: Frozen Elephant Trunk (FET), TEVAR, Distal Open Repair: Results  
*Martin Czerny (PowerPoint Presentation With Synched Audio)*
- 5:15 – 5:20** **Panel Discussion**
- CAROTID RELATED TOPICS**
- 5:20 – 5:25** New Findings Regarding Carotid In-Stent Restenosis: What Is Its Rate Of Progression And Its Clinical Significance  
*Zachary AbuRahma*  
*Ali F. AbuRahma*
- 5:25 – 5:30** Intracranial Angiography During TCAR: Technique And Value  
*Peter L. Faries*
- 5:30 – 5:35** Clinical Results Of A Micronet Covered Carotid-Stent (C-GUARD): Analysis Of 145 Patients At Two Sites: Advantages And Disadvantages  
*Christian Wissgott (PowerPoint Presentation With Synched Audio)*  
*Christoph Kopetsch*  
*Reimer Andresen*
- MORE AORTA RELATED TOPICS**
- 5:35 – 5:40** Improved Survival After Implementation Of A Large Scale Dedicated Network For Aortic Emergencies: Why The SOS Aorta System Works  
*Jean-Marc Alsac*
- 5:40 – 5:45** Physician Modified Gore C3 Excluder Endograft For TAAA Repair  
*Wayne W. Zhang*
- 5:45 – 5:50** The Sandwich-Periscope Technique For Left Subclavian Revascularization With Zone 2 TEVAR: It May Be The Best Way And How To Do It  
*Sukgu Han*
- 5:50 – 5:55** Role Of Endovascular And Open Treatment For Mid Aortic Syndrome In Children, Teenagers And Young Adults  
*Ramesh K. Tripathi*
- 5:55 – 6:00** Supra-Aortic Trunk Revascularization Of Any Sort With TEVAR Increases Stroke Risk  
*Mark K. Eskandari*
- 6:00 – 6:05** An Unrecognized Mechanism For Causing Aortic Dissections: Shock Wave Energy Rather Than Increased Arterial Pressure Causes The Tear: How Does It Work And How To Decrease The Risk  
*Erno Remsey-Semmelweis*
- 6:05 – 6:10** **Panel Discussion**  
**End of Program F**

## THURSDAY, NOVEMBER 17, 2022

- 6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor  
6:00 A.M. Faculty Registration – Gramercy Suite West, 2nd Floor  
6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

### CONCURRENT THURSDAY PROGRAMS

PROGRAM G: (SESSIONS 47-54)

**Exciting New Or Rediscovered Techniques, Concepts Or Devices; Progress In F/B/EVAR And Parallel Grafts For Complex AAAs; Tribute To Our Military; Progress In The Treatment Of Ruptured AAAs; More About New Devices, Techniques Or Concepts; Progress In Radiation Safety**

6:50 A.M. – 6:07 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM H: (SESSIONS 55-63)

**New Or Improved Devices For: Standard EVAR, EVAS And More Complex AAAs; Repairs Of TAAAs, The Ascending Aorta, The Aortic Arch, And The Descending Aorta (TEVAR); New Devices For Treating Lower Extremity Lesions By Endo Or Open Techniques; Update On Endoanchors And Fixation Devices And New Or Improved Devices For Endovascularly Removing Clot And Occluding Blood Vessels**

6:50 A.M. – 5:52 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM I: (SESSIONS 64-71)

**Superficial Venous Disease**

7:00 A.M. – 6:25 P.M.

Trianon Ballroom, 3rd Floor

PROGRAM J: (SESSIONS 72-75)

**Multidisciplinary Acute Stroke Management**

8:00 A.M. – 12:15 P.M.

Murray Hill Suites, 2nd Floor

PROGRAM G (SESSIONS 47-54)

**EXCITING NEW OR REDISCOVERED TECHNIQUES, CONCEPTS OR DEVICES; PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs; TRIBUTE TO OUR MILITARY; PROGRESS IN THE TREATMENT OF RUPTURED AAAs; MORE ABOUT NEW DEVICES, TECHNIQUES OR CONCEPTS; PROGRESS IN RADIATION SAFETY**

Grand Ballroom East, 3rd Floor

SESSION 47 (Grand Ballroom East, 3rd Floor)

**EXCITING NEW OR REDISCOVERED TECHNIQUES, DEVICES OR CONCEPTS**

**Moderators:** *Richard F. Neville*  
*Frank J. Veith*  
*Evan C. Lipsitz*

**6:50 – 6:55** Combating Bias In Medical And Vascular Studies And Therapeutic Decision Making: Why It Is Such A Big Deal And What To Do About It  
*Matthew T. Menard*

**6:56 – 7:01** Update On Remote Monitoring Of Vascular Grafts: Where Is It At And Where Is It Going  
*Richard F. Neville*



- 7:02 – 7:07** New Wearable Technologies For Telemonitoring Vascular Diseases And Their Treatments: How Will Innovation Improve Care During And After The COVID-19 Pandemic  
*Celia Riga*
- 7:08 – 7:13** Value Of Digital Health In Vascular Disease Management: Virtual And Otherwise  
*Tony S. Das (PowerPoint Presentation With Synched Audio)*
- 7:14 – 7:19** Update On Tissue Engineered Biological Arterial Grafts (Humacyte): How Well Are They Working In Patients And In What Vascular Bed  
*Todd E. Rasmussen*  
*Alexander Kersey*  
*Jeffrey H. Lawson*
- 7:20 – 7:25** Why Carotid Plaque Morphology Differs In Patients With An Acute MI And Those With Intermittent Claudication: Why It Matters  
*Henrik Sillesen*
- 7:26 – 7:31** **Panel Discussion**
- 7:31 – 7:36** Relining Occluded Vein Grafts With Viabahn (Gore) Stent-Grafts Or Supera (Abbott) Bare Stents Can Restore Patency And Avoid Thrombolysis: Techniques And Results  
*Hans Lindgren*
- 7:37 – 7:42** Measuring Aortic Diameters Is Inaccurate And Subjective: Even With Newer Imaging Technology, One Can Make The Diameter What You Want: What Are The Implications  
*Janet T. Powell*
- 7:43 – 7:48** Provider Skill Is Not Getting Appropriate Attention In The Health Care Value Equation Of Value = Outcome/ Cost: What To Do About It  
*Lars B. Lonn (PowerPoint Presentation With Synched Audio)*
- 7:49 – 7:54** Why Are Pig Organ Xenografts Now Feasible In Man: Update On Successes, Their Potential Role And What Are Their Limitations  
*Robert A. Montgomery*
- 7:55 – 8:00** Non-Compliant Endografts For TEVAR Have A Detrimental Effect On Systolic Blood Pressure And Cardiac Function; Compliant Endografts Are The Remedy  
*Juan C. Parodi (PowerPoint Presentation With Synched Audio)*
- 8:01 – 8:06** Update On Isolated Limb Perfusion To Enable Amputated Limb Reimplantation  
*Zachary M. Arthurs*
- 8:07 – 8:12** **Panel Discussion**
- SESSION 48 (Grand Ballroom East, 3rd Floor)  
PROGRESS IN FENESTRATED AND BRANCHED EVAR (F/B/EVAR) AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS  
*Moderators: James F. McKinsey*  
*Timothy A.M. Chuter*  
*Andres Schanzer*
- 8:12 – 8:17** The “Shaggy Aorta”: What Is It; How Is It Determined; How Shaggy Does It Have To Be To Matter  
*Germano Melissano*

- 8:18 – 8:23** The US Aortic Research Consortium (US-ARC): What Is It And How Can It Better Answer Questions About F/B/EVAR Like "Does The Aortic Neck Dilate After F/EVAR And If So, What Are Its Consequences"  
*Andres Schanzer*
- 8:24 – 8:29** Updated Experience With The STABILISE Technique For Acute And Subacute TBADs: Indications, Technical Tips, Precautions And Results  
*Germano Melissano*  
*Andrea Kahlberg*  
*Roberto Chiesa*
- 8:30 – 8:35** Branched EVAR For TAAA Repair Can Be Performed With Only Transfemoral Access Using Steerable Sheaths: How To Do It And What Is The Best Device For Stable Access  
*Tilo Kölbel*
- 8:36 – 8:41** With Steerable Sheaths Upper Extremity Access With B/EVAR Is Unnecessary: Which Sheath Is Best And Pitfalls To Be Avoided  
*Eric L.G. Verhoeven*
- 8:42 – 8:47** Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A US Perspective  
*Mark A. Farber*
- 8:48 – 8:53** Why Balloon Expandable Bridging Stent-Grafts Are Best For F/B/EVAR: Which One Is Best And Why: A European Perspective  
*Eric L.G. Verhoeven*
- 8:54 – 8:59** What Is The Best Bridging Covered Stent (Stent-Graft) For F/B/EVAR Based On An In Vitro Fatigue Testing Model And Other Considerations  
*Martin J. Austermann*  
*Giovanni B. Torsello*
- 9:00 – 9:05** With Complex AAAs, When F/B/EVAR; When Parallel Grafts; When Open Repair: All Have Their Pros And Cons  
*Chang Shu (PowerPoint Presentation With Synched Audio)*
- 9:06 – 9:11** How To Deal With Bad Necks In AAA Treatment: We Need All Options: Chimneys, Endoanchors, Fenestrated And Branched Solutions: Case Selection Is The Key: How To Do It  
*Götz M. Richter*
- 9:12 – 9:17** How To Simply, Safely And Effectively Treat TAAAs With Off-The-Shelf (OTS) Devices Including Chimney And Sandwich Stent-Grafts: The Docking Station And Staging Approach: How To Do It And Mid-Term Results  
*Manish Mehta*
- 9:18 – 9:26** **Panel Discussion**
- 9:26 – 9:38** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 49 (Grand Ballroom East, 3rd Floor)

**MORE PROGRESS IN F/B/EVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; AND RELATED TOPICS**

**Moderators:** *Frank J. Veith*  
*Nuno V. Dias*  
*Marcelo Ferreira*

- 9:38 – 9:43** Does Aortic Neck Dilatation Occur After F/EVAR And Is It A Problem  
*Michael P. Jenkins*

- 9:44 – 9:49** Percutaneous Femoral And Axillary Access For Complex Endovascular AAA Repair: How To Do It Safely And To Safely Downsize Femoral Sheaths To Restore Lower Extremity Flow  
*Darren B. Schneider*
- 9:50 – 9:55** The Lobato Parallel Graft Technique For Type B Aortic Dissection Complicated With Thoracoabdominal Aortic Aneurysm And Total True Lumen Occlusion Of The Infrarenal Aorta  
*Armando C. Lobato*
- 9:56 – 10:01** Value And Advantages Of Preloaded Wires And Catheters For F/B/EVAR: How Do They Work; Are There Pitfalls  
*Mark A. Farber*
- 10:02–10:07** **DEBATE:** The Case Against Ch/EVAR And Parallel Grafts For Complex AAA And TAAA Repairs: F/B/EVAR Is Much Better  
*Adam Beck*
- 10:08–10:13** **DEBATE:** Nonsense! Ch/EVAR And Parallel Grafts If Done Right Are As Safe And Effective As F/B/EVAR And In Some Cases Better And Cheaper  
*Manish Mehta*
- 10:14–10:19** Indications For And Challenges With Inner Branched B/EVAR: Why The Choice Of Bridging Grafts Matters In This Setting  
*Eric L.G. Verhoeven*
- 10:20–10:25** Pros And Cons Of Inner Versus Outer Branches In Off-The-Shelf Endovascular TAAA Repair  
*Timothy A. Resch*
- 10:26–10:31** Technical Tips To Deploy F/EVAR Endografts Precisely With Tortuous Anatomy: How To Compensate For Endograft Rotation And Still Match Fenestrations To Branch Orifices Perfectly  
*Nuno V. Dias*  
*Björn Sonesson*
- 10:32–10:37** Advantages Of Steerable (Variable Curve) Sheaths For Complex AAA And TAAA Repairs And TBADs: Which One Is Best And Why: Pitfalls And How To Prevent Them  
*W. Anthony Lee*
- 10:38–10:43** Technical Tips And Precautions For Using Steerable (Variable Curve) Sheaths For B/EVAR: Why They May Not Work And How To Make Them Work  
*Geert Willem H. Schurink*
- 10:44–10:52** **Panel Discussion**

SESSION 50 (Grand Ballroom East, 3rd Floor)

A TRIBUTE TO OUR MILITARY AND MILITARY PHYSICIANS: SOME MILITARY HISTORY; TREATMENT OF MILITARY AND CIVILIAN VASCULAR INJURIES AND CONTROL OF HEMORRHAGE; INNOVATIVE TECHNOLOGIES SUPPORTED BY THE DEFENSE DEPARTMENT

**Moderators:** *Todd E. Rasmussen*  
*Brandon Propper*

- 10:52–11:02** The World War II Naval Battle At Guadalcanal And Its Impact On The US Navy & Marines And The Japanese Imperial Navy: A Turning Point (10-Minute Talk)  
*Wayne F. Yakes*

- 11:03–11:08** Department of Defense Effort To Support Vascular Surgery Research And US National Preparedness For Mass Casualties  
*Todd E. Rasmussen*
- 11:09–11:24** A Vascular Surgeon's Impressions About War In The Ukraine (15-Minute Talk)  
*Andriy O. Nykonenko (PowerPoint Presentation With Synched Audio)*
- 11:25–11:30** Update On REBOA (Resuscitative Endovascular Balloon Occlusion Of The Aorta) For Treatment Of Hemorrhage, Trauma And Other Conditions: What Is New And Different: When And Where Should It Be Used And By Whom  
*Tal M. Hörer*
- 11:31–11:36** New Improvements In REBOA: How Will They Make It Worthwhile For Battlefield Hemorrhage  
*Brandon Propper*  
*Zachary M. Arthurs*  
*Todd E. Rasmussen*
- 11:37–11:42** How Will We Train The Next Generation Of Surgeons To Treat Vascular Trauma: For Military Practice: For Civilian Practice: What Issues Complicate It  
*Paul W. White*
- 11:43–11:48** What Vascular Injury Killed Martin Luther King, Jr. And Why He Might Have Survived Today  
*Cynthia K. Shortell*
- 11:49–11:54** Major Amputation Prosthetics Can Be Fixed Into Bone: How Does Osteointegration Work And How Is Infection Avoided  
*Zachary M. Arthurs*  
*Todd E. Rasmussen*
- 11:55–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 51 (Grand Ballroom East, 3rd Floor)

## PROGRESS IN THE TREATMENT OF RUPTURED INFRARENAL AAAs, COMPLEX AAAs, TAAAs AND RELATED TOPICS

**Moderators:** *Thomas L. Forbes*  
*Timur P. Sarac*  
*Frank J. Veith*

- 1:00 – 1:05** Value, Limitations And Technical Tips For Using The Nellix Endograft For Ruptured AAAs  
*Tal M. Hörer*
- 1:06 – 1:11** The Incidence Of Ruptured AAAs Is Decreasing And So Is Their Mortality: Why Are These 2 Facts So  
*Ross Milner*
- 1:12 – 1:17** Statins Decrease The Growth Rate And Rupture Risk Of AAAs As Well As The Perioperative Mortality: Statins Should Be Given To All AAA Patients: When And What Dose  
*Thomas L. Forbes*
- 1:18 – 1:23** A New System For Estimating AAA Wall Weakness From Gated Dynamic CT Scans: A Better Way To Predict Rupture Risk (From ViTAA Medical)  
*Randy D. Moore*
- 1:24 – 1:29** Long-Term Results Of The AJAX RCT Comparing EVAR With Open Repair For Ruptured AAAs: EVAR Wins In The End – Especially In Patients >80  
*Willem Wisselink*

- 1:30 – 1:35** Variation In Use Of EVAR Versus Open Repair For Ruptured AAAs Depends On Training And Bias Rather Than Data, Logic Or Facts: EVAR Is Clearly The Best Treatment If It Can Be Done  
*Martin Malina*
- 1:36 – 1:41** EVAR Should Be The Standard Of Care For Most Ruptured AAAs: Reasons Why It Is Not So And How To Overcome Them  
*Hans-Henning Eckstein*
- 1:42 – 1:47** Outcomes Of Ruptured AAA Repair Are Better In High Volume Institutions Both For EVAR And Open Repair: From A Meta-Analysis With >120,000 Cases  
*George A. Antoniou*
- 1:48 – 1:53** **DEBATE:** With Ruptured Complex AAAs And TAAAs, Off-The-Shelf F/B/EVAR Is The Best Treatment  
*Mark A. Farber*
- 1:54 – 1:59** **DEBATE:** Not So: With Ruptured Complex AAAs And TAAAs Parallel Grafts Are Simpler, More Effective And Less Costly  
*Manish Mehta*
- 2:00 – 2:06** **Panel Discussion**

SESSION 52 (Grand Ballroom East, 3rd Floor)

## MORE NEW DEVELOPMENTS IN RUPTURED AAAs AND TAAAs; WHAT IS AND WHAT SHOULD BE HAPPENING WITH AAA SCREENING

**Moderators:** *Keith D. Calligaro*  
*Benjamin W. Starnes*  
*Matthew J. Eagleton*

### NEW DEVELOPMENTS IN AAA SCREENING

- 2:06 – 2:11** Why The Current US PSTF Guidelines For AAA Screening Are Insufficient: Many At Risk Patients Are Not Screened  
*Malachi Sheahan*
- 2:12 – 2:17** Update On Current Screening For AAAs In The US: Most Ruptured AAAs Occur In Patients Not Being Screened: How Should US PSTF Recommendations Be Changed And How Should Screening Groups Be Expanded  
*Marc L. Schermerhorn*  
*Thomas F.X. O'Donnell*
- 2:18 – 2:23** New Developments In AAA Screening: What Is Its Value And Who Should Be Screened  
*Jes S. Lindholt*

### MORE ABOUT AAA RUPTURES AND THEIR TREATMENT

- 2:24 – 2:29** With Ruptured Abdominal Aortic Aneurysms: How To Decrease Turn Down Rates And Procedural Mortality By Greatly Decreasing Delays Before Treatment: How To Do It  
*Maarit Venermo*
- 2:30 – 2:35** AAA Rupture After EVAR Behaves Differently From De Novo Rupture: How Should Treatment Be Modified In Patients With Post EVAR Ruptures  
*Piotr Szopinski*

- 2:36 – 2:41** Update On Treating All (100%) Ruptured AAAs With EVAR: The Orebro/Zurich 12-Year Experience Shows It Is The Best Treatment And Lowers The Turndown Rate  
*David T. McGreevy*  
*Thomas Larzon*  
*Mario L. Lachat*  
*Tal M. Hörer*
- 2:42 – 2:47** Applicability And Results Of Cook t-Branch OTS Endograft In Complex Aortic Aneurysms (Ruptured And Elective) With Narrow Internal Aortic Lumens: Advantages And Limitations  
*Ciro Ferrer*  
*Rocco Giudice*
- 2:48 – 2:53** In Situ Laser Fenestration To Facilitate Endograft Treatment Of Ruptured TAAAs: When Is It Needed; How To Do It And Results  
*Stephan Haulon*  
*Dominique Fabre*
- 2:54 – 2:59** Open Repair For AAAs Should Not Be Used In Patients >80 Unless Their AAA Is >6 cm And They Are At Risk Of Rupture Or Ruptured: These Restrictions Do Not Apply To EVAR  
*Hence J.M. Verhagen*
- 3:00 – 3:05** How Can The Turndown Rate For Invasive Treatment Of Ruptured AAAs Be Decreased And Is It Beneficial  
*Matthew W. Mell*
- 3:06 – 3:11** Urgent And Emergent Treatment Of Symptomatic And Ruptured Thoracoabdominal And Juxtarenal Aortic Pathologies Using Physician Modified Stent-Graft Based On 3D Aortic Models  
*Daniela Branzan*  
*Andrej Schmidt*
- 3:12 – 3:17** Update On Advances In Treatment Of Abdominal Compartment Syndrome Associated With Ruptured AAAs: When And How To Treat Medically And When And How To Treat With Opening The Abdomen  
*Martin Björck*
- 3:18 – 3:20** **Panel Discussion**
- 3:20 – 3:30** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 53 (Grand Ballroom East, 3rd Floor)

**EXCITING NEW OR UPDATED CONCEPTS,  
TECHNIQUES AND TREATMENTS**

**Moderators:** *Nicholas J.W. Cheshire*  
*Reese A. Wain*

- 3:30 – 3:35** The Spur Stent System (Reflow Medical): A Temporary Stent With Pins To Penetrate The Arterial Wall And Facilitate DCB Drug Delivery: How Does It Work And Results To Date  
*Gunnar Tepe*  
*Marianne Brodmann*  
*Andrew Holden*  
*Thomas Zeller*
- 3:36 – 3:41** The Serranator Balloon Catheter (From Cagent Vascular) For Vessel Prep In BTK Arteries: It Makes Microserrations And Prevents Dissections With PTA: Current Status: The PRELUDE BTK Trial  
*Andrew Holden*

- 3:42 – 3:47** The No Intervention Option For Treatment Is More Commonly Elected For Women Than Men With CLTI, AAAs, Ruptured AAAs And Thoracic Aneurysms: It Is Wrong Headed And Unfair  
*Janet T. Powell*
- 3:48 – 3:53** Update On The Retrievable Rescue Stent-Graft To Control Massive Aortic Or Caval Bleeding: How Does It Work, How Is The Device Retrieved And Present Status: How Can It Be Used For Elective Aortic Repair  
*Bryan W. Tillman*
- 3:54 – 3:59** Transradial Approaches For Abdominal And Lower Extremity Interventions Including CTOs And As An Adjunct For EVARs And TEVARs: How To Make Them Work And Advantages Of The Terumo R<sub>2</sub>P System  
*David O'Connor*
- 4:00 – 4:05** Improving The Function Of A Hybrid Room: What Are The Elements And How Does The OR Black Box System Help  
*Isabelle Van Herzeele*
- 4:06 – 4:11** Update On A Clampless Sutureless Technique For Performing Aorto-Iliac Anastomoses Using Endograft Connectors: The VORTEC Technique – Useful When Arterial Control And Suturing Is Impossible  
*Mario L. Lachat (PowerPoint Presentation With Synched Audio)*
- 4:12 – 4:17** Endovascular Treatment Of Hepatic Artery Stenosis After Liver Transplantation: Indications, Techniques And Precautions To Make It Safe  
*W. Charles Sternbergh III*
- 4:18 – 4:23** Bariatric Left Gastric Artery Embolization Using The Novel Endobar Device For The Treatment Of Obesity: A Prospective Multicenter Randomized, Controlled IDE Trial  
*Robert E. Beasley*
- 4:24 – 4:29** The Many Possible Uses Of Femoral Veins For Arterial Procedures: How To Harvest Them Safely And Expediently  
*Timur P. Sarac*
- 4:30 – 4:38** **Panel Discussion**

SESSION 54 (Grand Ballroom East, 3rd Floor)

## PROGRESS IN RADIATION SAFETY AND MORE NEW CONCEPTS, DEVICES AND TECHNIQUES

Moderators: *Lindsay Machan*  
*Glenn Jacobowitz*

### PROGRESS IN RADIATION SAFETY

- 4:38 – 4:43** Endovascular Team Radiation Safety Performance: How To Monitor It: It Is More Than Dose Measurement  
*Isabelle Van Herzeele*
- 4:44 – 4:49** Myths And Facts Regarding Radiation Protection And Safety: Light Weight Lead Gowns Offer Less Protection  
*Lindsay Machan*
- 4:50 – 4:55** What Is New In Radiation Safety: Modern Standards For Optimal Radiation Protection During Endovascular Procedures And The Role Of Radiation Protection Guidelines  
*Bijan Modarai*

- 4:56 – 5:01** Small Tips And Modifications In Radiation Safety Can Make A Huge Impact On Staff Exposure: What Are They  
*Maarit Venermo*
- 5:02 – 5:05** **Panel Discussion**  
*NEW CONCEPTS, ETC.*
- 5:05 – 5:10** With Esophageal Cancer, When Is Prophylactic TEVAR Indicated To Prevent An Aorto-Esophageal Fistula  
*I-Hui Wu*
- 5:11 – 5:16** Endovascular Emergency Treatment Of Carotid Blowout From Head And Neck Cancer Or Carotid Patch Infections: Planning, Preparation And Technical Tips Are Essential  
*Michael B. Silva, Jr.*
- 5:17 – 5:22** What Is New In Gene And Stem Cell Therapy In 2022  
*Richard J. Powell*
- 5:23 – 5:28** Minimizing Contrast Induced Nephropathy With EVAR By Contrast Dilution  
*Naoki Fujimura*
- 5:29 – 5:34** Endovascular Options For The Control Of Submassive Hemoptysis: When And How To Do It  
*Jacob Cynamon*
- 5:35 – 5:40** Vascular Access Considerations For Children: How To Do It  
*Dawn M. Coleman*
- 5:41 – 5:46** Aortic Patch For Focal Aortic Lesions: A New Endovascular Approach: How Does It Work And What Is The Progress To Date  
*Vicente Rimbau*
- 5:47 – 5:52** Current Status Of AFX-3 And Ovation (With Anatomy Adaptive Sealing) Endografts (Both From Endologix) For AAA Repairs: Advantages And Limitations Of Each  
*Francesco Speziale*  
*Pasqualino Sirignano*
- 5:53 – 5:58** From Concept To Company: The Challenges, The Pain, The Rewards And How To Do It  
*Peter A. Schneider*
- 5:59 – 6:07** **Panel Discussion**  
**End of Program G**

PROGRAM H (SESSIONS 55-63)  
NEW OR IMPROVED DEVICES FOR: STANDARD EVAR, EVAS AND MORE COMPLEX AAAs; REPAIRS OF TAAAs, THE ASCENDING AORTA, THE AORTIC ARCH, AND THE DESCENDING AORTA (TEVAR); NEW DEVICES FOR TREATING LOWER EXTREMITY LESIONS BY ENDO OR OPEN TECHNIQUES; UPDATE ON ENDOANCHORS AND FIXATION DEVICES AND NEW OR IMPROVED DEVICES FOR ENDOVASCULARLY REMOVING CLOT AND OCCLUDING BLOOD VESSELS  
Grand Ballroom West, 3rd Floor



SESSION 55 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR INFRARENAL AAA REPAIR WITH STANDARD EVAR (5-MINUTE TALKS)

**Moderators:** *Thomas L. Forbes*  
*Rossi M. Silva*  
*Enrico Ascher*

- 6:55 – 7:00** Treo Endograft (Terumo Aortic) For Standard Infrarenal EVAR: Status Of Approval In US And Japan  
*Matthew J. Eagleton*
- 7:01 – 7:06** Real World Outcomes With The TREO Endograft (Terumo Aortic): Results From The TIGER Registry  
*Vicente Rimbau*
- 7:07 – 7:12** Update On The Gore Conformable Excluder With Variable Neck Angulation Control For AAAs With Imperfect Necks In The US: Mid-Term Data And FDA Status  
*Robert Y. Rhee*
- 7:13 – 7:18** Status Of The Gore Conformable Excluder For EVAR In Europe: 2-Year Results From The EXCeL Registry With 150 Implants  
*Marc R.H.M. van Sambeek*  
*Colin D. Bicknell*
- 7:19 – 7:24** Altura Endograft With Kissing Proximal Stents For Standard EVAR: Advantages And Limitations: From An Experience With 150 Patients And Up To 5-Year Follow-Up  
*Dainis K. Krievins*
- 7:25 – 7:31** **Panel Discussion**
- 7:32 – 7:37** Advantages And Limitations Of The Cook ZENITH Alpha (Low Profile) Endograft For EVAR: Based On 2-Year Results Of The European Multicenter ZEPHYR TRIAL  
*Philippe W.M. Cuypers*  
*Marc R.H.M. van Sambeek*  
*Dittmar Böckler*
- 7:38 – 7:43** How And Why Do The Endurant Endograft Results For EVAR In France Differ From The Global Results: What Are The Implications  
*Jean-Pierre Becquemin (PowerPoint Presentation With Synched Audio)*
- 7:44 – 7:49** AAA Repairs With The Endurant Endograft Outside The IFU Can Provide Acceptable Results In Some Patients: When Is This So And When Not: From The EAGLE Registry  
*Marc R.H.M. van Sambeek*
- 7:50 – 7:55** Head To Head Comparison Of Endurant And Excluder Endografts For EVAR In Challenging Asian AAA Anatomy  
*Naoki Fujimura*
- 7:56 – 8:01** Updated LEOPARD RCT Results Show That AFX Endografts Compare Favorably To Standard Proximally Fixed Endografts For AAA Repair  
*Christopher J. Kwolek*
- 8:02 – 8:07** AFX Endografts Work Well In Conical (Flared) AAA Necks: Why, Results And Are There Disadvantages  
*Naoki Fujimura*
- 8:08 – 8:14** **Panel Discussion**

SESSION 56 (Grand Ballroom West, 3rd Floor)

**NEW OR UPDATED DEVICES FOR STANDARD EVAR, EVAS (ENDOVASCULAR ANEURYSM SEALING) AND F/EVAR**

**Moderators:** *Cynthia K. Shortell*  
*Ramon Berguer*

- 8:14 – 8:19** Alto Endograft (From Endologix) For Standard EVAR: This Latest Modification Of The Ovation Endograft Has More Proximal Polymer Sealing Rings: Results From The ELEVATE Trial And 3-4-Year Results From The New Zealand Experience Show Advantages: What Is The JAGUAR RCT  
*Sean P. Lyden*  
*Andrew Holden*
- 8:20 – 8:25** Update On The Ovation/Alto Ultra Low-Profile Endograft (Now From Endologix): Advantages, Long-Term Results, New Modifications And Limitations  
*Gianmarco de Donato*
- 8:26 – 8:31** Experience With The Nellix Endograft In 120 Patients With Up To 10 Years Follow-Up: What Is The Device's Future  
*Dainis K. Krievins*
- 8:32 – 8:37** Novel 5-Branch Custom Made Endograft (From Cook) For Treating Type 1A Endoleaks After EVAR Or Open Repair With Short Aortic Body Grafts Below The Renal Arteries  
*Piotr M. Kasprzak*
- 8:38 – 8:43** Comparison Of Ch/EVAS And Ch/EVAR: When Is Ch/EVAS Indicated: Advantages And Limitations  
*Barend M.E. Mees*
- 8:44 – 8:49** Update On Multicenter Results With F/EVAR Using The Fenestrated Anaconda Endograft: Advantages And Limitations: From The Global FACT Registry  
*Clark J. Zeebregts*  
*Michel M.P. Reijnen*
- 8:50 – 8:55** Value Of The Fenestrated Anaconda Endograft For Treating Failed EVAR  
*Fadi Taher*  
*Afshin Assadian*
- 8:56 – 9:01** Update On The Incraft Endograft For Standard Infrarenal EVAR: Is Its Low Profile An Advantage  
*Giovanni B. Torsello*  
*Jean-Pierre Becquemin*  
*Matteo Orrico*  
*Nicola Mangialardi*
- 9:02 – 9:07** Are We Overtreating AAAs: Based On New Scrutiny Of Old Trials And Current Practice, And New Data On Rupture Risk  
*Timothy A. Resch*
- 9:08 – 9:15** **Panel Discussion**
- 9:15 – 9:26** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 57 (Grand Ballroom West, 3rd Floor)

**NEW OR IMPROVED DEVICES FOR THE ASCENDING AORTA, THE AORTIC ARCH OR NEAR THE ARCH**

**Moderators:** *Tilo Kölbel*  
*Rodney A. White*

- 9:26 – 9:31** Changes In The Aortic Valve And Aortic Morphometrics After Ascending Aorta And Arch Endograft Placement  
*Jean Bismuth*  
*Ross Milner*
- 9:32 – 9:37** Outcomes Of The Custom Relay Ascending Aorta Endograft (Terumo Aortic): The European Experience  
*Vicente Riambau*  
*Afshin Assadian*  
*Mo S. Hamady*
- 9:38 – 9:43** Status In The US Of The Relay Branch Investigational Device For Repair Of Aortic Arch Lesions: How Many Branches Can And Should Be Revascularized: Advantages And Limitations  
*Luis A. Sanchez*  
*Eric E. Roselli*
- 9:44 – 9:49** Long-Term Safety And Durable Effectiveness Of Relay (Terumo Aortic) Scalloped Endograft For TEVAR Treatment Of Lesions In Or Near The Aortic Arch  
*Mo S. Hamady*  
*Jean-Marc Alsac*
- 9:50 – 9:55** Nexus OTS Endograft From Endospan For Treating Zone 0 And 1 Lesions Of The Aortic Arch: How Does It Work And 3-Year Clinical Results: Status In The US  
*Felice Pecoraro*  
*Mario L. Lachat*  
*Ross Milner*  
*Andrew Holden*  
*Daniel G. Clair*  
*Nicola Mangialardi*
- 9:56 – 10:01** Status Of And When And How To Use The Gore Conformable CTAG Endograft With Variable Angulation Control Optimally: Advantages And Limitations  
*Sukgu Han*
- 10:02–10:07** Value Of Endo TAAA Repair In Patients With Connective Tissue Disorders And Why Is The Gap Between Fenestration And Aortic Wall Important In F/EVAR  
*Gustavo S. Oderich*
- 10:08–10:15** **Panel Discussion**

SESSION 58 (Grand Ballroom West, 3rd Floor)

NEW OR IMPROVED DEVICES FOR THORACIC AORTIC LESION REPAIRS WITH TEVAR, AND FOR THORACOABDOMINAL ANEURYSM (TAAA) REPAIRS (ALL TALKS ARE 4 ¾-MINUTES)

**Moderators:** *Giovanni B. Torsello*  
*James F. McKinsey*

**DEVICES FOR TEVAR**

- 10:15–10:20** Low Profile Devices For TEVAR: Disadvantages And Advantages Based On A 10-Year Experience  
*Giovanni B. Torsello*
- 10:20–10:25** Mid-Term Results With The Cook ZENITH Alpha Thoracic Endograft For TEVAR In 500 Patients In A Real World Experience  
*Germano Melissano*  
*Roberto Chiesa*
- 10:25–10:30** A Modified Candy Plug Technique For False Lumen Treatment After TEVAR For TBAD  
*Ali Azizzadeh*

- 10:30-10:35** Fenestrated Endovascular Aortic Repair Plus Chimney Graft For TAAA Repairs: The FEVARCh Technique  
*Ross Milner*
- 10:35-10:40** The Gore TAMBE Device: Lessons Learned To Facilitate Its Use For TAAA And Complex AAA Repairs  
*Bernardo C. Mendes*
- 10:40-10:46** **Panel Discussion**
- 10:46-10:51** The Relay Pro (Terumo Aortic) Endograft For TEVAR And Its Advantages In Treating TBADs: Why Is It Better Than The Older Relay Plus Device  
*Steven D. Abramowitz*  
*Edward Y. Woo*
- 10:51-10:56** Patient Specific Custom Designed Relay Pro Endografts (Terumo Aortic): How Do They Work And What Are Their Advantages In Various Circumstances  
*David M. Williams*
- 10:56-11:01** Relay Custom-Made Endografts (Terumo Aortic) For TEVAR: Why Do They Provide Better Wall Apposition For Sealing  
*Fadi Taher (PowerPoint Presentation With Synched Audio)*  
*Afshin Assadian*

**NEW OR IMPROVED ENDO DEVICES FOR TAAA REPAIRS**

- 11:01-11:06** The Novel Artivion (Formerly CryoLife/Jotec) Off-The-Shelf (OTS) Inner Branched Device For TAAAs: Why Is It Better Than Outer Branched OTS Devices: Are There Limitations  
*Lee Bouwman*
- 11:06-11:11** Colt Concept And Its Evolution Towards The Inner Branch Endograft For Complex AAAs: Colt 2.0: How It Works And Early Outcomes  
*Piotr Szopinski*
- 11:11-11:17** **Panel Discussion**
- 11:17-11:22** To Treat Complex TAAAs: Combination Of Relay (Terumo) TEVAR And Fenestrated And Branched EVAR Is Best: Technical Tips And Outcomes  
*Mo Hamady*
- 11:22-11:27** Target Vessel Outcomes With The Cook t-Branch OTS Endograft For TAAA Repair At 2 Years From A Multicenter Registry – Which Stent-Graft Types Are Better For Which Vessels  
*Nikolaos Tsilimparis*
- 11:27-11:32** Experience With The Cook t-Branch OTS Endograft Device For Juxta- And Pararenal AAAs: Advantages And Limitations  
*Matteo Orrico*  
*Nicola Mangialardi*
- 11:32-11:37** Comparison Of 3 OTS Endografts For Urgent TAAA Repairs: TAMBE (Gore) Versus E-nside (Jotec) Versus t-Branch (Cook): Advantages And Disadvantages Of Each  
*Luca Bertoglio*  
*Roberto Chiesa*  
*Germano Melissano*
- 11:37-11:42** Valiant Manifold OTS Endograft Device (Medtronic) For Repairing TAAAs: How Does It Work; Update On Clinical Experience And Future Prospects  
*Murray L. Shames*

**11:42–11:47** Innovative Treatment Of Thoracoabdominal And Pararenal Aortic Aneurysms Using Treovance Endografts (Terumo) And Parallel VBX Stent-Grafts (Gore)

*James F. McKinsey*

**11:48–11:53** Is There A Role For Hyperbaric Oxygen Therapy In Preventing Or Treating Spinal Cord Ischemia After TAAA Repair

*Thomas F. Lindsay*

**11:53–12:00** **Panel Discussion**

**12:00– 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 59 (Grand Ballroom West, 3rd Floor)

NEW OR UPDATED INFORMATION ON MRI SAFETY WITH COVERED STENTS, A NEW EMBOLIC AGENT FOR BLEEDING, LOWER EXTREMITY PROSTHETIC GRAFTS, PERIGRAFT SEROMA AND VALUE OF A PROSTHETIC PERIGRAFT SIROLIMUS PATCH (SEE ALSO SESSION 28)

*Moderators: Ali F. AbuRahma  
Patrick J. Lamparello*

**MRI SAFETY WITH STENT-GRAFTS**

**1:00 – 1:05** Safety Of MRI Early After Deployment Of Various Covered Stents

*Maria A. Ruffino*

**A NEW EMBOLIC AGENT**

**1:06 – 1:11** A New Liquid Embolic Agent (Lava LES) To Control Bleeding; How Does It Work And Pivotal Trial Results

*Mahmood Razavi*

**PROSTHETIC GRAFTS**

**1:12 – 1:17** 3-Year Results Of The ZILVERPASS RCT Comparing Prosthetic PTFE Bypasses With Zilver PTX (Cook) Stents To Treat Long Fempop Lesions: Clinical And Financial Results And Their Implications

*Michel J. Bosiers  
Marc Bosiers*

**1:18 – 1:23** The 3DH Spiral Flow Prosthetic Graft: Does It Prevent Neointimal Hyperplasia In Leg Bypasses Or A-V Access

*Hosam F. El Sayed*

**1:24 – 1:29** Heparin Coated (Propaten) PTFE Grafts (Gore) Versus Autologous Vein Grafts For Bypasses To Targets Above And Below The Knee: Are The Heparin Coated Grafts Better And Worth The Cost

*David J. Dexter*

**1:30 – 1:35** Perigraft Seromas After PTFE Lower Extremity And Aortic Arterial Grafts: Frequency, Etiology And What To Do About Them

*Jae S. Cho*

**1:36 – 1:41** Update On External Sirolimus Patch Wrap-Arounds For PTFE Graft Anastomoses: Do They Decrease Neointimal Hyperplasia

*Sriram S. Iyer*

**1:42 – 1:48** **Panel Discussion**

SESSION 60 (Grand Ballroom West, 3rd Floor)

**NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ATHERECTOMY, STENTS, TACKS, ACCESSORIES, ETC. (SEE ALSO SESSIONS 23-27)**

**Moderators:** *Kenneth Ouriel*  
*Enrico Ascher*

**ATHERECTOMY RELATED TOPICS**

- 1:48 – 1:53** Value And Limitations Of The Rotarex Device (From BD) For Atherectomy, Clot Removal And Treating ISR  
*Miguel Montero*
- 1:54 – 1:59** Atherectomy: When Is It The Best Vessel Prep: What Are Its Complications: How To Prevent And Treat Them  
*Theodosios Bisdas*
- 2:00 – 2:05** Value And Limitations Of 355 nm Auryon B-Laser™ (From AngioDynamics): It Enables Safe Crossing Of Difficult Lesions Not Crossed With A Guidewire: How Does It Work And Clinical Results  
*Luis R. Leon, Jr.*
- 2:06 – 2:11** Orbital And Laser Atherectomy: Indications, Advantages And Precautions With Above And Below Knee De Novo Lesions And ISR  
*Craig M. Walker*
- 2:12 – 2:17** Value Of Atherectomy And DCBs: Interim Results Of The REALITY Trial  
*Brian G. DeRubertis*

**ANCILLARY TECHNIQUES**

- 2:18 – 2:23** Value Of Wingman Catheter (Reflow Medical) For Crossing Difficult Lesions: How Does It Work And Results  
*John R. Laird*
- 2:24 – 2:29** Value Of New Dedicated Special Tools And Devices To Facilitate Trans-Radial Access For Lower Extremity Lesion Treatments: How Far Distally Can They Be Effective  
*Ramon L. Varcoe*
- 2:30 – 2:36** **Panel Discussion**

**NEW INFORMATION ON STENTS**

- 2:36 – 2:41** Advantages Of Supera (Vasculomimetic – VMI) Stent For Complex Fempop Occlusive Lesions: Technical Tips: They Work Even In The Subintimal Position  
*Erwin Blessing*
- 2:42 – 2:47** Value Of The Supera VMI Stent For Common Femoral Artery (CFA) Occlusive Lesions: Better Than Endarterectomy: 2-Year Results And Status Of The SUPERSURG RCT (Versus Open Surgery)  
*Yann Gouëffic*  
*Koen Deloose*
- 2:48 – 2:53** Temporary Stent Assisted DCB Angioplasty In BTK Lesions: Update On The DEEPER OUS Trial  
*Thomas Zeller*
- 2:54 – 2:59** Value And Advantages Of Eluvia DESs (Boston Scientific) For Lower Extremity Occlusive Lesions: When To Use Them And How To Optimize Their Results  
*Steven Kum*

**3:00 – 3:05** RCT Comparing A New Bare Metal Stent – Misago Versus Zilver PTX DESs For Fempop Lesions: 2-Year Results Of The BATTLE Trial: Misago Stents Can Be Deployed Via Radial Access  
*Yann Gouëffic*

**3:06 – 3:12** **Panel Discussion**

**3:12 – 3:24** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 61 (Grand Ballroom West, 3rd Floor)

## NEW OR IMPROVED ENDOVASCULAR DEVICES FOR LOWER EXTREMITY TREATMENTS: ANGIOPLASTY BALLOONS

**Moderators:** *John R. Laird*  
*Thomas Zeller*

**3:24 – 3:29** 3-Year Results Of TOBA II BTK Trial Of The Tack Device To Decrease Dissections With Balloon Angioplasty Of BTK Lesions Show Safety And 80% Patency  
*Patrick J. Geraghty*

**3:30 – 3:35** Value Of High-Pressure Non-Compliant Balloons For BTK Arterial Lesion Treatment: Why They Work Better And Other Technical Tips  
*Steven Kum*

**3:36 – 3:41** Update On The TANGO Trial Using The Bullfrog Balloon Device (Mercator Medical Systems) To Inject Sirolimus Drug Into Lesion Wall Before Angioplasty: How Does It Work And Updated Results  
*William A. Gray*

**3:42 – 3:47** Value Of The Passeo-18Lux DCB For Treating BTK Lesions With Or Without Bare Metal Stents  
*Gunnar Tepe*

**3:48 – 3:53** Unfavorable Balloon (Candy) Wrap Can Cause Dissections With Angioplasty: What Is The Mechanism: How Can It Be Recognized And Dissection Avoided  
*Jos C. van den Berg (PowerPoint Presentation With Synched Audio)*

**3:54 – 3:59** The Importance Of Dissection In Angioplasty Treatment Of BTK Lesions: How To Prevent And Treat Such Dissections: The Value Of Tacks (From Intact Vascular): How Do They Work  
*Andrew Holden*

**4:00 – 4:05** Chocolate Touch DCBs (From TriReme Medical): How Do They Work, Advantages And Updated Clinical Results  
*Andrew Holden*

**4:06 – 4:12** **Panel Discussion**

SESSION 62 (Grand Ballroom West, 3rd Floor)

## NEW OR IMPROVED DEVICES AND TECHNIQUES TO PREVENT OR TREAT ENDOLEAKS OR DEVICE MIGRATION: ENDOANCHORS, ETC.

**Moderators:** *William D. Jordan, Jr.*  
*Jean-Paul de Vries*

**4:12 – 4:17** Everything I Learned In Training Was Wrong: Endoanchors Work For Short Necks  
*Mathew D. Wooster*

- 4:18 – 4:23** New Developments From The ANCHOR Registry With Over 5 Years Of Follow-Up Show The Value Of Endoanchors When Used Prophylactically For Certain Indications Prevent Endoleaks And Migration: Large Diameter Necks Are One Of Those Indications  
*William D. Jordan, Jr.*
- 4:24 – 4:29** New Developments From The ANCHOR Registry With >5 Years Follow-Up Show That Endoanchors Can Be Used To Treat Endoleaks And Migration Effectively In Hostile Neck Anatomy: The Proof  
*Jean-Paul de Vries*
- 4:30 – 4:35** Vesteck – The Next Generation Of Endoanchor (Endosuturing) Technology: How Does It Work And Where Does It Stand  
*David H. Deaton*
- 4:36 – 4:41** Balloon Optimized Molding For Better Deployment And Sealing Of Ovation Alto Low Profile Endografts For EVAR: How To Do It And How It Helps Prevent Endoleaks And Migration  
*David J. Minion*
- 4:42 – 4:48** **Panel Discussion**

SESSION 63 (Grand Ballroom West, 3rd Floor)

**NEW OR IMPROVED ENDOVASCULAR DEVICES FOR CLOT REMOVAL OR EMBOLIZATION (SEE ALSO SESSION 30)**

**Moderators:** *Neal S. Cayne*  
*James F. Benenati*  
*Andrew Holden*

**CLOT REMOVING DEVICES**

- 4:48 – 4:53** Percutaneous Embolectomy Or Thrombectomy With The Indigo System (From Penumbra): What Makes It Different, Technical Tips, Results And Limitations  
*David J. Dexter*
- 4:54 – 4:59** Newer Pharmaco-Mechanical Endovascular Clot Removal Systems: When And Why Is Each Device Best To Use  
*Guillermo A. Escobar*
- 5:00 – 5:05** Catheter Based Vacuum Assisted Thrombectomy For Acute Limb Ischemia: How Does It Work: Advantages And Limitations: From A Multicenter Study: Key Findings From The INDIAN Trial  
*Carlo Setacci*  
*Gianmarco de Donato*

**VASCULAR OCCLUSIVE DEVICES**

- 5:06 – 5:11** Technical Tips For Effective Coil Embolization: Importance Of Dense Packing; Why Non-Fibered Coils Are Better Than Fibered Coils  
*James F. Benenati*  
*Constantino Pena*
- 5:12 – 5:17** Why Ruby Coils, The Penumbra Occlusion Device (POD) And Packing Coils Have Different Uses And Why They Are Valuable And Cost Effective For Different Lesions: Technical Tips For Optimizing  
*Sean P. Lyden*
- 5:18 – 5:23** Caterpillar™ Embolic Plug (From Bard): How Does It Work: Advantages And Clinical Results  
*Andrew Holden*



- 5:24 – 5:29** How To Treat Type 1A Endoleaks And Enlarging TBAD False Lumens With Ruby Coils: When Will They Work; When Will They Not: Technical Tips  
*Mazin Foteh*
- 5:30 – 5:35** How To Insert Large Vessel Embolization Devices (PODs) Through Low Profile Access  
*Frank R. Arko*
- 5:36 – 5:41** Newer Vascular Occlusion Devices: Caterpillar And Azur Devices: Advantages And Limitations  
*Karthik Kasirajan*
- 5:42 – 5:52** **Panel Discussion**  
**End of Program H**

PROGRAM I (SESSIONS 64-71)  
SUPERFICIAL VENOUS DISEASE

Trianon Ballroom, 3rd Floor

Course Leaders: **Jose I. Almeida**  
**Lowell S. Kabnick**  
**Peter Gloviczki**  
**Thomas W. Wakefield**  
**Steve Elias**

SESSION 64 (Trianon Ballroom, 3rd Floor)  
VENOUS CLINICAL EXAMINATION AND  
HEMODYNAMICS

Moderators: **Jose I. Almeida**  
**Lowell S. Kabnick**  
**Thomas W. Wakefield**  
**Steve Elias**

- 7:00 – 7:04** Introduction To Veins At VEITH  
*Jose I. Almeida*
- 7:05 – 7:10** AVF CEAP Revision And Workbook  
*Marc A. Passman*
- 7:11 – 7:16** CEAP, VCSS, HASTI: Their Significance And How To Utilize  
*Lowell S. Kabnick*
- 7:17 – 7:22** Physiology Of Venous Return  
*Brajesh K. Lal*
- 7:23 – 7:28** Causation Of Symptoms In C0 Patients: Implications For Therapy  
*Marc A. Passman*
- 7:29 – 7:34** Evaluation Of Venous Reflux: Going Beyond The Reflux Duration  
*Nicos Labropoulos*
- 7:35 – 7:40** Hemodynamics Of Reflux  
*Jose I. Almeida*
- 7:41 – 7:46** An Algorithm To Predict Disease Severity In C2 Patients  
*Mikel Sadek*
- 7:47 – 7:52** Pathophysiology Of Varicose Veins: Evidence Summary  
*Thomas W. Wakefield*
- 7:53 – 7:58** The Importance Of Glycocalyx: Veins And Lymphatics  
*Joseph D. Raffetto*
- 7:59 – 8:04** Saphenous And Sural Nerve Anatomy  
*Jean Luc Gerard*
- 8:05 – 8:10** Genetics In Varicose Vein Disease  
*Sarah Onida*

**8:11 – 8:16** Quality Of Life Tools Reflect Disease Severity, But They Can Be Improved  
*Alun H. Davies*

**8:17 – 8:22** **Panel Discussion**

SESSION 65 (Trianon Ballroom, 3rd Floor)

## VENOUS AND LYMPHATIC, IMAGING, AND BIOLOGY

**Moderators:** *Antonios P. Gasparis*  
*Joseph D. Raffetto*

**8:23 – 8:28** Identifying Reflux Pathways With Duplex Ultrasound Mapping  
*Neil M. Khilnani*

**8:29 – 8:34** How Common Are And Why Care About Ancillary Findings During Lower Extremity Venous Duplex Imaging  
*Michael C. Dalsing*

**8:35 – 8:40** Duplex Imaging: Is It Helpful For Reticular Or Telangiectatic Veins  
*Pauline Raymond-Martimbeau*

**8:41 – 8:46** Ambulatory Venous Pressure, Air Plethysmography, And The Role Of Calf Venous Pump In Chronic Venous Disease  
*Taimur Saleem*  
*Seshadri Raju*

**8:47 – 8:52** Role Of Foot Static Disorders In Chronic Venous Disease  
*Nicos Labropoulos*

**8:53 – 8:58** Inflammation And CVD  
*Joseph D. Raffetto*

**8:59 – 9:04** Does Deep Venous Reflux Matter With Superficial Ablation  
*Mikel Sadek*

**9:05 – 9:10** Genetics Involving Venous Leg Ulcers  
*Joseph D. Raffetto*

**9:11 – 9:16** Pharmacologic And Cell Based Therapies For Lymphedema  
*Monika Glociczki*

**9:17 – 9:22** Superficial Venous Disease Versus Outflow Obstruction: Treat Which First And Why  
*Antonios P. Gasparis*

**9:23 – 9:28** **Panel Discussion**

SESSION 66 (Trianon Ballroom, 3rd Floor)

## SUPERFICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES

**Moderators:** *Glenn Jacobowitz*  
*Alun H. Davies*

**9:29 – 9:34** Results Of The Recent Randomized Controlled Superficial Venous Device Trials And Their Importance  
*Alun H. Davies*

**9:35 – 9:40** “Choosing Wisely” Items For Chemical Or Thermal Ablation In The Treatment Of The Incompetent Saphenous Veins And Recurrence  
*Claudine M. Hamel-Desnos*

**9:41 – 9:46** Rethinking Endovenous Techniques To Define Cost-Effectiveness  
*Armando Mansilha*

**9:47 – 9:52** Saphenous Sparing: Instructions For Users  
*Erika Mendoza*

- 9:53 – 9:58 Thermal Saphenous Vein Recanalization: Risk Factors  
*Omar L. Esponda*
- 9:59 – 10:04 What Drugs Do I Recommend For Symptomatic Venous Disease  
*Jorge H. Ulloa*
- 10:05–10:10 Ablative Procedures And Cost Effectiveness  
*Alun H. Davies*
- 10:11–10:16 Chronic Venous Disease And Diabetic Microangiopathy: Pathophysiology And Commonalities  
*Armando Mansilha*
- 10:17–10:22 Anterior Accessory Saphenous Vein Ablation: Our Experience And Should We Continue  
*John F. Charitable*
- 10:23–10:28 Saphenous Ablation On Anticoagulation; Is It Safe, Effective And Durable  
*Glenn Jacobowitz*
- 10:29–10:34 **Panel Discussion**

SESSION 67 (Trianon Ballroom, 3rd Floor)

## TRUNCAL ABLATION OF THE SAPHENOUS VENOUS SYSTEM

Moderators: *Edward G. Mackay*  
*Cees H.A. Wittens*

### THERMAL AND NON-THERMAL TRUNCAL VEIN ABLATION I

- 10:35–10:40 Decision Making In Saphenous Ablation: What To Use When  
*Ellen D. Dillavou*
- 10:41–10:46 HIFU: Is It Ready For Prime Time  
*Mark S. Whiteley*
- 10:47–10:52 Which Variables In Superficial Venous Interventions Will Improve QOL?  
*Cees H. A. Wittens*
- 10:53–10:58 Tips, Tricks And Limitations: Perforator Ablation  
*Steve Elias*
- 10:59–11:04 Tips, Tricks And Limitations: Varithena  
*Edward G. Mackay*
- 11:05–11:10 Tips, Tricks, And Limitations: Ultrasound Guided Foam Sclerotherapy  
*Jean Luc Gerard*
- 11:11–11:16 **Panel Discussion**

### THERMAL AND NON-THERMAL ABLATION II

Moderators: *Lowell S. Kabnick*  
*Alan M. Dietzek*

- 11:17–11:22 Tips, Tricks, And Limitations: Liquid Sclerotherapy  
*Victor M. Canata*
- 11:23–11:28 Tips, Tricks And Limitations: ClariVein  
*Steve Elias*
- 11:29–11:34 Tips, Tricks And Limitations: Laser Truncal Ablation  
*Lowell S. Kabnick*
- 11:35–11:40 Tips, Tricks And Limitations: Radiofrequency Ablation  
*Alan M. Dietzek*
- 11:41–11:46 Tips, Tricks And Limitations: Phlebectomy  
*Gutenberg A. Gurgel*
- 11:47–11:52 Tips, Tricks And Limitations: Venaseal  
*Alun H. Davies*

- 11:53–11:58** Superficial Devices In Clinical Trials (Before Governmental Approval)  
*Lowell S. Kabnick*
- 11:59–12:04** Safety And Efficacy Of Endovenous Ablations In Octogenarians, Nonagenarians, And Centenarians  
*Anil P. Hingorani*  
*Enrico Ascher*
- 12:05–12:10** SVT Management: Anything New In 2022  
*Manj S. Gohel*
- 12:11–12:16** **Panel Discussion**
- 12:17–12:45** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 68 (Trianon Ballroom, 3rd Floor)

## SPIDER VEINS, TRUNCAL VEINS, TRIBUTARY VEINS, PELVIC VEIN TREATMENT

**Moderators:** *Kathleen D. Gibson*  
*Aleksandra Jaworucka-Kaczorowska*

- 12:45–12:50** Foam Therapies (PCF Versus PEM): When To Use And Does It Make A Difference  
*Edward G. Mackay*
- 12:51–12:56** Risks And Contraindications Of Medical Compression Treatment - A Critical Reappraisal - An International Consensus Statement  
*Mark H. Meissner*
- 12:57– 1:02** Randomized Controlled Study Of EVLA And Foam In The SSV-Fovellass Study: 3-Year Results  
*Claudine M. Hamel-Desnos*
- 1:03 – 1:08** CLACS In Paraguay Results Of The Aesthetic Phlebology Trial  
*Victor M. Canata*
- 1:09 – 1:14** Which Saphenous Vein Recanalization Should Be Treated  
*Kathleen D. Gibson*
- 1:15 – 1:20** Pelvic Origin Labial And Leg Varices: Choices And How I Do It  
*Aleksandra Jaworucka-Kaczorowska*
- 1:21 – 1:26** Is Combination Therapy Laser And Sclerotherapy More Efficacious For Telangiectatic Treatment  
*Gutenberg A. Gurgel*
- 1:27 – 1:32** How To Treat Pelvic Veins: Top Down Or Bottom Up  
*Aleksandra Jaworucka-Kaczorowska*
- 1:33 – 1:38** **Panel Discussion**

SESSION 69 (Trianon Ballroom, 3rd Floor)

## VENOUS SOCIETAL AND GOVERNANCE

**Moderators:** *Kathleen J. Ozsvath*  
*Mark D. Iafratii*

- 1:39 – 1:44** What Happened With 2022 CMS Reimbursement And The Future  
*John Blebea*
- 1:45 – 1:50** Economic Venous Reimbursement Impact: Now And Through 2025  
*John Blebea*
- 1:51 – 1:56** The Future Of Venous Reimbursement: Non CMS Insurance  
*Mark D. Iafrati*
- 1:57 – 2:02** What Evidence Is There For Compression Prior To Insurance Approval  
*Omar L. Esponda*

- 2:03 – 2:08** Who Should Fund The Management Of C2 Disease And Why  
*Sarah Onida*
- 2:09 – 2:14** The Irony Of Overtreatment And Undertreatment In Venous Disease: What Can Be Done  
*Manj S. Gohel*
- 2:15 – 2:20** Tackling The “Grey Areas” Of Appropriate Use For Chronic Venous Disease  
*Elna M. Masuda*
- 2:21 – 2:26** AVF Venous Patient Outreach Survey  
*Lowell S. Kabnick*
- 2:27 – 2:32** Insurance Coverage Gaps In Venous Disease  
*Kathleen J. Ozsvath*
- 2:33 – 2:38** Focused Practice Designation – Venous Disease Treatment  
*Brajesh K. Lal*
- 2:39 – 2:44** Prior Authorization As A Utilization Management Tool For Elective Superficial Venous Procedures Is Worthless  
*Todd Berland*
- 2:45 – 2:50** **Panel Discussion**

SESSION 70 (Trianon Ballroom, 3rd Floor)

## MORE SUPERFICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES

**Moderators:** *Raghu Kolluri*  
*Anil P. Hingorani*

- 2:51 – 2:56** EHIT Recommendations  
*Lowell S. Kabnick*
- 2:57 – 3:02** Physician Compounded Foam Sclerotherapy: To Use Or Not And When  
*Pauline Raymond-Martimbeau*
- 3:03 – 3:08** C2 Intervention: Evidence Summary  
*Peter Gloviczki*
- 3:09 – 3:14** Technical Aspects Of Sclerotherapy For Telangiectasia  
*Pauline Raymond-Martimbeau*
- 3:15 – 3:20** Unrecognized Consequences Of Superficial Venous Disease  
*Alun H. Davies*
- 3:21 – 3:26** Varithena® VLU Registry: The Effects Of Polidocanol Endovenous Microfoam On Wound Healing And Recurrence  
*Raghu Kolluri*
- 3:27 – 3:32** Phlebectomy And Foam Sclerotherapy For Varicose Veins: Which Is Better And When  
*Felipe Coelho Neto*
- 3:33 – 3:38** EHIT Analysis – 10,000 Cases  
*Anil P. Hingorani*  
*Enrico Ascher*
- 3:39 – 3:44** Ambulatory Phlebectomy: A Useful And Beneficial Procedure (AVKS Registry – 2,800 Procedures)  
*John Blebea*
- 3:45 – 3:50** Treatment of Leg Veins For Restless Leg Syndrome: Does It Work  
*Omar L. Esponda*
- 3:50 – 3:55** **Panel Discussion**

SESSION 71 (Trianon Ballroom, 3rd Floor)

## VENOUS CLINICAL TRIALS, LYMPHATIC, VEIN TREATMENT STRATEGIES

**Moderators:** *Manj S. Gohel*  
*Nicholas H. Osborne*

- 3:56 – 4:01** Update: SVS And AVF Varicose Vein Guidelines  
*Peter Gloviczki*
- 4:02 – 4:07** Ablation Of Incompetent Perforators In Patients With Chronic Insufficiency: Is It Worthwhile And What Is The Evidence  
*Ellen D. Dillavou*
- 4:08 – 4:13** Venaseal Spectrum Study: RCT Study Overview  
*Manj S. Gohel*
- 4:14 – 4:19** Update: Turkish Cyanoacrylate  
*Lowell S. Kabnick*
- 4:20 – 4:25** Treating Low And Moderate Severity Venous Disease Is Beneficial – Data From The VQI VVR  
*Nicholas H. Osborne*
- 4:26 – 4:31** Global Epidemiology Of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis  
*Sarah Onida*
- 4:32 – 4:37** What Are The Differences Between The SVS/AVF Venous Guidelines And The European Society for Vascular Surgery  
*Anil P. Hingorani*
- 4:38 – 4:43** **Panel Discussion**

### *LIPHEDEMA, LYMPHEDEMA, PHLEBOLYMPHEDEMA*

**Moderators:** *Thomas F. O'Donnell, Jr.*  
*Mark D. Iafrati*

- 4:44 – 4:49** Diagnosis Of Lipedema And Treatment  
*Steven Dean*
- 4:50 – 4:55** Overview Of Lymphatic Anatomy, Physiology And Imaging Techniques  
*Thomas F. O'Donnell, Jr.*
- 4:56 – 5:01** The American Venous Forum, American Vein And Lymphatic Society And The Society for Vascular Medicine Expert Opinion Consensus On Lymphedema Diagnosis And Treatment  
*Mark D. Iafrati*
- 5:02 – 5:07** Lymphedema And Compression: Evidence  
*Felipe Coelho-Neto*
- 5:08 – 5:13** Recurrence Of Varicose Veins After Endovenous Ablation  
*Mark D. Iafrati*
- 5:14 – 5:19** Management Of Phlebolymphe'dema – A Dual Problem  
*Steven Dean*
- 5:20 – 5:25** Long-Term Treatment Of Lymphedema: Compression With Manual Lymphatic Drainage Or Intermittent Apparative Compression: A Randomized Cross Over Study  
*B. Erika Mendoza*
- 5:26 – 5:31** **Panel Discussion**

### *EXAMINING THE EVIDENCE*

**Moderators:** *Jean Luc Gerard*  
*Gloria Salazar*

- 5:32 – 5:37** What Data Can We Use From VQI VVR To Advocate For Coverage Of Venous Procedures  
*Nicholas H. Osborne*
- 5:38 – 5:43** When Evaluating Superficial Disease When Do You Look For Deep Venous Obstruction  
*Gloria Salazar*
- 5:44 – 5:49** Ablative Risks Prior And After Flying: What Do You Tell Your Patients  
*Sarah Onida*
- 5:50 – 5:55** When To Use Dry Foam, Regular Foam, And Wet Foam: What Are The Differences  
*Alvaro Orrego*
- 5:56 – 6:01** Bone Perforator: What Is The Significance  
*Jean Luc Gerard*
- 6:02 – 6:07** Update: Outcomes After Truncal Ablation With Or Without Phlebectomy - C2 (VQI Registry)  
*Andrea T. Obi*
- 6:08 – 6:13** Are All Laser And RFA Devices Equivalent: Review Of The Literature  
*Alvaro Orrego*
- 6:14 – 6:19** What Is C3 Disease  
*Steve Elias*
- 6:20 – 6:25** **Panel Discussion**  
**End of Program I**

PROGRAM J (SESSIONS 72-75)  
MULTIDISCIPLINARY ACUTE STROKE  
MANAGEMENT

Murray Hill Suites, 2nd Floor

Course Leader: **Allan L. Brook**

SESSION 72 (Murray Hill Suites, 2nd Floor)

EMERGING TRENDS IN ISCHEMIC STROKE  
TREATMENT

**Moderators:** *Allan L. Brook*  
*Joshua A. Hirsch*

- 8:00 – 8:10** Introduction  
*Allan L. Brook*
- 8:11 – 8:18** Access Issues: Radial Artery And Arch Nuances: When To Go Groin  
*Sudhakar R. Satti*
- 8:19 – 8:26** Neurology: Latest Trials And Discoveries  
*Michael D. Hill*
- 8:27 – 8:34** Unique Anatomy That Influences Stroke Care  
*Peter K. Nelson*
- 8:35 – 8:42** Techniques To Deal With Tandem Lesions And When Is Stenting Appropriate  
*Mario Muto*
- 8:43 – 8:50** Why Anesthesia Participation Is Important In Stroke  
*James Milburn*
- 8:51 – 8:58** Stroke Access Is One Thing, But Closure Is Another Problem: My Solution  
*Ajay K. Wakhloo*
- 8:59 – 9:06** Healthcare Systems And Stroke Reimbursement: Is It Worth It  
*Joshua A. Hirsch*

**9:07 – 9:14** Acute Stroke Imaging: Factors Leading To Brain Hemorrhage  
*Richard L. Zampolin*

SESSION 73 (Murray Hill Suites, 2nd Floor)

## EMERGING TRENDS IN HEMORRHAGIC STROKE TREATMENT

**Moderators:** *David Gordon*  
*Joshua A. Hirsch*

**9:15 – 9:20** Update On MMA Embolization Trials  
*David Fiorella*

**9:21 – 9:26** Subdural Hemorrhage: MMA Embolization Is A New Standard Of Care, Or An Unproven Trend: Show Me The Data  
*Adam S. Arthur*

**9:27 – 9:34** How To Minimize Intracranial Hemorrhage During And After Thrombectomy  
*Fawaz Al-Mufti*

SESSION 74 (Murray Hill Suites, 2nd Floor)

## LATEST TRENDS IN NEUROINTERVENTIONAL SURGERY

**Moderators:** *Peter K. Nelson*  
*Allan L. Brook*

**9:35 – 9:42** Direct To Angio And Other Stroke Triage And Trials  
*J Mocco*

**9:43 – 9:48** **DEBATE:** Subarachnoid Hemorrhage: Wide Necked Aneurysms Should Go To Open Surgery  
*Howard A. Riina*

**9:49 – 9:54** **DEBATE:** Subarachnoid Hemorrhage: Wide Neck Aneurysms Can Be Treated Endovascularly  
*David J. Altschul*

**9:55 – 10:02** Recent Endovascular Devices And Those In The Pipeline: Clinical Difference Or A Disruptive Force  
*Aquilla S. Turk*

**10:03 – 10:10** Head And Neck Cancer And Hemorrhage: Role Of Endovascular Care  
*Guilherme Dabus*

**10:11 – 10:18** The Posterior Circulation Is Different And Why It Matters  
*Seon-Kyu Lee*

**10:19 – 10:26** Basilar Artery Thrombectomy: Latest Trials And Trends  
*Joshua A. Hirsch*

**10:27 – 10:34** Stroke Imaging Triage: Pearls And Nuances Of Daily Practice  
*R. Gilberto Gonzalez*

**10:35 – 10:42** When Patients Live Far From A Stroke Center: Options For Advanced Care  
*Christopher Kellner*  
*Reade A. De Leacy*

**10:43 – 10:50** Understanding And Optimizing Imaging In Acute Stroke Patients  
*Lawrence N. Tanenbaum*

**10:51 – 10:58** Management Of Complications  
*Breehan Chancellor*

**10:59 – 11:07** Dural Sinus Stenosis: Is There A Standard Of Care  
*Athos Patsalides*



- 11:08–11:15** Artificial Intelligence And Telemedicine: How It Is Changing And Influencing Our Daily Practice  
*Allan L. Brook*
- 11:16–11:23** Intraarterial Chemotherapy: What Needs To Improve And Future Areas Of Growth  
*Pascal Jabbour* (PowerPoint Presentation With Synched Audio)

SESSION 75 (Murray Hill Suites, 2nd Floor)

## CAROTID ARTERY LATEST TRENDS

**Moderators:** *Neil Haranhalli*  
*Don Heck*

- 11:24–11:31** Carotid Artery Disease: New Trials And Best Literature 2022  
*James F. Meschia*
- 11:32–11:39** TCAR Is Better Than True Percutaneous Carotid Stenting: Myth Or Reality  
*Peter A. Schneider*
- 11:40–11:47** New Micromesh CAS Improves Outcomes And Overrides Benefit Of TCAR  
*Don Heck*
- 11:48–11:55** Judging The New Techniques, Devices, And Medical Treatment For Treating Carotid Stenosis  
*Thomas G. Brott*
- 11:56–12:03** Neurovascular Robotic Infiltration: What Is Real And What Is Missing  
*Vitor Mendes Pereira*
- 12:03–12:15** **Discussion**
- 12:15** **Stroke Program Adjourns**
- 12:15 – 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**
- End of Program J**

## FRIDAY, NOVEMBER 18, 2022

- 6:00 A.M.** **General Registration** – Rhinelander Gallery, 2nd Floor
- 6:00 A.M.** **Faculty Registration** – Gramercy Suite West, 2nd Floor
- 6:15 A.M.** **Continental Breakfast** – Rhinelander Gallery, 2nd Floor

### CONCURRENT FRIDAY PROGRAMS

PROGRAM K: (SESSIONS 76–83)

**Progress In The Prevention And Treatment Of Spinal Cord Ischemia (SCI) With TAAAs And Complex Aortic Aneurysm Repairs; New Developments In Carotid Artery Disease And Its Treatment: Mesh Covered Stents And TCAR, Cognitive Changes, Timing Of Treatment, Medical Treatment, Update On Carotid Trials, Treatment Of Asymptomatic Carotid Stenosis (ACS), String Sign, Carotid Clot, Significance Of MRI Lesions, Carotid Controversies And More Carotid Topics; Other New Endovascular Treatment Concepts, Techniques; Update On Percutaneous Access Closure Devices And Wound Care**

6:40 A.M. – 6:02 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM L: (SESSIONS 84-91)

**New Developments In The Treatment Of Popliteal Disease: Aneurysms, Entrapment And Occlusive Lesions; Advances In Treating Arterial And Graft Infections; Advances In Vascular Imaging And Guidance; Augmented Reality And Artificial Intelligence; Recorded Live Complex Endovascular Cases From Münster, Germany; New Developments In Thoracic Outlet Syndrome Management; Advances In Medical, Drug, Anticoagulant And Rare Vascular Disease Treatment; And Advances In The Treatment Of Vascular Trauma**

7:00 A.M. – 5:42 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM M: (SESSIONS 92-101)

**DEEP VEIN DISEASE**

6:30 A.M. – 4:57 P.M.

Trianon Ballroom, 3rd Floor

**Course Leaders:** Jose I. Almeida  
Lowell S. Kabnick  
Peter Gloviczki  
Thomas W. Wakefield  
Steve Elias

PROGRAM K (SESSIONS 76-83)

**PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) WITH TAAAs AND COMPLEX AORTIC ANEURYSM REPAIRS; NEW DEVELOPMENTS IN CAROTID ARTERY DISEASE AND ITS TREATMENT: MESH COVERED STENTS AND TCAR, COGNITIVE CHANGES, TIMING OF TREATMENT, MEDICAL TREATMENT, UPDATE ON CAROTID TRIALS, TREATMENT OF ASYMPTOMATIC CAROTID STENOSIS (ACS), STRING SIGN, CAROTID CLOT, SIGNIFICANCE OF MRI LESIONS, CAROTID CONTROVERSIES AND MORE CAROTID TOPICS; OTHER NEW ENDOVASCULAR TREATMENT CONCEPTS, TECHNIQUES; UPDATE ON PERCUTANEOUS ACCESS CLOSURE DEVICES AND WOUND CARE**

Grand Ballroom East, 3rd Floor

SESSION 76 (Grand Ballroom East, 3rd Floor)

**PROGRESS IN THE PREVENTION AND TREATMENT OF SPINAL CORD ISCHEMIA (SCI) ASSOCIATED WITH THE TREATMENT OF THORACIC, THORACOABDOMINAL AND COMPLEX ABDOMINAL ANEURYSMS**

**Moderators:** Richard P. Cambria  
Germano Melissano  
Christian D. Etz

**6:40 – 6:45**

Progress In Complex Aneurysm Repair And Preventing Associated SCI: How To Apply Lessons Learned About Risk Factors And Experience With Advanced Technology  
*Patrick W. Kelly*

**6:46 – 6:51**

Strategies To Minimize Paraplegia After TAAA Repairs: Prediction And Prognostic Evaluation Of Spinal Cord Ischemia After TAAA Repair  
*Bijan Modarai*  
*Adam Beck*

- 6:52 – 6:57** New Developments In Preventing SCI With Endo And Open TAAA Repairs And Complex TEVARs  
*Germano Melissano*  
*Roberto Chiesa*
- 6:58 – 7:03** Update On The Value Of Motor Evoked Potentials To Decrease SCI With TAAA Repairs: What Is The Difference Between Peripheral And Central SCI  
*Geert Willem H. Schurink*  
*Barend M.E. Mees*  
*Michael J. Jacobs*
- 7:04 – 7:09** **DEBATE:** Cerebrospinal Fluid (CSF) Drainage To Decrease SCI With TAAA Repair Is Not A Benign Procedure: Why: When Not And When To Use It  
*Gustavo S. Oderich*
- 7:10 – 7:15** **DEBATE:** Cerebrospinal Fluid Drains Need Not Be Associated With High Rates Of Complications: How To Prevent Them And The Case For Prophylactic Placement  
*Salvatore T. Scali*
- 7:16 – 7:21** Prevention Of Spinal Cord Ischemia In TAAA Repair: Lessons Learned And Results Achieved In The US Aortic Research Consortium  
*Mark A. Farber*  
*Adam Beck*
- 7:22 – 7:27** Near Infrared Spectrometry (NIRS) Monitoring Is Helpful In Decreasing SCI And Avoiding Spinal Drainage With TAAA Repairs  
*Carlos H. Timaran*
- 7:28 – 7:33** The Intraspinal Collateral Arterial Network And Its Importance In Preventing SCI And Paraplegia With Complex Aortic Repairs  
*Martin Czerny (PowerPoint Presentation With Synched Audio)*
- 7:34 – 7:39** Current Strategies To Minimize SCI With TAAA Repairs, Endo And Open: Updated Status Of Intercostal Embolization As Preconditioning To Prevent Ischemia (MIS2ACE): Status Of PAPA-ARTIS RCT  
*Christian D. Etz*
- 7:40 – 7:45** Updated Clinical Experience With Intercostal Coil Embolization (MIS2ACE) To Prevent SCI With Endovascular TAAA Repair  
*Daniela Branzan*  
*Andrej Schmidt*  
*Christian D. Etz*
- 7:46 – 7:53** **Panel Discussion**

SESSION 77 (Grand Ballroom East, 3rd Floor)

## NEW DEVELOPMENTS IN THE TREATMENT OF CAROTID STENOSIS WITH MESH COVERED STENTS AND TCAR (TRANSCERVICAL CAROTID ARTERY REVASCULARIZATION)

**Moderators:** *Frank J. Veith*  
*Klaus D. Mathias*  
*Sumaira Macdonald*

### MESH COVERED STENTS

- 7:53 – 7:58** Long-Term Results Of Micromesh Stents Show Their Value In Carotid Artery Stenting (CAS): Are There Limitations: Do The Differences In The 3 Micromesh Stents Matter  
*Piotr Musialek*  
*Max Amor*

- 7:59 – 8:04** Update On Carotid And Other Uses Of MicroNet-Covered Stents (C-Guard) In High-Risk Lesions And Aneurysms: What Are The Long-Term Outcomes – And Are There Downsides  
*Piotr Musialek*  
*Stefan Müller-Hülsbeck*
- 8:05 – 8:10** New Multicenter Data Showing The Long-Term Value Of The C-Guard MicroNet Mesh Covered Stent For CAS In High Risk Carotid Lesions (Thrombotic, Calcified And Symptomatic) From The FLOW-GUARD And Other Trials  
*D. Christopher Metzger*  
*Piotr Musialek*
- 8:11 – 8:16** Results From A Multicenter Italian Study Of The C-Guard Micromesh Stent For CAS: Advantages And Complications  
*Francesco Speziale*  
*Gianmarco de Donato*  
*Wassim Mansour*  
*Pasqualino Sirignano*  
*Carlo Setacci*

**TCAR RELATED TOPICS**

- 8:17 – 8:22** TCAR Versus Transfemoral CAS (TFCAS) And CEA (Carotid Endarterectomy): From Propensity Matched VQI Studies: What Do They Show Re Stroke, Death And Complication Rates: TCAR Approval Should Be Expanded To Non-High-Risk Patients  
*Marc L. Schermerhorn*  
*Mahmoud B. Malas*
- 8:23 – 8:28** Real World Single Center (100-Patient Experience) With TCAR: How And Why 30-Day And One Year Outcomes Differ From Those In ROADSTER 1 And ROADSTER 2  
*Zach AbuRahma*  
*Ali F. AbuRahma*
- 8:29 – 8:34** **DEBATE:** TCAR Is Better Than TFCAS And Brachial/Radial Access For CAS: TCAR Approval Should Be Expanded To Non-High-Risk Patients  
*Mahmoud B. Malas*  
*Marc L. Schermerhorn*
- 8:35 – 8:40** **DEBATE:** Not So: TCAR Is No Better And Is More Costly Than TFCAS And Brachial/Radial Access CAS If One Has Appropriate Skills  
*D. Christopher Metzger*  
*William A. Gray*
- 8:41 – 8:46** Adjunctive EEG Can Help With TCAR And Decrease The Stroke Rate: When And How  
*Todd R. Vogel*
- 8:47 – 8:52** **DEBATE:** Based On Data To Date Including 1-Year Results From ROADSTER 2, TCAR Should Replace CEA In Most Cases: When Is TCAR Contraindicated  
*Vikram S. Kashyap*
- 8:53 – 8:58** **DEBATE:** Not So: CEA Is Routinely Better Than TCAR And Remains The Gold Standard: It Should Be Used In Most Cases Requiring Invasive Treatment  
*Michel S. Makaroun*
- 8:59 – 9:07** **Panel Discussion**
- 9:07 – 9:17** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 78 (Grand Ballroom East, 3rd Floor)

**MORE CAROTID HOT TOPICS RELATED TO TCAR,  
MINI-INCISION CEA, SIGNIFICANCE OF DW  
MRI DEFECTS AND COGNITIVE FUNCTION**

**Moderators:** *Thomas G. Brott*  
*Ross Naylor*  
*Michael B. Silva, Jr*

- 9:17 – 9:22** TCAR Is Safe In Recently Symptomatic Patients And Those With Contralateral Carotid Occlusions: Why It Should Be The Procedure Of Choice In Those Conditions  
*Peter A. Schneider*
- 9:23 – 9:28** Pre-Dilatation And Post Dilatation Strategies For TCAR: Do They Differ From TFCAS  
*Vikram S. Kashyap*
- 9:29 – 9:34** TCAR Has A Steeper Learning Curve Than Commonly Thought: Some Precautions To Prevent Adverse Events  
*Michael B. Silva, Jr.*  
*Charles Thang*
- 9:35 – 9:40** Image Analysis Using AI Can Improve Prediction Of Stroke Risk In Carotid Disease: How Does It Work And How Reliable Is It  
*Ravi K. Veeraswamy*

**CAROTID STENOSIS AND COGNITIVE FUNCTION**

- 9:41 – 9:46** Asymptomatic Carotid Stenosis (ACS) Is Associated With Cognitive Impairment In CREST 2: Is There Evidence That Invasive Intervention Will Stop Or Improve It: Will CREST 2 Provide Answers  
*Wesley S. Moore (PowerPoint Presentation With Synched Audio)*  
*Brajesh K. Lal*  
*Thomas G. Brott*
- 9:47 – 9:52** **DEBATE:** Carotid Intervention Improves Cognitive Function Of Patients With Severe Carotid Atherosclerosis: Should More ACS Patients Undergo Invasive Treatment  
*Wei Zhou*
- 9:53 – 9:58** **DEBATE:** Not So Fast: There Is Still Great Doubt That Eliminating ACS Improves Cognitive Function: It Should Not Be A Reason For Treating More ACS Patients  
*Ross Naylor*

**SIGNIFICANCE OF SMALL DW MRI DEFECTS AFTER  
CEA/CAS**

- 9:59 – 10:04** **DEBATE:** Silent DW MRI Brain Lesions (Small Infarcts) After CEA/CAS Don't Matter  
*James F. Meschia*
- 10:05-10:10** **DEBATE:** Not So: How Size And Number Of Silent Brain Infarcts (DW MRI Defects) After CEA/CAS Affect Cognitive Changes: They Really Do Matter  
*Wei Zhou*
- 10:11-10:16** Highlights of the 2022 SVS US Guidelines For the Management Of Carotid Disease  
*Ali F. AbuRahma*
- 10:17-10:22** Highlights Of The 2023 European Guidelines For The Management Of Carotid Disease And How They Differ From The US Guidelines  
*Ross Naylor*
- 10:23-10:30** **Panel Discussion**

SESSION 79 (Grand Ballroom East, 3rd Floor)

MORE CAROTID NEW DEVELOPMENT TOPICS  
RELATED TO TCAR, NEW DEVICES, MESH COVERED  
STENTS, MINI-INCISION CEA, TIMING OF  
TREATMENT, MEDICAL TREATMENT AND DEALING  
WITH DISTAL (HIGH) CAROTID LESIONS

**Moderators:** *Richard J. Powell*  
*Wei Zhou*  
*Frank J. Veith*

**10:30-10:35** Comparative Cost Effectiveness Of TCAR, CEA, TFCAS: CEA Is More Cost Effective Than TCAR And TCAR Is More Cost Effective Than TFCAS

*Mohammad H. Eslami*

**10:36-10:41** Is TCAR Yet Ready To Replace CEA: Not So Fast: We Still Need Further Proof And More Studies Including An RCT

*Bruce A. Perler*

**10:42-10:47** Value Of Lithotripsy (Shockwave) For CAS In Heavily Calcified Lesions: How To Do It Safely And Technical Tips: Limitations And Precautions: A Quick Word About The Value Of Lithotripsy In All Vascular Beds

*Karthik Kasirajan*

*Max Amor*

**10:48-10:53** Value Of Mesh Covered Stents With TCAR: Is It The Best Of All Worlds: Limitations

*Ralf R. Kolvenbach* (PowerPoint Presentation With Synched Audio)

**10:54-10:59** OCT Proves CAS Is Rendered Safer Because Emboli Are Decreased By Mesh Covered Stents: The Evidence And What It Shows About The Interaction Between Stent And Plaque

*Carlo Setacci*

*Francesco Setacci*

**11:00-11:05** Minimal Incision CEA (MICE) Versus TCAR: Cost Effectiveness, Advantages And Limitations Of Both

*Robert M. Proczka*

**11:06-11:12** **Panel Discussion**

**TIMING OF CAROTID INTERVENTIONS AFTER  
SYMPTOM ONSET**

**11:12-11:17** Optimal Timing Of Carotid Revascularization (CEA, TFCAS, TCAR) After Symptom Onset: Within 48 Hours Risk Is Increased For All Procedures; After 48 Hours Risk Is Less With CEA And TCAR Than With TFCAS: Based On A Large National Database Study

*Mahmoud B. Malas*

**11:18-11:23** **DEBATE:** It's Reasonable To Perform CEA Within 48 Hours After A Stroke's Symptoms Start: Under What Conditions And What Precautions Should Be Taken

*R. Clement Darling III*

**11:24-11:29** **DEBATE:** Not So Fast: If The Presenting Stroke Is Severe By NIH Severity Score, The Outcome Of Urgent Interventions (CEA, CAS, TCAR, Etc.) Is Poor: Should They Be Avoided

*Hernan A. Bazan*

**11:30-11:35** When Is CEA Within 48 Hours Of Stroke Symptom Onset Necessary: What Are The Risks: How To Make It Reasonably Safe: When Is It Totally Contraindicated

*Domenico Valenti*

- 11:36–11:41** What Is The Best Medical Treatment For Patients With Carotid Stenosis (Asymptomatic And Symptomatic): Can High Risk Plaques Be Made Low Risk And Can They Be Made Smaller: Are Some Plaques Resistant To Medical Treatment And Why  
*J. David Spence (PowerPoint Presentation With Synched Audio)*
- 11:42–11:47** Technical Tips And Maneuvers To Make Treatment Of High Carotid Lesions Safe And Relatively Simple  
*Richard J. Powell*
- 11:48–11:53** CEA And CAS For Asymptomatic Carotid Stenosis (ACS) Cause More Cognitive Impairment Than They Prevent: How To Get Non-Compliant ACS Patients To Comply With Medical Treatment By Showing Them Their Duplex Scans And Pictures Of Threatening Plaques  
*J. David Spence (PowerPoint Presentation With Synched Audio)*
- 11:54–12:00** **Panel Discussion**
- 12:00– 1:00** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 80 (Grand Ballroom East, 3rd Floor)

MORE HOT CAROTID TOPICS: UPDATES ON KEY CAROTID RCTs; NEW INFORMATION ON TREATMENT OF TANDEM LESIONS, CAROTID ANEURYSMS AND STROKES DURING INTERVENTION

**Moderators:** *Sriram S. Iyer*  
*Christopher J. Kwolek*  
*Anne L. Abbott*

- 1:00 – 1:05** How Best To Treat Strokes Apparent During Or Right After CEA, CAS Or TCAR: Best Diagnostic Modalities And Treatments: What Skills Are Needed  
*Gert J. de Borst*

**UPDATE ON CAROTID RCTs**

- 1:06 – 1:11** Update On SPACE 2: CEA Versus Best Medical Treatment (BMT) And CAS Versus BMT For ACS: Interesting 5-Year Results From A Stopped RCT  
*Hans-Henning Eckstein*
- 1:12 – 1:17** Update On ACST 2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates And Implied That Both Invasive Treatments Were Superior To BMT: Does CEA Prevent Dementia  
*Richard Bulbulia*  
*Alison Halliday*
- 1:18 – 1:23** Not So Fast! ACST 2 Has Flaws That Invalidate Its Conclusions: Invasive Therapies May NOT Be Better Than BMT  
*J. David Spence (PowerPoint Presentation With Synched Audio)*
- 1:24 – 1:29** Update On CREST 2: CEA Versus BMT And CAS Versus BMT For ACS: Findings To Date And When Will We Have Final Results  
*Brajesh K. Lal*  
*Thomas G. Brott*
- 1:30 – 1:35** CEA Versus CAS For High-Grade ACS: RCTs (ACT 1 And CREST) Analyzed By Age And Sex: Are There Important Differences  
*Jon S. Matsumura*

TANDEM CAROTID LESIONS

- 1:36 – 1:41** **DEBATE:** Tandem Lesions At The Carotid Bifurcation Plus The Common Carotid Or Innominate Arteries: Stroke And Mortality Risks With Treatment Are Higher Than For Simple Bifurcation Lesions: How Best To Treat: Endo, Open, Staged, Hybrid  
*W. Darrin Clouse*  
*Mark Conrad*
- 1:42 – 1:47** **DEBATE:** Tandem Carotid Lesions: Treatment Risks Need NOT Be Increased: Based On A Meta-Analysis: How Best To Treat To Minimize Risk  
*Ross Naylor*
- 1:48 – 1:53** Silent Coronary Ischemia As Detected By FFR<sub>CT</sub> Is Common In CEA Patients: What Does It Mean, What Should Be Done About It And When  
*Christopher K. Zarins*  
*Dainis K. Krievins*
- 1:54 – 2:02** **Panel Discussion**

SESSION 81 (Grand Ballroom East, 3rd Floor)

MORE HOT CAROTID TOPICS: TREATMENT IN 2022 OF PATCH INFECTIONS, STRING SIGN, CAROTID DISSECTIONS; MANAGEMENT OF ARTERIAL INJURIES DURING CENTRAL VENOUS CATHETERIZATION; OPTIMAL PLATELET AND PROTAMINE STRATEGIES; BENIGNANCY OF ACS; VALUE OF LOCAL ANESTHESIA; STROKE RISK WITH ACS PLAQUES - A WAY TO PREDICT HIGH RISK PLAQUES

**Moderators:** *Glenn M. LaMuraglia*  
*Samuel R. Money*  
*Peter L. Faries*

- 2:02 – 2:07** Optimal Management Of Carotid Patch Infections  
*Clark J. Zeebregts*
- 2:08 – 2:13** How Best To Diagnose And Treat Near Occlusion Of The Internal Carotid Artery (ICA) In 2022: Based On A Meta-Analysis: Is This The ICA String Sign Of Past Descriptions  
*Gert J. de Borst*
- 2:14 – 2:19** Management Of Arterial Injuries During Placement Of Central Venous Catheters: Techniques For Avoiding Major Complications  
*Oscar J. Ojeda*
- 2:20 – 2:25** Are Patients With 80-99% Asymptomatic Carotid Stenoses (ACS) At Greater Risk For Stroke Than Patients With <80% Stenoses: Should Any ACS Patient Undergo Invasive Treatment  
*Ross Naylor*
- 2:26 – 2:31** Value Of Protamine Use During CEA, CAS And TCAR: How Should It Be Used And With What Precautions  
*David H. Stone*
- 2:32 – 2:38** **Panel Discussion**
- 2:38 – 2:43** Restenosis After CEA And CAS Is Benign And Should Rarely Be Treated: When Can It Cause Strokes Justifying Prophylactic Treatment  
*Ross Naylor*
- 2:44 – 2:49** **DEBATE:** Local Anesthesia And Intraoperative Control With Duplex Or Angiography Is Key To Safe CEA: How To Do Them  
*Hans-Henning Eckstein*



- 2:50 – 2:55** **DEBATE:** Not So: CEA Can Be Performed Safely And Optimally Under General Anesthesia And Without Completion Duplex Or Angio Control: What Is Required To Do So And Are There Downsides To Duplex Or Angio Controls  
*Ali F. AbuRahma*
- 2:56 – 3:01** Are Symptomatic And Asymptomatic Carotid Stenosis Really 2 Different Diseases As Some Suggest  
*James F. Meschia*  
*Thomas G. Brott*
- 3:02 – 3:07** What Vascular Surgeons And Vascular Specialists Need To Know About What Can Be Learned From MRI And MRA Studies Of The Head And Neck  
*Emmanuel M. Houdart*
- 3:08 – 3:13** When An Asymptomatic Carotid Stenosis (ACS) Patient Has A Stroke What Is Its Magnitude: Does It Make The Case For More Or Fewer Prophylactic CEAs And CASs  
*Gianluca Faggioli*
- 3:14 – 3:20** **Panel Discussion**
- 3:20 – 3:30** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 82 (Grand Ballroom East, 3rd Floor)

**MORE HOT AND CONTROVERSIAL CAROTID TOPICS AND NEW OR UPDATED CONCEPTS FOR ENDOVASCULAR TREATMENTS**

**Moderators:** *Anne L. Abbott*  
*Ali F. AbuRahma*  
*Michael H. Wholey*

**NEW OR UPDATED CONCEPTS FOR ENDO TREATMENTS**

- 3:30 – 3:35** Transvenous Transcaval Liver Biopsy: A Better Way And How To Do It: Transfemoral Versus Transjugular  
*Jacob Cynamon*
- 3:36 – 3:41** Endovascular Suturing Devices At The Tip Of An 8-9 French Catheter To Close Large Bore Sheath Access From Inside: The NovelRad Device: How Does It Work And Present Status  
*Elchanan Bruckheimer*
- 3:42 – 3:47** Clinical Judgment Is Required In The Application Of Evidence Based Medicine: RCTs Can Have Flaws Leading To Misleading Conclusions  
*J. David Spence (PowerPoint Presentation With Synched Audio)*
- 3:48 – 3:53** Progress In Open And Endovascular Treatment For Erectile Dysfunction: Diagnosis And Treatment Of Cavernous Leak And Other Pathology: A New Horizon  
*Eric Allaire*
- 3:54 – 3:59** **Panel Discussion**

**HOT CAROTID TOPICS**

- 3:59 – 4:04** Risks And Causes Of Non-Ipsilateral Stroke Complicating CEA  
*W. Darrin Clouse*  
*Mark Conrad*
- 4:05 – 4:10** Why Is CTA An Imperfect And Non-Objective Way To Assess Degree Of Carotid Stenosis  
*Reese A. Wain*

- 4:11 – 4:16** Floating Clot At The Carotid Bifurcation Is A Prime Indication For Flow Reversal Technology During Treatment Of Carotid Stenosis: How Can Flow Reversal Best Be Achieved In This Setting  
*Juan C. Parodi (PowerPoint Presentation With Synched Audio)*
- 4:17 – 4:22** What Is Carotid Near Occlusion And How Is It Best Treated Currently: Conservatively, CEA, CAS  
*Weiguo Fu (PowerPoint Presentation With Synched Audio)*
- 4:23 – 4:28** **DEBATE:** CAS Is The Best Treatment For Young Patients With A High-Grade Asymptomatic Carotid Stenosis (ACS)  
*D. Christopher Metzger*
- 4:29 – 4:34** **DEBATE:** Not So: Young Patients With A High-Grade ACS Should Not Be Treated With CEA, CAS Or TCAR  
*Anne L. Abbott*
- 4:35 – 4:40** Why We Need A RCT Comparison Of TCAR With TFCAS, Transradial CAS And Best Medical Treatment For ACS And Symptomatic Carotid Stenosis  
*Michael H. Wholey*
- 4:41 – 4:46** What Percent Of The Carotid Plaques Are Really High Stroke Risk: How To Detect Them With Ultrasound To See Neovascularization: Can High Risk Plaques Be Made Low Risk By Lipid Lowering  
*Henrik Sillesen*
- 4:47 – 4:54** **Panel Discussion**

SESSION 83 (Grand Ballroom East, 3rd Floor)

## NEW CONCEPTS AND NEW DEVELOPMENTS IN PERCUTANEOUS ACCESS CLOSURE AND WOUND CARE

**Moderators:** *Mark A. Adelman*  
*Kenneth Ouriel*

- 4:54 – 4:59** The Femoral Fascial Suture Technique For Percutaneous Access Closure: Technique, Value And Contraindications  
*Tal M. Hörer*  
*Thomas Larzon*
- 5:00 – 5:05** Embolic Treatment Of Hemorrhoids: How To Do It And How Well Does It Work  
*Gloria Salazar*
- 5:06 – 5:11** Update On Large Bore Percutaneous Access Closure Devices Including Perclose, ProGlide, Manta, PerOseal, InSeal And Others: Which Device Is Best For Which Application: There Are Serious Complications And How To Avoid Them  
*Zvonimir Krajcer*
- 5:12 – 5:17** Access Complications Despite Old And New Closure Devices And Endovascular Suturing: Strategies For Best Outcomes  
*Martin Storck*  
*Peter Reimer*
- 5:18 – 5:23** RCT Comparing Collagen Versus Suture Based Vascular Closure Devices After Lower Extremity Endo Arterial Revascularizations  
*Yann Gouëffic (PowerPoint Presentation With Synched Audio)*

PROGRESS IN WOUND CARE

- 5:24 – 5:29** Best Treatment Strategies For Complex Infected Groin Wounds After Vascular Surgery: When To Do What: Wide Debridement, Antibiotics, Muscle Flap Reconstruction Or Graft Removal  
*Jan-Willem Elshof*
- 5:30 – 5:35** Optimal Treatment For Groin Infection After Prosthetic Bypasses From The Common Femoral Artery: How To Save The Graft And The Leg  
*Hosam F. El Sayed*
- 5:36 – 5:41** New Developments In The Treatment Of Mixed Arterial And Venous Wounds And Ulcers  
*Katherine A. Gallagher (PowerPoint Presentation With Synched Audio)*
- 5:42 – 5:47** Interface Pressure Delivered by Air-Inflated Inelastic Compression Wrap  
*Antonios P. Gasparis*  
*Sundaram Ravikumar*
- 5:48 – 5:53** A New More Efficient Method (TWO2) For Administering Localized Oxygen Therapy To Facilitate Wound Healing  
*Anil P. Hingorani*  
*Enrico Ascher*
- 5:54 – 6:02** **Panel Discussion**  
**End of Program K**

PROGRAM L (SESSIONS 84-91)

NEW DEVELOPMENTS IN THE TREATMENT OF POPLITEAL DISEASE: ANEURYSMS, ENTRAPMENT AND OCCLUSIVE LESIONS; ADVANCES IN TREATING ARTERIAL AND GRAFT INFECTIONS; ADVANCES IN VASCULAR IMAGING AND GUIDANCE; AUGMENTED REALITY AND ARTIFICIAL INTELLIGENCE; RECORDED LIVE COMPLEX ENDOVASCULAR CASES FROM MÜNSTER, GERMANY; NEW DEVELOPMENTS IN THORACIC OUTLET SYNDROME MANAGEMENT; ADVANCES IN MEDICAL, DRUG, ANTICOAGULANT AND RARE VASCULAR DISEASE TREATMENT; AND ADVANCES IN THE TREATMENT OF VASCULAR TRAUMA

Grand Ballroom West, 3rd Floor

SESSION 84 (Grand Ballroom West, 3rd Floor)

POPLITEAL DISEASE TOPICS RELATED TO NEW GUIDELINES, ANEURYSM TREATMENT (PRIMARY AND REDO), ENTRAPMENTS AND ATHERECTOMY FOR OCCLUSIVE LESIONS

**Moderators:** *Enrico Ascher*  
*Martin Björck*

**POPLITEAL ANEURYSMS AND THEIR BEST CURRENT TREATMENTS**

- 7:00 – 7:05** High Points Of New SVS Guidelines For The Treatment Of Popliteal Aneurysms: Roles Of Endo And Open Repairs  
*Alik Farber*  
*Patrick J. Geraghty*

- 7:06 – 7:11** Contemporary Treatment Of Popliteal Aneurysms In 14 Countries: There Is Great Variation In Treatment, Techniques, Complications And Outcomes: When To Repair Endo; When Open: The Take Home Message Is . . .  
*Martin Björck*
- 7:12 – 7:17** **DEBATE:** Endovascular Repair Is The Best Option For Most Popliteal Aneurysms Requiring Repair: Recent Progress In The Procedure: When Is Open Repair Indicated  
*Irwin V. Mohan*
- 7:18 – 7:23** **DEBATE:** Open Repair With Prosthetic Bypass Graft Is Better Than Endovascular Treatment For Popliteal Aneurysms Requiring Repair  
*Laurent Chiche*
- 7:24 – 7:29** Update On Optimal Treatment For Popliteal Aneurysms: When Observation; When Endo Repair; When Open Repair And How  
*Fred A. Weaver*
- 7:30 – 7:36** **Panel Discussion**
- 7:36 – 7:41** What Are Complex Popliteal Aneurysms And How Should They Be Fixed: When Endo; When Open  
*Jacques Busquet*
- 7:42 – 7:47** Rescue Procedures For Failed Endovascular Repairs Of Popliteal Aneurysms: Observation May Be Enough: If Not, Hybrid Versus Open Repair: Technical Tips  
*Jose Fernandes e Fernandes*

#### POPLITEAL ENTRAPMENTS

- 7:48 – 7:53** Surgical Management Of Functional Popliteal Artery Entrapment Syndrome In Athletes  
*Jason T. Lee*

#### POPLITEAL ARTERY INJURY

- 7:54 – 7:59** Surgical Approach And Graft Usage For Popliteal Artery Injury From Posterior Knee Dislocation  
*Charles J. Fox*

#### POPLITEAL ARTERY ATHERECTOMY

- 8:00 – 8:05** Value Of Orbital Atherectomy For Popliteal Artery Occlusive Lesions: New Developments And Expanded Versatility Of The Device  
*Brian G. DeRubertis*

- 8:06 – 8:12** **Panel Discussion**

SESSION 85 (Grand Ballroom West, 3rd Floor)

### NEW DEVELOPMENTS IN TREATING ARTERIAL (INCLUDING AORTIC) GRAFT INFECTIONS

**Moderators:** *Keith D. Calligaro*  
*Peter F. Lawrence*

- 8:12 – 8:17** Update On The NAIS Procedure (Deep Vein Reconstruction For Infected Aortic Grafts): How To Make The Operation Easier And Better  
*John F. Eidt*

#### TREATMENT OF MYCOTIC ANEURYSMS

- 8:18 – 8:23** Optimal Treatment Of Mycotic AAAs In 2022: Value Of And Precautions With EVAR: Is It Ever A Stand-Alone Treatment  
*Timur P. Sarac*

- 8:24 – 8:29** Rifampin Soaked Endografts To Treat Mycotic AAAs: How To Prepare Them And When To Use Them: Are They Stand-Alone Treatment Or Do They Need Adjunctive Techniques  
*Guillermo A. Escobar*
- 8:30 – 8:35** Why Open Repair Is The Best Treatment For Mycotic AAAs: Is EVAR Ever Of Value  
*Yamume Tshomba*
- 8:36 – 8:41** Updated Best Treatment For Mycotic Aortic Aneurysms In The Thorax And Abdomen Based On Long-Term Results  
*Samy S. Nitecki*
- 8:42 – 8:48** **Panel Discussion**  
  
*TREATMENT OF AORTIC AND ARTERIAL GRAFT AND ENDOGRAFT INFECTIONS*
- 8:48 – 8:53** Infected Endografts After EVAR: Etiological Factors, Diagnosis, Treatment, Outcomes  
*Mohammad H. Eslami*
- 8:54 – 8:59** Optimal Techniques For Treating Aorto-Iliac Graft And Endograft Infections In 2022  
*Anders Wanhainen*
- 9:00 – 9:05** Update Of Surgical Treatment For Infected Aortic Grafts And Aortic-Enteric And Aortic-Bronchial Fistulas: Current Results In A Committed Center: Value Of An Antimicrobial Silver/Triclosan Graft  
*Luca Bertoglio*  
*Roberto Chiesa*  
*Germano Melissano*  
*Andrea Kahlberg*
- 9:06 – 9:11** Update On Progress In The Optimal Treatment Of Aortic And Arterial Graft Infections: What's New In 2022: When Is Percutaneous Drainage Acceptable And Helpful  
*Jean-Paul de Vries*
- 9:12 – 9:17** Semi-Conservative Therapy – Saving All Or Part Of An Infected Aortic Graft: When Is It The Best Treatment And How To Make It Work: From The MAGIC Registry And VASGRA Study  
*Zoran Rancic*
- 9:18 – 9:23** EVAR Endograft Infections Can Be Treated By Local Catheter Techniques: How, When And When Not  
*Tal M. Hörer*
- 9:24 – 9:29** Open Repair Of Suprarenal Aortic Graft Infections: Technical Tips And Long-Term Results  
*Thomas C. Bower*  
*Manju Kalra*
- 9:30 – 9:35** Management Of Mid-Visceral Aortic Infections (Mycotic Suprarenal And TAAAs Before And After Repair)  
*Salvatore T. Scali*  
*Gilbert R. Upchurch*
- 9:36 – 9:52** **Panel Discussion And Break**  
**(Visit Exhibits And Pavilions – 2nd and 3rd Floors)**

SESSION 86 (Grand Ballroom West, 3rd Floor)

## PROGRESS IN VASCULAR IMAGING AND GUIDANCE FOR ENDOVASCULAR TREATMENTS WITH LESS RADIATION EXPOSURE OR CONTRAST TOXICITY

Moderators: *Barry T. Katzen*  
*Matthew J. Eagleton*

### VASCULAR HOLOGRAPHY

- 9:52 – 9:57** How Will The Microsoft Hololens Look Through Patients' Bodies And Facilitate Endovascular Interventions: The ARCUS System Of Augmented Reality And Its Value In Vascular Surgery  
*Jan M.M. Heyligers*
- 9:58 -10:03** Real View Holographic Imaging: How Will It Help In Endovascular Treatments: Is It Available In The US  
*Elchanan Bruckheimer*
- 10:04-10:09** Holographic Guidance Of Endovascular Procedures Guidance (With Augmented Reality Goggles And No Screen): How Does It Work: What Is Possible And What Is Not  
*Claude Mialhe*

### DUPLEX AND INTRAVASCULAR ULTRASOUND

- 10:10-10:15** Duplex Ultrasound Guidance: How, Where And When Can It Replace Fluoroscopy For Endovascular Procedures: Advantages, Limitations, And Why Its Use Is Increasing  
*Enrico Ascher*  
*Natalie A. Marks*
- 10:16-10:21** Intravascular Ultrasound (IVUS) Assistance In EVAR And TEVAR: Advantages And Limitations - Based On A Multicenter Study  
*Jean-Baptiste Ricco (PowerPoint Presentation With Synched Audio)*
- 10:22-10:28** **Panel Discussion**

### IMPROVED IMAGING

- 10:28-10:33** Contrast Induced Nephropathy Is Over-Exaggerated: When Patients Need A Contrast Study, They Should Get It: How To Minimize Consequences  
*Lindsay Machan*
- 10:34-10:39** Totally Radiation Free Deployment Of A Complex AAA Endograft Using An Intraoperative Positioning System (IOPS From Centerline) And Positional Markers On Graft Components As Well As Catheters And Wires To Enable Accurate 3D Guidance: It Is Analogous To Precise GPS Targeting  
*Gustavo S. Oderich*
- 10:40-10:45** Update On Cydar Medical System's Evolution To Facilitate Fusion With All Digital Fluoroscopes: How The System Uses AI To Improve EVAR Planning, Guidance And Deployment  
*Jan M.M. Heyligers*
- 10:46-10:51** The Cydar System Deformation Tool For Improving Image Fusion Accuracy: How Does It Work And Why Does It Help  
*Cynthia K. Shortell*
- 10:52-10:57** New Imaging And Navigation Technologies To Facilitate And Improve Complex AAA Repair: Comparison Of Cydar, FORS (Philips) And Centerline Biomedical IOPS Systems  
*Venkatesh G. Ramaiah*

**10:58–11:05 Panel Discussion**

SESSION 87 (Grand Ballroom West, 3rd Floor)

**AUGMENTED REALITY (AR), MIXED REALITY AND ARTIFICIAL INTELLIGENCE (AI): HOW WILL THEY IMPROVE VASCULAR IMAGING AND ENDOVASCULAR DEVICE GUIDANCE WHILE MINIMIZING RADIATION**

**Moderators:** *Gustavo S. Oderich*  
*Alan B. Lumsden*

**11:05–11:10** IOPS Guidance For In Situ Fenestrations Without Fluoroscopy  
*Animesh Rathore*

**11:11–11:16** Intra-Operative Prediction Of Endoleaks With Deep Learning  
*Kak Khee Yeung* (PowerPoint Presentation With Synched Audio)

**11:17–11:22** Automated Measurements Of Aortic Diameter Simplify Follow Up Of Complex Aneurysms  
*Stephan Haulon*

**11:23–11:28** Can Computational Fluid Dynamics Predict Which Patients Will Fail Complex Aortic Repair  
*Kenneth Tran*

**11:29–11:34** Virtual Reality And Intraoperative Position System During Aortic Aneurysm Repair  
*Aleem Mirza*

**11:35–11:40** Leveraging Machine Learning And Artificial Intelligence To Improve Cardiovascular Outcomes In Peripheral Arterial Disease  
*Elsie Ross*

**11:41–11:46** Will Virtual Reality Simulation Offsets Decrease Number Of Cases For Vascular Trainees  
*Isabelle Van Herzeele*

**11:47–12:00 Panel Discussion**

**12:00–1:00 Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 88 (Grand Ballroom West, 3rd Floor)

**TWO PRESENTATIONS AND CHALLENGING RECORDED LIVE CASES FROM MÜNSTER, GERMANY**

**Moderators:** *Martin J. Austermann*  
*Giovanni B. Torsello*

**1:00 – 1:05** F/B/EVAR In The Treatment Of Chronic TBADs With TAAAs: Comparative Indications And Results For B/EVAR And F/EVAR  
*Michel J. Bosiers*  
*Giovanni B. Torsello*  
*Martin J. Austermann*

**1:06 – 1:11** An Update On The EMINENT RCT Comparing The Eluvia DES Versus Bare Metal Stents  
*Giovanni B. Torsello*

**1:12 – 1:44** Complex Cases From Münster With Questions And Discussion: Huge Ruptured AAA Involving Iliac Arteries And Thoracic Aneurysm After Failed Open Repair Treated Endovascularly With Parallel Graft Chimps  
*Martin J. Austermann*  
*Giovanni B. Torsello*

SESSION 89 (Grand Ballroom West, 3rd Floor)

## NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOSs)

**Moderators:** *Mark A. Adelman*  
*Robert W. Thompson*

- 1:44 – 1:49** Minimal Access Transaxillary First Rib Resection Under Loco-Regional Anesthesia: How To Do It And Advantages  
*Francesco Spinelli*
- 1:50 – 1:55** Supraclavicular Approach To Arterial And Neurogenic TOSs (Video Presentation)  
*Ramesh K. Tripathi*
- 1:56 – 2:01** New Developments In The Diagnosis And Treatment Of Neurogenic TOS: The Roles Of Physical Therapy And Surgical Decompression: Based On The STOPNTOS RCT  
*Joep Teijink*  
*Marc R.H.M. van Sambeek*

### VENOUS TOSs

- 2:02 – 2:07** Current Optimal Management Of Venous Thoracic Outlet Syndromes  
*Robert W. Thompson*
- 2:08 – 2:13** Spectrum Of Treatment Options For Venous TOS: What Are The Outcomes And How Do They Differ  
*Jason T. Lee*
- 2:14 – 2:19** Thoracic Outlet Syndrome: Trials And Tribulations Of Pectoralis Minor Syndrome  
*Michael J. Singh*
- 2:20 – 2:26** **Panel Discussion**
- 2:26 – 2:36** **Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 90 (Grand Ballroom West, 3rd Floor)

## NEW DEVELOPMENTS IN MEDICAL AND DRUG TREATMENTS: BEST ANTIPLATELET REGIMENS; UPDATE ON RARE VASCULAR DISEASES

**Moderators:** *Caron B. Rockman*  
*James H. Black, III*

### ANTIPLATELET REGIMENS

- 2:36 – 2:41** Current Optimal Anticoagulation And Antiplatelet Treatment For High Risk Lower Extremity Bypasses – Vein And PTFE: How Are DOACs Useful  
*Peter Henke*
- 2:42 – 2:47** Why One Should Have A Stock On Hand Of Balloon-Expandable And Self-Expandable Covered Stents To Deal With Emergencies From Iatrogenic And Other Traumatic Vascular Injuries: What Should Be In The Stock  
*Maria A. Ruffino*
- 2:48 – 2:53** Why Clopidogrel Is Effective In <50% Of Patients At Standard Doses: How To Identify And Fix This Problem  
*Karthik Kasirajan*
- 2:54 – 2:59** Optimal Antiplatelet Management With CEAs, Lower Extremity Bypasses And Open AAA Repairs  
*David H. Stone*



NEW DEVELOPMENTS IN LIPID MANAGEMENT –  
STATINS

- 3:00 – 3:05** Safety And Benefit Of Statins And Medical Treatment In Vascular Patients: Shockingly These Treatments Are Underutilized – Especially In Women: Why Is This So: Statin Intolerance Has Been Over Emphasized  
*Christian A. Behrendt (PowerPoint Presentation With Synched Audio)*
- 3:06 – 3:11** The Importance Of Lipoprotein Little a [Lp(a)] Levels In Determining Atherosclerotic Risk: When Should It Be Measured And If High, How Treated: Do PCSK-9 Inhibitors Help: Will An Oral PCSK-9 Inhibitor Be Available  
*Caron B. Rockman*  
*Jeffrey S. Berger*
- 3:12 – 3:17** Value And Limitations Of Statins And Non-Statins Lipid Lowering Agents In Patients With Carotid Artery Stenosis  
*Kosmas I. Paraskevas*
- 3:18 – 3:23** Lowering LDL-C And Controlling Elevated Blood Pressure Can Lower Cardiovascular Risk 80%: Doing These Things Should Be A Lifetime Goal  
*Richard Bulbulia*
- 3:24 – 3:32** **Panel Discussion**

## OTHER DISEASE RELATED TOPICS

- 3:32 – 3:37** Current (2022) Status Of Diagnosis And Treatment Of Buerger's Disease: Does It Exist Or Is It Just A Variant Of Atherosclerosis  
*Kamphol Laohapensang*
- 3:38 – 3:43** How To Make Operations For Complications Of Vascular Ehlers Danlos Syndrome Go Well  
*James H. Black, III*
- 3:44 – 3:49** Medical Treatment Of Patients With Vascular Ehlers Danlos Syndrome: How Does Celiprolol Treatment Work And How Does It Help  
*Martin Björck*
- 3:50 – 3:55** Temporary Diaphragm Pacing For Patients At Risk Of Prolonged Mechanical Ventilation To Maintain Muscular Integrity Of The Diaphragm: How Does It Work And Value  
*Jae S. Cho*
- 3:56 – 4:00** **Panel Discussion**

SESSION 91 (Grand Ballroom West, 3rd Floor)

ADVANCES IN THE ENDO AND OPEN TREATMENT  
OF VASCULAR TRAUMAModerators: *Timur P. Sarac*  
*Todd E. Rasmussen*

- 4:00 – 4:05** Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA): When Is It A Valuable Procedure And When Is It Not: Limitations And Precautions  
*Gilbert R. Upchurch*
- 4:06 – 4:11** Value Of REBOA For Pending And Actual Cardiac Arrest: What Is Partial And Intermittent REBOA And How Is It Helpful  
*Tal M. Hörer*
- 4:12 – 4:17** Value Of Simulator Based Training For REBOA: How Does It Work: Can It Improve Results And Decrease Mishaps  
*Lars B. Lonn (PowerPoint Presentation With Synched Audio)*

- 4:18 – 4:23 Advances In Endovascular Control Of Hemorrhage: Techniques: When Should They Be Used And When Not  
*Ravi R. Rajani*
- 4:24 – 4:29 Most Effective Antiplatelet Management After Lower Extremity Interventional Treatments For CLTI – POBA, DCBs, Stents, Etc.  
*Maciej L. Dryjski*
- 4:30 – 4:35 Contrary To Current Teaching, With Complex Extremity Injuries Involving Fractures And Large Blood Vessels, Revascularization Should PRECEDE External Bone Fixation: How To Get The Vascular Repair Length Right  
*Erica L. Mitchell*
- 4:36 – 4:41 For Major Venous Injuries: Repair Versus Ligation – Which Is Currently Best And When  
*Samy S. Nitecki*
- 4:42 – 4:47 Update On Best Current Management Of Pediatric Vascular Injuries: When Conservative; When Open; When Endo And Precautions  
*Michael C. Dalsing*
- 4:48 – 4:54 **Panel Discussion**

**BLUNT THORACIC AORTIC INJURY (BTAI)**

- 4:54 – 4:59 Blunt Traumatic Injuries Can Occur At Unusual Aortic Locations: What Are These Locations, What Are The Mechanisms Of Injury And What Are The Best Treatments  
*James W. Dennis*
- 5:00 – 5:05 When Can Minor BTAI Be Treated By Observation Without TEVAR: What Precautions Are Necessary  
*Elina Quiroga*
- 5:06 – 5:11 Are We Overtreating BTAI – Especially Lesser Injuries  
*Pedro Teixeira*  
*Joseph DuBose*
- 5:12 – 5:17 How To Manage Heparin In TEVAR For BTAI When Head Or Other Injuries Are Also Present: Some, None Or Just Sheath Flushing  
*Charles J. Fox*
- 5:18 – 5:23 Why Rapid And Complete Aortic Healing After TEVAR For BTAI Allows Minimization Of The Seal Zone And Endograft Length Used  
*Shang Loh*
- 5:24 – 5:29 New Findings From The Aortic Trauma Foundation Global Registry On Outcomes Of TEVAR For Repair Of Traumatic Aortic Injuries: Do Lesser Degrees Of BTAI Require TEVAR  
*Ali Azizzadeh (PowerPoint Presentation With Synched Audio)*
- 5:30 – 5:35 Advantages Of An Endovascular Trauma Service: How To Set One Up And How To Finance It: Who Does The Cases Requiring Open Repairs Or Other Surgery  
*Charles J. Fox*
- 5:36 – 5:42 **Panel Discussion**
- End of Program L**

PROGRAM M (SESSIONS 92-101)  
DEEP VEIN DISEASE

Trianon Ballroom, 3rd Floor

Course Leaders: **Jose I. Almeida**  
**Lowell S. Kabnick**  
**Peter Gloviczki**  
**Thomas W. Wakefield**  
**Steve Elias**

SESSION 92 (Trianon Ballroom, 3rd Floor)  
VENOUS IMAGING, CHRONIC VEIN  
OBSTRUCTION, PELVIC VEIN DISORDERS

Moderators: **Jose I. Almeida**  
**Lowell S. Kabnick**  
**Peter Gloviczki**  
**Thomas W. Wakefield**

- 6:30–6:34** Introduction: Deep System  
*Lowell S. Kabnick*
- 6:35–6:40** Defining The Role Of Risk Stratification And Duplex  
Ultrasound In The Diagnosis Of Acute Lower Extremity  
Deep Vein Thrombosis  
*Fedor Lurie*
- 6:41–6:46** The Conundrum Of 50% Stenosis In Veins  
*Arjun Jayaraj*  
*Seshadri Raju*
- 6:47–6:52** Outcome Of Venous Stents In Adolescents, Teenagers,  
And Pregnancy  
*Mahmood Razavi*
- 6:53–6:58** The Pitfalls And Confusion About IVUS Measurements  
For Deep Vein Stenting: How To Avoid Migration  
*Paul J. Gagne*
- 6:59–7:04** Iliac Vein Post-Thrombotic Disease Stent  
Considerations  
*Jose I. Almeida*
- 7:05–7:10** Iliocaval Duplex Ultrasound With Image Optimization  
*Jan M. Sloves*
- 7:11–7:16** Tilt Table Plethysmography – A Must Prior To Stenting  
Venous Obstructions  
*B. Erika Mendoza*
- 7:17–7:22** Venographic Techniques To Identify Pelvic Anatomy  
And Escape Points  
*Mark H. Meissner*
- 7:23–7:28** Ovarian Vein Embolization: Which Patient Benefits  
And Reimbursement  
*Kathleen D. Gibson*
- 7:29–7:34** Open Surgery For Nutcracker: Techniques And Results  
*Cynthia K. Shortell*
- 7:35–7:40** We Need Dedicated Venous Stents For Nutcracker  
Syndrome And Why We Need Them  
*Peter Gloviczki*
- 7:41–7:46** **Panel Discussion**

## CHRONIC VEIN OBSTRUCTION

Moderators: **Marzia Lugli**  
**Patrick E. Muck**

- 7:47–7:52** Using The Femoral Vein As A Tunneling Conduit For  
An Arterial Bypass: Venous Outcomes In PQ Bypass—  
1 And 2-Year Results  
*Mark A. Adelman*

- 7:53 – 7:58** Deep Reflux: What Happens After Concomitant Obstruction Correction  
*Marzia Lugli*
- 7:59 – 8:04** Does Vein Stenting Reduce Great And Small Saphenous Venous Reflux  
*Natalie A. Marks*
- 8:05 – 8:10** Contralateral Limb Improvement After Unilateral Iliac Vein Stenting: Argument Against Simultaneous Bilateral Stenting  
*Arjun Jayaraj*  
*Seshadri Raju*
- 8:11 – 8:16** Utilizing The Radiofrequency Power Wire To Vaporize A Channel Through Chronic Iliocaval Venous Obstructions (CICVO)  
*Patrick E. Muck*
- 8:17 – 8:22** Complex Iliocaval Reconstruction: How I Do It  
*Kush R. Deasi*
- 8:23 – 8:28** **Panel Discussion**

SESSION 93 (Trianon Ballroom, 3rd Floor)

## FEMORO-ILIOCAVAL INTERVENTIONAL STRATEGIES TO REDUCE VENOUS HYPERTENSION

**Moderators:** *Ellen D. Dillavou*  
*Rabih A. Chaer*

- 8:29 – 8:34** Outcomes And Predictors Of Failure Of Iliac Vein Stenting  
*Rabih A. Chaer*
- 8:35 – 8:40** Validation Of A Chronic Venous Obstruction Classification System  
*Houman Jalaie*
- 8:41 – 8:46** Best Anticoagulation After Deep Venous Stenting  
*Ellen D. Dillavou*
- 8:47 – 8:52** Impact Of Stent Structure On Venous Flow (In Vitro Investigations With A Designed Fluid Dynamic Model)  
*Houman Jalaie*
- 8:53 – 8:58** What Should The 3rd Generation Stents Look Like  
*Cees H.A. Wittens*
- 8:59 – 9:04** Does PMT Now Lead To Over-Stenting  
*Stephen A. Black*
- 9:05 – 9:10** **Panel Discussion**

SESSION 94 (Trianon Ballroom, 3rd Floor)

## HYBRID TECHNIQUES AND STENT PROBLEMS POST-IMPLANTATION

**Moderators:** *Houman Jalaie*  
*Steven D. Abramowitz*

- 9:11 – 9:16** A Randomized Controlled Trial Comparing Venous Stenting With Conservative Treatment In Patients With Deep Venous Obstruction  
*Houman Jalaie*
- 9:17 – 9:22** Neointima Formation Following Venous Placement Of Self-Expanding Nitinol Stents Of Different Porosity: Clinical And Experimental Results  
*Houman Jalaie*
- 9:23 – 9:28** My Worst Venous Complications  
*Erin H. Murphy*
- 9:29 – 9:34** Reinterventions Following Vein Stent Placements – Lessons Learned From 166 Cases  
*Windsor Ting*

**9:35 – 9:40** Techniques For Endovenectomy And Concomitant Iliocaval Stenting With And Without Adjuvant Arteriovenous Fistula Creation  
*Steven D. Abramowitz*

**9:41 – 9:46** **Panel Discussion**

SESSION 95 (Trianon Ballroom, 3rd Floor)

## WOUNDS AND NEW HORIZONS

**Moderators:** *Peter F. Lawrence*  
*William A. Marston*

**9:47 – 9:52** What Is The Standard Of Care For Venous Wounds  
*William A. Marston*

**9:53 – 9:58** Adjuvant Pharmacologic Treatment Of Venous Ulcers  
*Monika L. Gloviczki*

**9:59 – 10:04** Treatment Of Superficial And Perforator Reflux And Deep Venous Stenosis Improves Healing Of Chronic Venous Leg Ulcers  
*Peter F. Lawrence*

**10:05–10:10** Skin Substitutes To Promote Venous Leg Ulcer Healing  
*Sarah Onida*

**10:11–10:16** Do The EVRA Study Results Apply For Ulcers >6 Months Chronicity  
*Manj S. Gohel*

**10:17–10:22** The Economic Impact Of Infections In Venous Leg Ulcer Patients  
*Thomas F. O'Donnell, Jr.*

**10:23–10:28** **Panel Discussion**

SESSION 96 (Trianon Ballroom, 3rd Floor)

## VENOUS STENT TRIALS AND CONCEPTS

**Moderators:** *Jose I. Almeida*  
*Lowell S. Kabnick*

**10:29–10:34** Aspect Ratio Of Iliac Stenosis: Does It Matter  
*Jose I. Almeida*

**10:35–10:40** What Is Aspect Ratio And What Does The Clinical Data Reveal  
*Lowell S. Kabnick*

**10:41–10:46** VERNACULAR Trial: 3-Year Update  
*Michael K.W. Lichtenberg*

**10:47–10:52** What Can The Arnsberg Registry Tell Us  
*Michael K.W. Lichtenberg*

**10:53–10:58** Zilver Vena Stent Trial: Three-Year Outcomes  
*Anthony J. Comerota* (PowerPoint Presentation With Synched Audio)

**10:59–11:04** ABRE Trial Results  
*Stephen A. Black*

**11:05–11:10** Update On The IGUIDEU (Philips) Trial  
*Paul J. Gagne*

**11:11–11:16** **Panel Discussion**

SESSION 97 (Trianon Ballroom, 3rd Floor)

## MORE ILIOFEMORAL FLOW, PELVIC, AND SITE OF SERVICE ISSUES

**Moderators:** *Paul J. Gagne*  
*Erin H. Murphy*

**11:17–11:22** Models Of OBL Development: Start And Finance  
*Paul J. Gagne*

**11:23–11:28** Home Care Of Venous Leg Ulcers Using A Novel, Self-Applied, Inelastic Air Compression Garment And Air-Bolster Wound Dressings  
*Sundaram Ravikumar*

- 11:29–11:34** Do Venous Stent Fractures Matter  
*David J. Dexter*
- 11:35–11:40** Criteria To Predict Mid-Term Outcome After Stenting Of Chronic Iliac Vein Obstructions (PROMISE Trial)  
*Iris Baumgartner*
- 11:41–11:46** Complications From Landing Iliofemoral Stents On A Curve  
*Erin H. Murphy*
- 11:47–11:52** A Novel Technique And Outcomes For Iliocaval Extravascular Reconstruction (TIER) For Iliocaval Agenesis  
*Steven D. Abramowitz*
- 11:53–11:58** Deep Venous Reflux In Patients Undergoing Venous Treatments  
*Mikel Sadek*
- 11:59–12:04** Stent Complications In The ABRE Trial At 24 Months  
*Erin H. Murphy*
- 12:05 –12:10** Male Pelvic Congestion And Varicose Veins: How Much Of A Problem  
*Mark S. Whiteley*
- 12:11–12:16** Shortcomings Of Stents: Positioning, Migration, Patency And Anticoagulation  
*Cees H.A. Wittens*
- 12:17–12:22** When Deep Venous Reflux Repair Is Not Effective: What Next  
*Marzia Lugli*
- 12:23–12:28** **Panel Discussion**
- 12:29– 12:45** **Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)**

SESSION 98 (Trianon Ballroom, 3rd Floor)

## STRATEGIES FOR THROMBOEMBOLIC EVENTS AND VENOUS ANEURYSMS

**Moderators:** *Thomas W. Wakefield*  
*David J. Dexter*

### VTE INTERVENTIONAL

- 12:46–12:51** CLOUT Registry For The Inari CloTrier  
*David J. Dexter*
- 12:52–12:57** DVT Removal Without Thrombolytics – Mechanical Thrombectomy Is Now The Standard Of Care For Both Upper And Lower Extremity DVT  
*Constantino Pena*
- 12:58–1:03** P-Max Study: Mechanical Thrombectomy For Iliofemoral DVT With The Aspirex Device  
*Michael K.W. Lichtenberg*
- 1:04 – 1:09** Thrombolysis For Acute DVT: Utilization And Guidance From Current Clinical Trials  
*Brian G. DeRubertis*
- 1:10 – 1:15** Why Iliofemoral Deep Venous Stents Fail, And How To Manage It  
*Kush R. Desai*
- 1:16 – 1:21** Angiovac Venous Thrombectomy: Where, When, And How  
*David J. Dexter*
- 1:22 – 1:27** Venous Aneurysms: Should They Be Treated  
*Peter F. Lawrence*
- 1:28 – 1:33** Closed Plication Is A Safe And Effective Method For Treating Popliteal Venous Aneurysms  
*Thomas W. Wakefield*

**1:34 – 1:39 Panel Discussion**

SESSION 99 (Trianon Ballroom, 3rd Floor)

**COVID-19; VENOUS THROMBOSIS****Moderators:** *Jose I. Almeida*  
*Mikel Sadek*

- 1:40 – 1:45** Our Experience With DVT/PE During The COVID Era  
*Young Erben*
- 1:46 – 1:51** Treatment Of Venous Thrombosis In Hospitalized Patients With COVID-19  
*Mikel Sadek*
- 1:52 – 1:57** We Need To Pay More Attention To The Micro-circulation  
*Jose I. Almeida*
- 1:58 – 2:03** Duration Of Anticoagulation  
*Rachel Rosovsky*
- 2:04 – 2:09** Inflammation, Selectins And Venous Thrombosis  
*Thomas W. Wakefield*
- 2:10 – 2:15** Thoracic Outlet Acute VTE: What To Do And When  
*Thomas S. Maldonado*
- 2:16 – 2:21** Venous Thromboembolism In The Context Of Chronic Venous Disease  
*Thomas W. Wakefield*
- 2:22 – 2:27** Should All Patients With Acute VTE Be Treated With A Statin: When And Dose  
*Anthony J. Comerota* (PowerPoint Presentation With Synched Audio)
- 2:28 – 2:33** The Dexterity Study: Anti-Inflammatory Potential In Treating Venous Disease  
*Stephen A. Black*
- 2:34 – 2:39 Panel Discussion**

SESSION 100 (Trianon Ballroom, 3rd Floor)

**MORE VENOUS THROMBOSIS STRATEGIES****Moderators:** *Joann Lohr*  
*Peter Henke*  
*Jose I. Almeida*

- 2:40 – 2:45** Pediatric DVT: An Evidence Based Summary  
*Dawn M. Coleman*
- 2:46 – 2:51** DOAC Revolution – Which Drug For What Disease: Review Of Ongoing Trials  
*Andrea T. Obi*
- 2:52 – 2:57** Update In Experimental DVT Pathogenesis And Resolution  
*Peter Henke*
- 2:58 – 3:03** Role Of Thrombophilia Testing  
*Rachel Rosovsky*
- 3:04 – 3:09** Mesenteric Vein Thrombosis: What Is The Best Strategy For Management  
*Mark G. Davies*
- 3:10 – 3:15** Update On Reversal Agents For The DOACs  
*Timothy K. Liem*
- 3:16 – 3:21** IVC Clot Management In Pregnant Patients  
*Joann Lohr*
- 3:22 – 3:27** Open Removal Of Chronically Occluded IVC And Iliofemoral Stents  
*Steven D. Abramowitz*

**3:28 – 3:33** What To Do When Iliac Vein Stenting As Well As Endovenous Ablation Fail To Heal The Venous Ulcer: Tips And Tricks  
*Ramesh K. Tripathi*

**3:34 – 3:39** **Panel Discussion**

SESSION 101 (Trianon Ballroom, 3rd Floor)

DEEP VEIN VALVE TECHNOLOGIES; MANAGEMENT OF IVC FILTER PROBLEMS AND TUMORS; WHEN ILIAC VEIN STENTING PLUS SUPERFICIAL ABLATION; TREATMENT OF SUPERIOR VENA CAVA SYNDROME

**Moderators:** *Paul J. Gagne*  
*Jorge H. Ulloa*

**3:40 – 3:45** Advanced IVC Filter Retrieval: When And How  
*Kush R. Desai*

**3:46 – 3:51** Why Temporary Filters Are Not Removed: Clinical Predictors In 1,000 Consecutive Cases  
*Kush R. Desai*  
*Heron E. Rodriguez*

**3:52 – 3:57** Safety And Efficacy Report On The Venovalve (First In Man) IDE Feasibility Study  
*Jorge H. Ulloa*

**3:58 – 4:03** Tips And Tricks For Optimal Management Of Primary And Secondary IVC Tumors  
*Jill J. Colglazier*

**4:04 – 4:09** Surgical Removal Of IVC Filters For Perforation Or Infiltration  
*Timothy K. Liem*

**4:10 – 4:15** An Update On The Cook Venous Valve Project  
*Paul J. Gagne*

**4:16 – 4:21** The Preserve IVC Filter Study Results  
*David L. Gillespie*

**4:22 – 4:27** Combining Iliac Vein Stenting With Superficial Vein Ablation: When Are They Both Indicated  
*Elna M. Masuda*

**4:28 – 4:33** Deep Vein Valve Devices; What Outcome Measures Should Be Used  
*Fedor Lurie*

**4:34 – 4:39** What To Do With Fractured Filters And Embolic Filter Fragments  
*Constantino Pena*

**4:40 – 4:45** US Experience Of The BlueLeaf<sup>®</sup> Endovenous Valve Formation: Update  
*William A. Marston*

**4:46 – 4:51** Open Surgical And Endovascular Treatment Of Superior Vena Cava Syndrome  
*Manju Kalra*

**4:52 – 4:57** **Panel Discussion**  
**End of Program M**



**SATURDAY, NOVEMBER 19, 2022**

6:15 A.M. General Registration — Gramercy Suite East, 2nd Floor

6:00 A.M. Faculty Registration — Gramercy Suite West, 2nd Floor

6:30 A.M. Continental Breakfast — 3rd Floor Promenade/Foyer

**CONCURRENT SATURDAY PROGRAMS**

PROGRAM N: (SESSIONS 102-106)

**Topics Too Important To Miss In The Treatment Of Lower Extremity, Aortic Or Carotid Disease**

6:55 A.M. – 1:30 P.M.

Grand Ballroom East, 3rd Floor

PROGRAM O: (SESSIONS 107-112)

**Improving Outcomes In Hemodialysis Access**

8:00 A.M. – 4:05 P.M.

Grand Ballroom West, 3rd Floor

PROGRAM N (SESSIONS 102-106)

**TOPICS TOO IMPORTANT TO MISS IN THE TREATMENT OF LOWER EXTREMITY, AORTIC OR CAROTID DISEASE**

Grand Ballroom East, 3rd Floor

SESSION 102 (Grand Ballroom East, 3rd Floor)

**LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)**

*Moderators: Keith D. Calligaro  
Brian G. DeRubertis*

**6:55 – 7:00** Late Breaking Trial With FLEX Vessel Prep And DCBs Show Better 12-Month Results With Fempop Lesions  
*Eric A. Secemsky (PowerPoint Presentation With Synched Audio)*

**7:00 – 7:05** How To Achieve And Maintain Skills In Tibial And Pedal Bypasses  
*Peter A. Schneider*

**7:05 – 7:10** When Should Endovascular Treatments Be The First Choice For Common Femoral Artery (CFA) Occlusive Lesions  
*Brian G. DeRubertis*

**7:10 – 7:15** Technical Tips For Retrograde Tibial And Pedal Access Under Ultrasound (Duplex) Guidance: Contraindications When Fluoro Is Better  
*Steven Kum (PowerPoint Presentation With Synched Audio)*

**7:15 – 7:20** How Does Dynamic Imaging With Angiography Or Ultrasound Help In The Diagnosis And Treatment Of Popliteal Entrapment Syndromes  
*Niten Singh*

**7:20 – 7:25** **DEBATE:** An Endo First Approach Is Best For Treating CLTI In All Patients: Is There Any Role For Open Bypasses  
*Christopher J. Abularrage*

**7:25 – 7:30** **DEBATE:** Not So: Open Bypass Should Be The First Treatment For Some CLTI Patients: When Is This So And In What Percentage Of CLTI Patients  
*Karan Garg*

**7:30 – 7:35** **Panel Discussion**

**7:35 – 7:40** When Is Pedal Loop Recanalization And Below The Ankle Angioplasty Indicated, And How Do I Do Them  
*Venita Chandra*

- 7:40 – 7:45** Isolated Pedal Interventions For CLTI: When Are They Worthwhile And Who Should Do Them  
*Mark G. Davies*
- 7:45 – 7:50** **DEBATE:** Multivessel Tibial Revascularization Does Not Improve Limb Salvage In CLTI Patients: From A VQI Study  
*Venita Chandra*
- 7:50 – 7:55** **DEBATE:** Not So: In Some Circumstances Multivessel Tibial Revascularization Does Improve Outcomes In CLTI Patients: Which Circumstances  
*Brian G. DeRubertis*
- 7:55 – 8:00** **Panel Discussion**
- 8:00 – 8:05** Indication And Technical Tips For Performing Retrograde Popliteal Artery Access  
*Jeffrey J. Siracuse*
- 8:05 – 8:10** Prograde SFA Access Can Be Safe And Effective For Lower Extremity Endo Procedures; When And How To Do It Safely  
*Karan Garg*
- 8:10 – 8:15** Infrainguinal Revascularization In Young Patients With PAD: What Works, What Doesn't, And What Factors Impact Outcome  
*William P. Robinson*
- 8:15 – 8:20** What Defines The No-Option CLTI Foot As A Candidate For Venous Arterialization: What Is The Medial Arterial Calcium (MAC) Score And How Does It Help  
*Miguel F. Montero*
- 8:20 – 8:25** **Panel Discussion**

SESSION 103 (Grand Ballroom East, 3rd Floor)

**MORE LOWER EXTREMITY TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)**

**Moderators:** *Kim J. Hodgson*  
*Alan M. Dietzek*

- 8:25 – 8:30** How To Cross Any CTO And Technical Tips For Retrograde Access Via The Popliteal, Tibial And Peroneal Arteries: How To Do It  
*Lorenzo Patrone*
- 8:30 – 8:35** Vascular Lesion Recurrence: How To Monitor And When To Re-Intervene: Are There Differences Between Lesion Recurrence After Endo And After Open Procedures  
*Venita Chandra*
- 8:35 – 8:40** Impact Of A Dedicated Limb Preservation/Limb Salvage Service On Amputation Rates: Must It Include An Open Bypass Surgery Component  
*Niten Singh*
- 8:40 – 8:45** Limb Salvage In Patients With Neuroischemic Diabetic Feet: How To Do It From Start To Finish  
*Ignacio Escotto*
- 8:45 – 8:50** Endo Versus Open Reinterventions To Assist In Maintaining Patency Of Distal Vein Grafts: Both Are Needed And When  
*Francesco Spinelli*
- 8:50 – 8:55** **Panel Discussion**
- 8:55 – 9:00** Relationship Between Zinc Deficiency And The Outcomes Of Lower Extremity Bypasses For CLTI: Should All CLTI Patients Be Given Zinc  
*Kimihiko Komori* (PowerPoint Presentation With Synched Audio)

- 9:00 – 9:05** Open Versus Endo Revascularizations In Dialysis Patients With CLTI: What Is The Role Of Each  
*Rabih A. Chaer*
- 9:05 – 9:10** Value Of Leg Open Bypasses After Multiple Endo Treatment Failures For CLTI: They Can Produce Long-Term (>10 Years) Limb Salvage  
*Julien G. Sfeir*
- 9:10 – 9:15** What Is The Real World Role Of Drug-Eluting Stents In Patients With CLTI And Infrapopliteal Arterial Disease: Which Stents To Use In A Single-Center Experience  
*Ali F. AbuRahma*
- 9:15 – 9:25** **Panel Discussion**
- 9:25 – 9:30** Value Of Duplex Gray Scale In Predicting Successful SFA CTO Crossing, Re-Entry And The Need For Distal Access  
*Natalie A. Marks*
- 9:30 – 9:35** Effect Of Short-Term Complications Of Lower Extremity Revascularizations On Long-Term Outcomes And Patient Survival  
*Panos Kougiias*  
*Sherene E. Sharath*  
*Joseph L. Mills*
- 9:35 – 9:40** Endovascular Diagnosis And Control Of Hemorrhage After Fempop Open Operations: It Is A Better Way And How To Do It  
*Francesco Setacci*  
*Carlo Setacci*
- 9:40 – 9:45** How To Use Microcatheters To Facilitate Complex Peripheral Interventions  
*Jos C. van den Berg*
- 9:45 – 9:50** **Panel Discussion**
- 9:50 -10:00** **Break – Visit Exhibits And Pavilions (3rd Floor)**

SESSION 104 (Grand Ballroom East, 3rd Floor)

**NEW DEVELOPMENTS IN COVID-19 TREATMENTS AND THE EFFECTS OF COVID-19 ON THE VASCULAR SYSTEM AND MISCELLANEOUS TOPICS INCLUDING TRAINING ISSUES, THE VALUE OF COMBINED VASCULAR AND CARDIAC SURGERY RESIDENCIES AND MORE CAROTID TOPICS**

**Moderators:** *Mark A. Adelman*  
*Ronald L. Dalman*

- 10:00-10:05** Update On The Relationship Between COVID-19 And AAAs  
*Ronald L. Dalman*
- 10:06-10:11** What Will Be The Post-Pandemic Steady State Of Novel Infection And Acquired Immunity: Is “Herd Immunity” A Realistic Concept  
*Clayton J. Brinster*
- 10:12-10:17** How Is COVID-19 Affecting Vascular Surgery Practice And Training  
*Ashraf Mansour*
- 10:18-10:23** Timing Of A Major Operative Intervention After A Positive COVID-19 Test Affects Postoperative Mortality: When To Retest And When Best To Intervene  
*Panos Kougiias*

**10:24–10:29** Endovascular Management Of COVID-19 Induced Arterial Pathologies: When Are They Effective And When Not  
*Karthik Kasirajan*

**MISCELLANEOUS TOPICS**

**10:30–10:35** The Impact Of COVID-19 On Vascular Surgical Training: Are We On The Road To Recovery  
*Celia Riga*

**10:36–10:41** Integrated (0+5) Vascular Residency Plus CT Surgery Fellowship – How Many Are There; Are They Over Trained And Underutilized: What Are The Advantages  
*Jennifer L. Perri*

**10:42–10:47** Lifeline Proprietary Carotid Screening: Who Profits: Is It A Good Thing Or A Hoax: What Can It Tell Us About The Prevalence Of ACS  
*Peter A. Schneider*  
*William A. Gray*

**10:48–10:54** **Panel Discussion**

SESSION 105 (Grand Ballroom East, 3rd Floor)

**AORTIC TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS) AND SPINE EXPOSURE (7-MINUTE TALKS)**

**Moderators:** *Timur P. Sarac*

*Jesse M. Manunga*

**10:54–10:59** Fenestrated EVAR Versus Chimney EVAR For Juxtarenal AAAs: When Is One Better Than The Other And What Are The Critical Considerations  
*Piergiorgio Cao*

**11:00–11:05** Improved System For Evaluating Aortic Neck Anatomy And Suitability For EVAR And Need For F/EVAR  
*David J. Minion*

**11:05–11:10** First-In-Man Evaluation Of A Novel Endovascular Robotic-Assisted Aortic Repair  
*Qingsheng Lu (PowerPoint Presentation With Synched Audio)*  
*Zaiping Jing*

**SPINE EXPOSURE SURGERY**

**11:10–11:17** Technical Tips And Tools For The Vascular Surgeon To Provide Anterior Exposure For Spine Procedures (7-Minute Presentation)  
*Jeffrey Jim*

**11:18–11:25** Vascular Complications Of Anterior Spine Exposures; How To Avoid Them And How To Treat Them If They Occur (7-Minute Presentation)  
*William P. Robinson*

**11:25–11:30** Outcomes Of EVAR In 18,416 High-Risk Patients Ineligible For Open Repair: When Is EVAR Justified Over No Intervention In Such Patients: Is EVAR 2 Still Relevant  
*George A. Antoniou*

**11:30–11:35** Should The Celiac Artery Be Stented Or Not During Complex Aortic Aneurysm Repair In Patients With Median Arcuate Ligament Syndrome (MALS) Or In Any Patients With MALS  
*Jesse M. Manunga*

**11:35–11:40** **Panel Discussion**

**11:40–11:45** How To Avoid Axillary Artery Complications After Large Sheath Use In Complex AAA Repairs  
*Michael C. Stoner*

- 11:45–11:50** Reasons For And Proportion Of Open Repair In A High Volume Center With Good F/B/EVAR Results  
*Athanasios Katsargyris*  
*Eric L.G. Verhoeven*
- 11:50–11:55** How To Optimize Blood Pressure Management With TBADs: It Is Not Simple  
*Loay S. Kabbani, MHSA*
- 11:55–12:00** Left Subclavian Revascularization With TEVAR: Technical Tips And Tools To Make In Situ Fenestration Easy  
*Wayne W. Zhang*
- 12:00–12:05** 9-Year Safety And Effectiveness Of Endoanchors For Fenestrated EVAR: They Support Shortening Main Endograft Length And Reducing Procedural Complexity  
*Jörg Tessarek*
- 12:05–12:10** Transcaval Access For TEVAR: When And How To Do It  
*Ross Milner*
- 12:10–12:15** **Panel Discussion**  
**Lunch Available (3rd Floor Foyer)**

SESSION 106 (Grand Ballroom East, 3rd Floor)

**AORTIC AND CAROTID TOPICS TOO IMPORTANT TO MISS (4 ¾-MINUTE TALKS)**

**Moderators:** *Sean P. Lyden*  
*Enrico Ascher*  
*Frank J. Veith*

**AORTIC AND ITS BRANCHES TOPICS**

- 12:15–12:20** When And How To Treat Isolated Visceral Artery Dissections  
*Paulo E. Ocke-Reis*
- 12:20–12:25** Venous Anomalies Around The Neck Of AAAs – How To Diagnose Them: What Are The Pitfalls And How To Deal With Injuries If They Occur  
*Ramesh K. Tripathi*
- 12:25–12:30** Techniques For Improving Proximal Landing Zones For TEVARs And Aortic Dissections Involving The Aortic Arch; Parallel Grafts And Extra-Anatomic Bypasses  
*R. Clement Darling III*
- 12:30–12:35** Upper Extremity Access For Complex Endo AAA Repairs Is Associated With A High Rate Of Stroke: From A VQI Study  
*Mark L. Schermerhorn*
- 12:35–12:40** **DEBATE:** The Vast Majority Of Failed EVARs Can Be Treated Endovascularly  
*Ross Milner*
- 12:40–12:45** **DEBATE:** Not So: Many Failed EVARs Are Best Repaired By Open Conversion  
*Michel S. Makaroun*
- 12:45–12:50** F/EVARs With Larger Diameter Aortas (34–36 mm) Are Associated With Higher Incidence Of Type 1 And 3 Endoleaks: How Can These Be Prevented  
*Jason T. Lee*
- 12:50–12:55** Value Of 3D Flow Models To Analyze The Cause Of Failure After F/EVAR And TEVAR  
*Maciej L. Dryjski*
- 12:55– 1:00** **Panel Discussion**

**CAROTID TOPICS**

- 1:00 - 1:05** Optimal Anticoagulant And Antiplatelet Treatment For Symptomatic And Asymptomatic Patients With Carotid Stenosis  
*Anne L. Abbott*
- 1:05 - 1:10** How To Use The Silk Road TCAR Device In The Treatment Of Tandem Carotid Lesions: Technical Tips And Results  
*Michael C. Stoner*
- 1:10 - 1:15** Radiation And Carotid Stenosis: What Is The Relationship And How Is Radiation Stenosis Best Treated When Asymptomatic And When Symptomatic  
*Cynthia K. Shortell*
- 1:15 - 1:20** Mini-Incision CEA With Standard Or Eversion Techniques: How To Do It Safely: It's Better Than Transfemoral CAS Or TCAR  
*Alan M. Dietzek*
- 1:20 - 1:25** Tips And Tricks For Successful TCAR And When Is CEA And Best Medical Treatment Better Than TCAR  
*Jeffrey Jim*
- 1:25 - 1:30** **Panel Discussion**  
**End of Program N**  
**VEITH Symposium continues with the Hemodialysis Access Program in the Grand Ballroom West.**

PROGRAM O (SESSIONS 107-112)  
**IMPROVING OUTCOMES IN HEMODIALYSIS ACCESS**

Grand Ballroom West, 3rd Floor

Course Leaders: **Larry A. Scher**  
**Anton N. Sidawy**  
**Haimanot (Monnie) Wasse**

- 8:00 – 8:05** Introduction  
*Anton N. Sidawy*  
*Larry A. Scher*  
*Haimanot (Monnie) Wasse*

SESSION 107 (Grand Ballroom West, 3rd Floor)  
**IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)**

Moderators: **Larry A. Scher**  
**Anton N. Sidawy**

- 8:06 – 8:13** Role Of The Surgeon In Educating Patients For Hemodialysis Access  
*Dori R. Schatell*
- 8:14 – 8:21** Update On VasQ Device: The Economic Impact Of Better Fistulasse  
*Ellen D. Dillavou*
- 8:22 – 8:29** FLEX Vessel Prep System: Clinical Outcomes And Utility In HD Access Practice  
*John E. Aruny*
- 8:30 – 8:37** Selecting The Right Access In The Chronically Hypotensive Patient  
*Aisha Shaikh*
- 8:38 – 8:45** Current KDOQI Recommendations Regarding Use Of Ultrasound In Hemodialysis Access  
*Charmaine Lok*
- 8:46 – 8:53** Management Of Central Venous Stenosis: To Stent Or Not To Stent  
*Theodore F. Saad*

- 8:54 – 9:04 Panel Discussion**
- 9:05 – 9:12** Use Of Plastic Cannulas For Hemodialysis Access  
*Dori R. Schatell*
- 9:13 – 9:20** Wearable Technology For Remote Patient Monitoring During Home Hemodialysis  
*Richard F. Neville*
- 9:21 – 9:28** Point Of Care Ultrasound In The Practice Of Nephrology  
*Vandana D. Niyyar*
- 9:29 – 9:36** Challenges To Endovascular AV Fistula Maturation  
*Neghae Mawla*
- 9:37 – 9:44** Novel Hemostatic Device For Management Of Hemodialysis Access Cannulation Sites  
*Sundaram Ravikumar*
- 9:45 – 9:52** Creating Successful Hemodialysis Access In Children  
*William Jennings*
- 9:53 – 10:03 Panel Discussion**
- 10:04–10:25 Break – Visit Exhibits (3rd Floor)**

SESSION 108 (Grand Ballroom West, 3rd Floor)

**MORE IMPORTANT ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)**

**Moderators:** *Haimanot (Monnie) Wasse*  
*Evan C. Lipsitz*

- 10:26–10:33 DEBATE:** Reducing Flow In High Flow AV Fistulas In Asymptomatic Patients  
*Moro Salifu*
- 10:34–10:41 DEBATE:** There Is No Role For Routine Flow Reduction In High Flow Fistulas  
*Surendra Shenoy*
- 10:42–10:49** Use Of The Frame FR External Stent For AV Fistula Flow Reduction  
*Robert Shahverdyan*
- 10:50–10:57** Post-Transplant Management Of The Hemodialysis Access  
*Haimanot (Monnie) Wasse*
- 10:58–11:05** Telemedicine For Vascular Access Patients – Preop Planning, Postoperative Visits, Access Maintenance  
*Aisha Shaikh*
- 11:06–11:13** Outpatient Vascular Access Disasters: Help!  
*John E. Aruny*
- 11:14–11:24 Panel Discussion**

SESSION 109 (Grand Ballroom West, 3rd Floor)

**MINISYMPOSIUM ON PREVENTION AND MANAGEMENT OF DIALYSIS ACCESS STEAL SYNDROME**

**Moderators:** *John E. Aruny*  
*Clifford M. Sales*

- 11:25–11:32** Avoiding Hemodialysis Access Induced Ischemia: An Ounce Of Prevention Is Worth A Pound Of Cure  
*Williams Jennings*
- 11:33–11:40** Management Strategies For Dialysis Access Related Steal And Neuropathy  
*Matthew J. Dougherty*
- 11:41–11:48** Modified Banding For Treatment Of Vascular Access Induced Digital Ischemia  
*Yana Etkin*

- 11:49–11:56** Vascular Access Hemorrhage: Prevalence, Prevention And Medicolegal Issues  
*Theodore F. Saad*
- 11:57–12:04** **Panel Discussion**
- 12:05– 1:00** **Lunch Break – Visit Exhibits And Pavilions (3rd Floor)**

SESSION 110 (Grand Ballroom West, 3rd Floor)  
**POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)**

**Moderators:** *Larry A. Scher*  
*Anton N. Sidawy*

- 1:00 – 1:07** How To Survive In An OBL In The Current Economic Climate  
*Clifford M. Sales*
- 1:08 – 1:15** Who Is Best Served By Using An Early Cannulation AV Graft  
*David Kingsmore*
- 1:16 – 1:23** Clinical And Economic Strategy For Building An Outpatient Peritoneal Dialysis Program  
*Jason K. Wagner*
- 1:24 – 1:31** Miniaturized Kidney Dialysis: Issues And Challenges With Blood Compatibility And Vascular Access  
*Buddy D. Ratner*
- 1:32 – 1:39** CMS Reevaluation Of Cost And Quality Measures For Hemodialysis Access  
*Evan C. Lipsitz*
- 1:40 – 1:50** **Panel Discussion**

SESSION 111 (Grand Ballroom West, 3rd Floor)  
**NEW TECHNOLOGIES FOR AV ACCESS CREATION (7-MINUTE TALKS)**

**Moderators:** *Haimanot (Monnie) Wasse*  
*Theodore F. Saad*

- 1:51 – 1:58** Use Of The Surfacar Device (Inside-Out Technique) In Occluded Central Veins: What Are The Results  
*Dirk M. Hentschel*
- 1:59 – 2:06** Choosing The Best Endo AV Fistula Device  
*Robert Shahverdyan*
- 2:07 – 2:14** Holly™: A Fully Implantable Continuous Hemodialysis Device  
*Dirk M. Hentschel*
- 2:15 – 2:22** A Non-Biologic Vascular Prosthesis That Heals And Integrates: Applications For Hemodialysis Access  
*Buddy D. Ratner*
- 2:23 – 2:30** Polymer Based Platform For Endogenous Tissue Restoration: FIH Study Of The aXess Dialysis Graft  
*Frans L. Moll (PowerPoint Presentation With Synched Audio)*
- 2:31 – 2:38** Amplifi Vein Dilatation For AV Access  
*Surendra Shenoy*
- 2:39 – 2:49** **Panel Discussion**

SESSION 112 (Grand Ballroom West, 3rd Floor)  
**UPDATE ON CLINICAL CHALLENGES IN HEMODIALYSIS ACCESS (7-MINUTE TALKS)**

**Moderators:** *Larry A. Scher*  
*Surendra Shenoy*



- 2:50 – 2:57** Results Of A Randomized Multicenter AV Fistula Trial Using An Intraoperative Sirolimus Formulation To Improve Clinical Outcomes  
*Sriram S. Iyer*
- 2:58 – 3:05** Tips And Tricks For Avoiding Early Access Failure  
*William Jennings*
- 3:06 – 3:13** Percutaneous Sutureless Anastomosis In Hemodialysis Access: How I do It  
*John R. Ross, Sr.*
- 3:14 – 3:21** Creating The Perfect Basilic Vein Transposition  
*Karl A. Illig*
- 3:22 – 3:29** The Challenges Of Obesity In Hemodialysis Access  
*Mark G. Davies*
- 3:30 – 3:37** HeRO Graft Modifications To Optimize Hemodialysis Access  
*Jesse Garcia*
- 3:38 – 3:45** LIMA Steal Syndrome After Ipsilateral AV Fistula – Is It Real  
*Jeffrey E. Indes*
- 3:46 – 3:53** Challenges To Endovascular AV Fistula Cannulation  
*Deborah Brouwer-Maier (PowerPoint Presentation With Synched Audio)*
- 3:54 – 4:05** **Panel Discussion**  
**End of Program O**

# FACULTY

## A

**Anne-L. Abbott, MD, PhD, FRACP**

*Melbourne, Australia*

**Dorothy B. Abel, BSBME**

*New York, New York*

**Cherrie Z. Abraham, MD**

*Portland, Oregon*

**Steven D. Abramowitz, MD**

*Washington, District Of Columbia*

**Christopher J. Abularrage, MD**

*Baltimore, Maryland*

**Ali F. AbuRahma, MD**

*Charleston, West Virginia*

**Zach AbuRahma, DO**

*Charleston, West Virginia*

**George L. Adams, MD, FACS**

*Raleigh, North Carolina*

**Mark A. Adelman, MD**

*New York, New York*

**Sam S. Ahn, MD, FACS, MBA**

*Fort Worth, Texas*

**Fawaz Al-Mufti, MD**

*Valhalla, New York*

**Eric Allaire, MD, PhD**

*Paris, France*

**Jose I. Almeida, MD, FACS, RPVI,  
RVT**

*Miami, Florida*

**Jean-Marc Alsac, MD, PhD**

*Paris, France*

**David J. Altschul, MD**

*Bronx, New York*

**Ali Amin, MD, RVT, FACS, FACC**

*Reading, Pennsylvania*

**Gary M. Ansel, MD**

*Columbus, Ohio*

**George A. Antoniou, MD, PhD,  
MSc, FEBVS**

*Manchester, United Kingdom*

**Frank R. Arko, MD**

*Charlotte, North Carolina*

**Adam S. Arthur, MD**

*Memphis, Tennessee*

**Zachary M. Arthurs, MD**

*Charleston, South Carolina*

**John E. Aruny, MD**

*Orangeburg, South Carolina*

**Enrico Ascher, MD**

*New York, New York*

**Afshin Assadian, MD**

*Vienna, Austria*

**Martin J. Austermann, MD**

*Münster, Germany*

**Ali Azizzadeh, MD**

*Los Angeles, California*

**Nobuyoshi Azuma, MD**

*Asahikawa, Hokkaido, Japan*

## B

**Martin R. Back, MD**

*Gainesville, Florida*

**Michael E. Barfield, MD**

*Chattanooga, Tennessee*

**Iris Baumgartner, MD**

*Bern, Switzerland*

**Joseph E. Bavaria, MD**

*Philadelphia, Pennsylvania*

**Hernan A. Bazan, MD, DFSVS,  
FACS**

*New Orleans, Louisiana*

**Robert E. Beasley, MD, FSIR, FSCAI**

*Miami Beach, Florida*

**Carlos F. Bechara, MD**

*Chicago, Illinois*

**Adam Beck, MD**

*Birmingham, Alabama*

**Jean-Pierre Becquemin, MD, FRCS**

*Saint Clément De Rivière, France*

**Christian A. Behrendt, MD**

*Hamburg, Germany*

**James F. Benenati, MD**

*Miami, Florida*

**Jeffrey S. Berger, MD, MS, FAHA,  
FACC**

*New York, New York*

**Ramon Berguer, MD, PhD**

*Ann Arbor, Michigan*

**Todd Berland, MD**

*New York, New York*

**Luca Bertoglio, MD**

*Milan, Italy*

**Colin D. Bicknell, MD, FRCS**

*London, United Kingdom*

**Theodosios Bisdas, MD**

*Maroussi, Greece*

**Jean Bismuth, MD**

*Houston, Texas*

**Martin Björck, MD, PhD**

*Uppsala, Sweden*

**James H. Black, III, MD**

*Baltimore, Maryland*

**Stephen A. Black, MD**

*London, United Kingdom*

**Jan D. Blankensteijn, MD**

*Amsterdam, The Netherlands*

**John Blebea, MD, MBA**

*Saginaw, Michigan*

**Erwin Blessing, MD**

*Karlsbad, Germany*

**Dittmar Böckler, MD**

*Heidelberg, Germany*

**Michel J. Bosiers, MD**

*Bern, Switzerland*

**Lee Bouwman, MD, PhD, MSc**

*Spaubeek, The Netherlands*

**Thomas C. Bower, MD**

*Rochester, Minnesota*

**Daniela Branzan, MD**

*Leipzig, Germany*

**Clayton J. Brinster, MD**

*New Orleans, Louisiana*

**Marianne Brodmann, MD**

*Graz, Austria*

**Allan L. Brook, MD**

*Bronx, New York*

**Thomas G. Brott, MD**

*Jacksonville, Florida*

**Deborah Brouwer-Maier, RN, CNN**

*Lansdale, Pennsylvania*

**O. William Brown, MD, JD**  
Royal Oak, Michigan

**Elchanan Bruckheimer, MBBS**  
Petah-Tikva, Israel

**Richard Bulbulia, MA, MD, FRCS**  
Oxford & Cheltenham, United Kingdom

**Jacques Busquet, MD**  
Paris, France

## C

**Keith D. Calligaro, MD**  
Philadelphia, Pennsylvania

**Richard P. Cambria, MD**  
Brighton, Massachusetts

**Victor M. Canata, MD, PhD**  
Asuncion, Paraguay

**Ludovic Canaud, MD, PhD**  
Montpellier, France

**Piergiorgio Cao, MD, FRCS**  
Rome, Italy

**Laura Capoccia, MD, PhD**  
Rome, Italy

**Neal S. Cayne, MD**  
New York, New York

**Rabih A. Chaer, MD**  
Pittsburgh, Pennsylvania

**Elliot L. Chaikof, MD, PhD**  
Boston, Massachusetts

**Breehan Chancellor, MD**  
New York, New York

**Venita Chandra, MD**  
Stanford, California

**Heepeel Chang, MD**  
Valhalla, New York

**Robert W. Chang, MD**  
San Francisco, California

**John F. Charitable, MD**  
New York, New York

**Kenneth J. Cherry, MD**  
Norfolk, Virginia

**Nicholas J.W. Cheshire, MD**  
London, United Kingdom

**Laurent Chiche, MD, FEBVS**  
Paris, France

**Jae S. Cho, MD**  
Cleveland, Ohio

**Timothy A.M. Chuter, DM**  
San Francisco, California

**Daniel G. Clair, MD**  
Nashville, Tennessee

**Rachel E. Clough, PhD, FRCS**  
London, United Kingdom

**W. Darrin Clouse, MD**  
Charlottesville, Virginia

**Felipe Coelho Neto, MD, MSc, PhD**  
Londrina, Brazil

**Dawn M. Coleman, MD**  
Ann Arbor, Michigan

**Jill J. Colglazier, MD**  
Rochester, Minnesota

**Anthony J. Comerota, MD, FACS, FACC**  
Alexandria, Virginia

**Mark Conrad, MD, MMSc**  
Brighton, Massachusetts

**Michael S. Conte, MD**  
San Francisco, California

**Joseph S. Coselli, MD**  
Houston, Texas

**D. Mark Courtney, MD**  
Dallas, Texas

**Frank J. Criado, MD**  
Baltimore, Maryland

**Jack L. Cronenwett, MD**  
Lebanon, New Hampshire

**Philippe W.M. Cuypers, MD, PhD**  
Eindhoven, The Netherlands

**Jacob Cynamon, MD, FACR, FSIR**  
New York, New York

**Martin Czerny, MD**  
Freiburg, Germany

## D

**Guilherme Dabus, MD**  
Miami, Florida

**Michael D. Dake, MD**  
Tucson, Arizona

**Ronald L. Dalman, MD**  
Stanford, California

**Michael C. Dalsing, MD**  
Indianapolis, Indiana

**R. Clement Darling III, MD**  
Albany, New York

**Tony S. Das, MD**  
Dallas, Texas

**Alun H. Davies, MA, DM, DSC, FRCS, FHEA, FEBVS, FACPH**  
London, United Kingdom

**Mark G. Davies, MD**  
San Antonio, Texas

**Gert de Borst, MD, PhD**  
Utrecht, The Netherlands

**Gianmarco de Donato, MD**  
Siena, Italy

**Jean-Paul de Vries, MD, PhD**  
Groningen, The Netherlands

**Steven M. Dean, DO**  
Columbus, Ohio

**David H. Deaton, MD, FACS**  
Crownsville, Maryland

**Sebastian E. Debus, MD, PhD**  
Hamburg, Germany

**James W. Dennis, MD**  
Jacksonville, Florida

**Brian G. DeRubertis, MD**  
New York, New York

**Kush R. Desai, MD**  
Chicago, Illinois

**David J. Dexter, MD**  
Norfolk, Virginia

**Nuno V. Dias, MD, PhD**  
Malmö, Sweden

**Alan M. Dietzek, MD, RPVI, FACS**  
Danbury, Connecticut

**Ellen D. Dillavou, MD**  
Raleigh, North Carolina

**Hasan H. Dosluoglu, MD**  
Buffalo, New York

# FACULTY

**Matthew J. Dougherty, MD**  
*Philadelphia, Pennsylvania*

**Maciej L. Dryjski, MD, PhD**  
*Buffalo, New York*

**Anahita Dua, MD, MS, MBA**  
*Boston, Massachusetts*

**David M. Dudzinski, MD**  
*Boston, Massachusetts*

**Audra A. Duncan, MD**  
*London, Ontario, Canada*

## E

**Matthew J. Eagleton, MD**  
*Boston, Massachusetts*

**Hans-Henning Eckstein, MD, PhD**  
*Munich, Germany*

**John F. Eidt, MD**  
*Dallas, Texas*

**Hosam F. El Sayed, MD**  
*Norfolk, Virginia*

**Jens Eldrup-Jorgensen, MD**  
*Portland, Maine*

**Steve Elias, MD**  
*Englewood, New Jersey*

**Jan-Willem Elshof, MD**  
*Venlo, The Netherlands*

**Young Erben, MD**  
*Jacksonville, Florida*

**Guillermo A. Escobar, MD**  
*Atlanta, Georgia*

**Ignacio Escotto, MD**  
*Mexico City, Mexico*

**Mark K. Eskandari, MD**  
*Chicago, Illinois*

**Mohammad H. Eslami, MD, MPH**  
*Pittsburgh, Pennsylvania*

**Omar L. Esponda, MD**  
*Boca Raton, Florida*

**Anthony L. Estrera, MD**  
*Houston, Texas*

**Yana Etkin, MD**  
*Lake Success, New York*

**Christian D. Etz, MD, PhD**  
*Leipzig, Germany*

## F

**Dominique Fabre, MD, PhD**  
*Le Plessis-Robinson, France*

**Gianluca Faggioli, MD**  
*Bologna, Italy*

**Fabrizio Fanelli, MD, EBIR**  
*Florence, Italy*

**Alik Farber, MD, MBA**  
*Boston, Massachusetts*

**Mark A. Farber, MD**  
*Chapel Hill, North Carolina*

**Peter L. Faries, MD, FACS**  
*New York, New York*

**John M. Felder, MD**  
*St. Louis, Missouri*

**Jose Fernandes e Fernandes, MD,  
PhD, FRCS (ENG), FACS, FESC, FEBVS**  
*Lisbon, Portugal*

**Roberto Ferraresi, MD**  
*Milano, Italy*

**Marcelo Ferreira, MD**  
*Rio De Janeiro, Brazil*

**Ciro Ferrer, MD, PhD**  
*Rome, Italy*

**David Fiorella, MD, PhD**  
*Stony Brook, New York*

**Thomas L. Forbes, MD**  
*Toronto, Ontario, Canada*

**Mazin Foteh, MD**  
*Austin, Texas*

**Charles J. Fox, MD, FACS**  
*Baltimore, Maryland*

**Weiguo Fu, MD**  
*Shanghai, China*

**Naoki Fujimura, MD, PhD**  
*Tokyo, Japan*

**Markus K. Furrer, MD**  
*Chur, Switzerland*

## G

**Paul J. Gagne, MD**  
*Darien, Connecticut*

**Peter Gaines, MD**  
*Sheffield, United Kingdom*

**Katherine A. Gallagher, MD**  
*Ann Arbor, Michigan*

**Ripal T. Gandhi, MD, FSVM, FSIR**  
*Miami, Florida*

**Jesse Garcia, MD**  
*Washington, District of Columbia*

**Lawrence A. Garcia, MD**  
*Boston, Massachusetts*

**Karan Garg, MD**  
*New York, New York*

**Antonios P. Gasparis, MD**  
*Stony Brook, New York*

**Patrick J. Geraghty, MD**  
*Saint Louis, Missouri*

**Jean Luc Gerard, MD**  
*Creteil, France*

**George Geroulakos, MD, PhD**  
*Athens, Greece*

**Brian B. Ghoshhajra, MD, MBA**  
*Boston, Massachusetts*

**Richard G.J. Gibbs, FRCS**  
*London, United Kingdom*

**Kathleen D. Gibson, MD**  
*Bellevue, Washington*

**Joseph S. Giglia, MD**  
*Cincinnati, Ohio*

**David L. Gillespie, MD**  
*Falmouth, Massachusetts*

**Jay Giri, MD, MPH**  
*Philadelphia, Pennsylvania*

**Rocco Giudice, MD**  
*Rome, Italy*

**Monika L. Gloviczki, MD, PhD**  
*Rochester, Minnesota*

**Peter Gloviczki, MD**  
*Scottsdale, Arizona*

**Manj S. Gohel, MD, FRCS, FEBVS**  
*Cambridge, United Kingdom*

# FACULTY

**Jerry Goldstone, MD, FACS,  
FRCSEd**

*Cleveland, Ohio &  
Stanford, California*

**R. Gilberto Gonzalez, MD, PhD**

*Boston, Massachusetts*

**Philip P. Goodney, MD, MS**

*Lebanon, New Hampshire*

**David Gordon, MD**

*Mt. Kisco, New York*

**Yann Gouëffic, MD, PhD**

*Paris, France*

**Peter C.J. Goverde, MD**

*Antwerp, Belgium*

**Juan F. Granada, MD**

*New York, New York*

**William A. Gray, MD**

*Philadelphia, Pennsylvania*

**Franco Grego, MD**

*Padua, Italy*

**Marcelo Guimaraes, MD, MBA,  
FSIR**

*Charleston, South Carolina*

**Wei Guo, MD**

*Beijing, China*

**Gutenberg A. Gurgel, MSc, MD**

*Natal, RN, Brazil*

## H

**Mo S. Hamady, MD, FRCR, EBIR,  
FSIR**

*London, United Kingdom*

**Claudine M. Hamel-Desnos, MD**

*Paris, France*

**Sukgu Han, MD**

*Los Angeles, California*

**Neil Haranhalli, MD**

*Bronx, New York*

**Linda M. Harris, MD**

*Buffalo, New York*

**Stephan Haulon, MD**

*Paris, France*

**Don Heck, MD**

*Winston Salem, North Carolina*

**Peter Henke, MD**

*Ann Arbor, Michigan*

**Michel C. Henry, MD**

*Luxembourg & Hyderabad, India*

**Dirk M. Hentschel, MD**

*Boston, Massachusetts*

**Jan M.M. Heyligers, MD, PhD,  
FEBVS**

*Tilburg, The Netherlands*

**Caitlin W. Hicks, MD, MS**

*Baltimore, Maryland*

**Michael D. Hill, MD**

*Calgary, Alberta, Canada*

**Anil P. Hingorani, MD**

*Brooklyn, New York*

**Jade S. Hiramoto, MD**

*San Francisco, California*

**Joshua A. Hirsch, MD**

*Boston, Massachusetts*

**Kim J. Hodgson, MD**

*Springfield, Illinois*

**Andrew Holden, MBChB**

*Auckland, New Zealand*

**Tal M. Hörer, MD, PhD**

*Örebro, Sweden*

**Emmanuel M. Houdart, MD**

*Paris, France*

## I

**Mark D. Iafrati, MD**

*Nashville, Tennessee*

**Karl A. Illig, MD**

*Houston, Texas*

**Jeffrey E. Indes, MD**

*Bronx, New York*

**Sriram S. Iyer, MD, FACC**

*New York, New York*

## J

**Pascal Jabbour, MD**

*Philadelphia, Pennsylvania*

**Benjamin M. Jackson, MD**

*Philadelphia, Pennsylvania*

**Glenn Jacobowitz, MD**

*New York, New York*

**Michael J. Jacobs, MD**

*Maastricht, The Netherlands*

**Michael R. Jaff, DO**

*Boston, Massachusetts*

**Krishna Jain, MD**

*Kalamazoo, Michigan*

**Houman Jalaie, MD, PhD**

*Aachen, Germany*

**Aleksandra Jaworucka-Kaczorowska,  
MD, PhD**

*Gorzów Wlkp, Poland*

**Arjun Jayaraj, MD**

*Jackson, Mississippi*

**Michael P. Jenkins, MBBS, BSC, MS,  
FRCS, FEBVS**

*London, United Kingdom*

**William Jennings, MD**

*Tulsa, Oklahoma*

**Jeffrey Jim, MD, MPH**

*Minneapolis, Minnesota*

**William D. Jordan Jr., MD**

*Atlanta, Georgia*

## K

**Loay S. Kabbani, MD, MHSA**

*Detroit, Michigan*

**Lowell S. Kabnick, MD, FACS,  
FAVLS**

*Lake Worth, Florida*

**Andrea Kahlberg, MD**

*Milano, Italy*

**Stavros K. Kakkos, MD, PhD**

*Patras, Greece*

**Manju Kalra, MBBS**

*Rochester, Minnesota*

**Vikram S. Kashyap, MD**

*Cleveland, Ohio*

**Karthik Kasirajan, MD**

*Pleasanton, California*

# FACULTY

**Piotr M. Kasprzak, MD**  
Regensburg, Germany

**Konstantinos Katsanos, MSc, MD, PhD, EBIR**  
Patras, Greece

**Athanasios Katsargyris, MD**  
Nuremberg, Germany &  
Athens, Greece

**Barry T. Katzen, MD**  
Miami, Florida

**John A. Kaufman, MD, MS**  
Portland, Oregon

**William B. Keeling, MD**  
Atlanta, Georgia

**Christopher Kellner, MD**  
New York, New York

**Patrick W. Kelly, MD**  
Sioux Falls, South Dakota

**Neil M. Khilnani, MD**  
New York, New York

**Ali B. Khojnehad, MD, PhD**  
Los Angeles, California

**David Kingsmore, MD, FRCS (ED),  
MBChB, BMedBiol**  
Glasgow, United Kingdom

**Lee Kirksey, MD**  
Cleveland, Ohio

**Tilo Kölbl, MD, PhD**  
Hamburg, Germany

**Raghu Kolluri, MD**  
Columbus, Ohio

**Ralf R. Kolvenbach, MD**  
Duesseldorf, Germany

**Kimihiro Komori, MD, PhD**  
Nagoya, Japan

**Panos Kougias, MD, MSc**  
Brooklyn, New York

**Zvonimir Krajcer, MD, FACC**  
Houston, Texas

**Dainis K. Krievins, MD**  
Riga, Latvia

**Steven Kum, MD**  
Singapore

**Toru Kuratani, MD, PhD**  
Osaka, Japan

**Christopher J. Kwolek, MD, MBA**  
Boston, Massachusetts

**Nicos Labropoulos, BSc (MED),  
PhD, DIC, RVT**  
Stony Brook, New York

**Mario L. Lachat, MD**  
Zurich, Switzerland

**John R. Laird, MD**  
St. Helena, California

**Brajesh K. Lal, MD**  
Baltimore, Maryland

**Patrick J. Lamparello, MD**  
New York, New York

**Glenn M. LaMuraglia, MD**  
Boston, Massachusetts

**Gregg S. Landis, MD**  
New Hyde Park, New York

**Werner Lang, MD**  
Erlangen, Germany

**Kamphol Laohapensang, MD**  
Chiang Mai, Thailand

**Igor A. Laskowski, MD, PhD**  
Valhalla, New York

**George S. Lavenson, MD**  
Bethesda, Maryland

**Peter F. Lawrence, MD**  
Los Angeles, California

**Jeffrey H. Lawson, MD, PhD**  
Durham, North Carolina

**Linda Le, MD**  
Houston, Texas

**Jason T. Lee, MD**  
Stanford, California

**Seon-Kyu Lee, MD, PhD**  
New York, New York

**W. Anthony Lee, MD**  
Boca Raton, Florida

**Luis R. Leon, MD, RVT, FACS**  
Tucson, Arizona

**Martin B. Leon, MD**  
New York, New York

**Christos D. Liapis, MD**  
Athens, Greece

**Michael K.W. Lichtenberg, MD**  
Arnsberg, Germany

**Timothy K. Liem, MD, MBA**  
Portland, Oregon

**Francesco Liistro, MD**  
Arezzo, Italy

**Hans Lindgren, MD, PhD**  
Helsingborg, Sweden

**Jes S. Lindholt, MD**  
Odense, Denmark

**Thomas F. Lindsay, MDCM, FRCS**  
Toronto, Ontario, Canada

**Evan C. Lipsitz, MD, MBA**  
New York, New York

**Armando C. Lobato, MD, PhD**  
São Paulo, Brazil

**Ian Loftus, MD**  
London, United Kingdom

**Shang Loh, MD**  
Philadelphia, Pennsylvania

**Joann Lohr, MD**  
Columbia, South Carolina

**Charmaine Lok, MD**  
Toronto, Ontario, Canada

**Joseph V. Lombardi, MD, MBA**  
Camden, New Jersey

**Lars B. Lonn, MD, PhD**  
Copenhagen, Denmark

**Robert A. Lookstein, MD, MHCDL,  
FSIR, FAHA**  
New York, New York

**Qingsheng Lu, MD**  
Shanghai, China

**Marzia Lugli, MD**  
Modena, Italy

**Alan B. Lumsden, MD, FACS**  
Houston, Texas

**Fedor Lurie, MD, PhD**  
Toledo, Ohio & Ann Arbor, Michigan

**Sean P. Lyden, MD**  
Cleveland, Ohio

# FACULTY

## M

**Sumaira Macdonald, MD, PhD**  
Sunnyvale, California

**Lindsay Machan, MD**  
Vancouver, British Columbia, Canada

**Edward G. Mackay, MD**  
St. Petersburg, Florida

**Michel Makaroun, MD**  
Pittsburgh, Pennsylvania

**Mahmoud B. Malas, MD, MHS**  
San Diego, California

**Thomas S. Maldonado, MD**  
New York, New York

**Martin Malina, MD, PhD**  
London, United Kingdom

**Nicola Mangialardi, MD**  
Rome, Italy

**Armando Mansilha, MD, PhD,**  
FEBVS  
Porto, Portugal

**Ashraf Mansour, MD**  
Grand Rapids, Michigan

**Jesse M. Manunga, MD**  
Minneapolis, Minnesota

**Marco G. Manzi, MD**  
Abano Terme, Italy

**Michael L. Marin, MD**  
New York, New York

**Natalie A. Marks, MD, RPVI, RVT,**  
FSVM  
Brooklyn, New York

**William A. Marston, MD**  
Chapel Hill, North Carolina

**Tara M. Mastracci, MD**  
London, United Kingdom

**Elna M. Masuda, MD**  
Honolulu, Hawaii

**Klaus D. Mathias, MD**  
Hamburg, Germany

**Jon S. Matsumura, MD**  
Madison, Wisconsin

**Mark A. Mattos, MD**  
Flint, Michigan

**Neghae Mawla, MD, FASDIN**  
Dallas, Texas

**David T. McGreevy, MD**  
Örebro, Sweden

**James F. McKinsey, MD**  
New York, New York

**Robert B. McLafferty, MD, MBA**  
Portland, Oregon

**Barend M.E. Mees, MD, PhD,**  
FEBVS  
Maastricht, The Netherlands

**Roxana Mehran, MD**  
New York, New York

**Manish Mehta, MD, MPH**  
Latham, New York

**Mark H. Meissner, MD**  
Seattle, Washington

**Germano Melissano, MD**  
Milano, Italy

**Matthew W. Mell, MD, MS**  
Sacramento, California

**Matthew T. Menard, MD**  
Boston, Massachusetts

**Bernardo C. Mendes, MD**  
Rochester, Minnesota

**Vitor Mendes Pereira, MD, MSc**  
Toronto, Ontario, Canada

**B. Erika Mendoza Borrmann, MD,**  
PhD  
Wunstorf, Germany

**Valerie M. Merkle, PhD**  
Silver Spring, Maryland

**Geno J. Merli, MD, MACP, FHM,**  
FSVM  
Philadelphia, Pennsylvania

**James F. Meschia, MD**  
Jacksonville, Florida

**D. Christopher Metzger, MD**  
Kingsport, Tennessee

**Mark W. Mewissen, MD, RVT**  
Milwaukee, Wisconsin

**Claude Mialhe, MD**  
Nice, France

**James Milburn, MD**  
New Orleans, Louisiana

**Charles C. Miller, PhD**  
Houston, Texas

**Joseph L. Mills, MD**  
Houston, Texas

**Ross Milner, MD**  
Chicago, Illinois

**David J. Minion, MD**  
Lexington, Kentucky

**Aleem K. Mirza, MD**  
Houston, Texas

**Erica Mitchell, MD, MEd**  
Memphis, Tennessee

**J Mocco, MD, MS**  
New York, New York

**Bijan Modarai, PhD, FRCS**  
London, United Kingdom

**Irwin V. Mohan, MBBS, MD, RCS,**  
FEBVS, FRACS  
Sydney, Australia

**Frans L. Moll, MD, PhD**  
Utrecht, The Netherlands

**Samuel R. Money, MD, MBA**  
New Orleans, Louisiana

**Miguel F. Montero, MD**  
Houston, Texas

**Robert A. Montgomery, MD,**  
DPhil  
New York, New York

**Randy D. Moore, MD**  
Chestermere, Alberta, Canada

**Wesley S. Moore, MD**  
Los Angeles, California

**Robert A. Morgan, MD**  
London, United Kingdom

**Patrick E. Muck, MD, FACS**  
Cincinnati, Ohio

**Stefan Müller-Hülsbeck, MD**  
Flensburg, Germany

**Dipankar Mukherjee, MD**  
Falls Church, Virginia

**Erin H. Murphy, MD**  
Charlotte, North Carolina

# FACULTY

**Piotr Musialek, MD, DPhil**  
*Krakow, Poland*

**Firas F. Mussa, MD**  
*London, United Kingdom*

**Jihad A. Mustapha, MD**  
*Grand Rapids, Michigan*

**Pramook Mutirangura, FRCS**  
**(EDINBURGH)**  
*Bangkok, Thailand*

**Mario Muto, MD**  
*Naples, Italy*

**Piotr Myrcha, MD, PhD**  
*Warsaw, Poland*

## N

**Ross Naylor, MD, FRCS**  
*Leicester, United Kingdom*

**Peter K. Nelson, MD**  
*New York, New York*

**Richard F. Neville, MD**  
*Fairfax, Virginia*

**Christoph A. Nienaber, MD, PhD**  
*London, United Kingdom*

**Sigrid Nikol, MD**  
*Hamburg, Germany*

**Samy S. Nitecki, MD**  
*Haifa, Israel*

**Vandana D. Niyayar, MD**  
*Atlanta, Georgia*

**Katariina M. Noronen, MD, PhD**  
*Helsinki, Finland*

**Furuzan Numan, MD**  
*Istanbul, Turkey*

**Andriy O. Nykonenko, MD**  
*Zaporizhzhia, Ukraine*

## O

**David O'Connor, MD**  
*Hackensack, New Jersey*

**Thomas F. O'Donnell, Jr., MD**  
*Boston, Massachusetts*

**Andrea T. Obi, MD**  
*Ann Arbor, Michigan*

**Paulo E. Ocke Reis, MD, PhD**  
*Niterói, Rio de Janeiro, Brazil*

**Gustavo S. Oderich, MD, FACS**  
*Houston, Texas*

**Oscar L. Ojeda, MD, FACS**  
*Quito, Ecuador*

**Sarah Onida, MD, PhD**  
*London, United Kingdom*

**Alvaro Orrego, MD, FACS**  
*Vina Del Mar, Chile*

**Matteo Orrico, MD**  
*Rome, Italy*

**Nicholas H. Osborne, MD, MS**  
*Ann Arbor, Michigan*

**Kenneth Ouriel, MD, MBA**  
*New York, New York*

**Kathleen J. Ozsvath, MD**  
*Troy, New York*

## P

**Jean M. Panneton, MD**  
*Norfolk, Virginia*

**Rajiv Parakh, MBBS, MS, FRCS**  
*Gurgaon, India*

**Kosmas I. Paraskevas, MD**  
*Athens, Greece*

**Sahil A. Parikh, MD**  
*New York, New York*

**Juan C. Parodi, MD**  
*Buenos Aires, Argentina*

**Marc A. Passman, MD**  
*Birmingham, Alabama*

**Lorenzo Patrone, MD**  
*London, United Kingdom*

**Athos Patsalides, MD, MPH**  
*Manhasset, New York*

**Felice Pecoraro, MD**  
*Palermo, Italy*

**Constantino Pena, MD**  
*Miami, Florida*

**Bruce A. Perler, MD, MBA**  
*Baltimore, Maryland*

**Jennifer L. Perri, MD, MBA**  
*Durham, North Carolina*

**Ivo Petrov, MD, PhD**  
*Sofia, Bulgaria*

**Janet T. Powell, MD, PhD**  
*London, United Kingdom*

**Richard J. Powell, MD**  
*Lebanon, New Hampshire*

**Carlo Pratesi, MD**  
*Florence, Italy*

**Giovanni Pratesi, MD**  
*Genoa, Italy*

**Ourania Preventza, MD**  
*Houston, Texas*

**Robert M. Proczka, MD, PhD**  
*Warsaw, Poland*

**Brandon Propper, MD**  
*Bethesda, Maryland*

## Q

**William Quinones-Baldrich, MD**  
*Los Angeles, California*

**Elina Quiroga, MD, MPH**  
*Seattle, Washington*

## R

**Joseph D. Raffetto, MD**  
*West Roxbury, Massachusetts*

**Ravi R. Rajani, MD**  
*Atlanta, Georgia*

**Venkatesh G. Ramaiah, MD**  
*Scottsdale, Arizona*

**Bhama Ramkhalawon, PhD**  
*New York, New York*

**Zoran Rancic, MD, PhD, EMBA HSG**  
*Zurich, Switzerland*

**Hisham Rashid, FRCS, FRCS(GEN)**  
*London, United Kingdom*

**Todd E. Rasmussen, MD, FACS**  
*Rochester, Minnesota*



# FACULTY

**Animesh Rathore, MD**

*Norfolk, Virginia*

**Buddy D. Ratner, PhD**

*Seattle, Washington*

**Sundaram Ravikumar, MD**

*Dobbs Ferry, New York*

**Pauline Raymond-Martimbeau, MD,  
CRF, FAVLS, DABVLM**

*Dallas & Houston, Texas*

**Mahmood Razavi, MD**

*Orange, California*

**Michel M.P. Reijnen, MD, PhD**

*Arnhem, The Netherlands*

**Erno Remsey-Semmelweis, MD**

*Marburg, Germany*

**Timothy A. Resch, MD, PhD**

*Copenhagen, Denmark*

**Robert Y. Rhee, MD**

*Brooklyn, New York*

**Vicente Riambau, MD, PhD**

*Barcelona, Spain*

**Jean-Baptiste Ricco, MD, PhD**

*Poitiers, France*

**Götz M. Richter, MD, PhD**

*Stuttgart, Germany*

**Joseph J. Ricotta II, MD, MS,  
DFSVS, FACS**

*Boca Raton, Florida*

**Celia Riga, MD, FRCS**

*London, United Kingdom*

**Howard A. Riina, MD**

*New York, New York*

**William P. Robinson, MD**

*Springfield, Illinois*

**Caron B. Rockman, MD**

*New York, New York*

**Sean P. Roddy, MD**

*Albany, New York*

**Heron E. Rodriguez, MD**

*Chicago, Illinois*

**Sonia Ronchey, MD, PhD**

*Rome, Italy*

**Kenneth Rosenfield, MD**

*Boston, Massachusetts*

**Rachel Rosovsky, MD, MPH**

*Boston, Massachusetts*

**Elsie Ross, MD, MSc**

*Palo Alto, California*

**John R. Ross, Sr., MD**

*Orangeburg, South Carolina*

**Vincent I. Rowe, MD**

*Los Angeles, California*

**Maria A. Ruffino, MD, EBIR**

*Torino, Italy*

**S**

**Theodore F. Saad, MD**

*Newark, Delaware*

**Mikel Sadek, MD**

*New York, New York*

**Hazim J. Safi, MD**

*Houston, Texas*

**Natzi Sakalihan, MD, PhD**

*Sart Tilman, Liege, Belgium*

**Gloria Salazar, MD**

*Chapel Hill, North Carolina*

**Taimur Saleem, MD**

*Jackson, Mississippi*

**Clifford M. Sales, MD, MBA, FACS**

*Summit, New Jersey*

**Moro Salifu, MD**

*Brooklyn, New York*

**Russell H. Samson, MD, DFSVS,  
RVT, FACS**

*Sarasota, Florida*

**Luis A. Sanchez, MD**

*St. Louis, Missouri*

**Timur P. Sarac, MD**

*Columbus, Ohio*

**Pierre G. Sarradon, MD**

*Monaco*

**Sudhakar R. Satti, MD**

*Newark, Delaware*

**Sal Scali, MD**

*Gainesville, Florida*

**Andres Schanzer, MD**

*Worcester, Massachusetts*

**Dori R. Schatell, MS**

*Catonsville, Maryland*

**Dierk Scheinert, MD**

*Leipzig, Germany*

**Larry A. Scher, MD**

*Bronx, New York*

**Marc L. Schermerhorn, MD**

*Boston, Massachusetts*

**Andrej Schmidt, MD**

*Leipzig, Germany*

**Darren B. Schneider, MD**

*Philadelphia, Pennsylvania*

**Peter A. Schneider, MD**

*San Francisco, California*

**Geert Willem H. Schurink, MD,  
PhD**

*Maastricht, The Netherlands*

**Eric A. Secemsky, MD, MSc**

*Newton, Massachusetts*

**Carlo Setacci, MD**

*Siena, Italy*

**Francesco Setacci, MD**

*Milan, Italy*

**Julien G. Sfeir, MD**

*Beirut, Lebanon*

**Robert Shahverdyan, MD**

*Hamburg, Germany*

**Aisha Shaikh, MD**

*New York, New York*

**Murray L. Shames, MD**

*Tampa, Florida*

**Palma M. Shaw, MD, FACS, RPVI,  
DFSVS**

*Syracuse, New York*

**Malachi Sheahan, MD**

*New Orleans, Louisiana*

**Surendra Shenoy, MD, PhD**

*St. Louis, Missouri*

**Chun Che Shih, MD, PhD**

*Taipei, Taiwan*

**Cynthia K. Shortell, MD**

*Durham, North Carolina*

**Chang Shu, MD**

*Beijing, China & ChangSha,  
Hunan Province, China*

# FACULTY

**Anton N. Sidawy, MD, MPH**  
*Washington, District of Columbia*

**Adnan H. Siddiqui, MD, PhD**  
*Buffalo, New York*

**Horst Sievert, MD**  
*Frankfurt, Germany*

**Henrik Sillesen, MD, DMSC**  
*Copenhagen, Denmark*

**Michael B. Silva, Jr., MD**  
*Galveston, Texas*

**Rossi M. Silva, MD**  
*Rio De Janeiro, Brazil*

**Jessica P. Simons, MD, MPH**  
*Worcester, Massachusetts*

**Michael J. Singh, MD**  
*Pittsburgh, Pennsylvania*

**Niten Singh, MD**  
*Seattle, Washington*

**Jeffrey J. Siracuse, MD**  
*Boston, Massachusetts*

**Jan M. Sloves, RVT**  
*New York, New York*

**Christopher J. Smolock, MD**  
*Cleveland, Ohio*

**J. David Spence, MD**  
*London, Ontario, Canada*

**Francesco Speziale, MD**  
*Rome, Italy*

**Francesco Spinelli, MD**  
*Rome, Italy*

**James C. Stanley, MD**  
*Ann Arbor, Michigan*

**Benjamin W. Starnes, MD**  
*Seattle, Washington*

**Keith M. Sterling MD**  
*Alexandria, Virginia*

**W. Charles Sternbergh III, MD**  
*New Orleans, Louisiana*

**Johnny Steuer, MD, PhD**  
*Stockholm, Sweden*

**Scott L. Stevens, MD**  
*Knoxville, Tennessee*

**David H. Stone, MD**  
*Hanover, New Hampshire*

**Gregg W. Stone, MD**  
*New York, New York*

**Michael C. Stoner, MD**  
*Rochester, New York*

**Martin Storck, MD, PhD**  
*Karlsruhe, Germany*

**Sherif A.H. Sultan, MD, PhD, FRCS, EBQS-VASC, FACS**  
*Galway, Ireland*

**Gabriel Szendro, MD**  
*Beer Sheva, Israel*

**Wilson Y. Szeto**  
*Philadelphia, Pennsylvania*

**Piotr Szopinski, MD, PhD**  
*Warsaw, Poland*

## T

**Fadi Taher, MD**  
*Vienna, Austria*

**Lawrence N. Tanenbaum, MD**  
*Riverside, Connecticut*

**Joep A.W. Teijink, MD, PhD**  
*Maastricht & Eindhoven, The Netherlands*

**Pedro Teixeira, MD**  
*Austin, Texas*

**Gunnar Tepe, MD**  
*Rosenheim, Germany*

**Jörg Tessarek, MD**  
*Lingen, Germany*

**Pierre-Olivier Thiney, MD**  
*Lyon, France*

**Matt M. Thompson, MD**  
*Irvine, California & Cleveland, Ohio*

**Robert W. Thompson, MD**  
*St. Louis, Missouri*

**Bryan W. Tillman, MD, PhD**  
*Columbus, Ohio*

**Carlos H. Timaran, MD**  
*Dallas, Texas*

**Giovanni Tinelli, MD, PhD**  
*Roma, Italy*

**Windsor Ting, MD**  
*New York, New York*

**Giovanni B. Torsello, MD**  
*Münster, Germany*

**Kenneth Tran, MD**  
*Stanford, California*

**Santi Trimarchi, MD, PhD**  
*Milan, Italy*

**Ramesh K. Tripathi, MD, FRCS, FRACS**  
*Brisbane, Australia*

**Yamume Tshomba, MD**  
*Rome, Italy*

**Nikolaos Tsilimparis, MD, PhD**  
*Munich, Germany*

**Aquilla S. Turk, DO**  
*Greenville, South Carolina*

## U

**Jorge H. Ulloa, MD, FACS**  
*Bogota, Colombia*

**Gilbert R. Upchurch, MD**  
*Gainesville, Florida*

## V

**Claude D. Vaislic, MD**  
*Le Chesnay, France*

**Domenico Valenti, DMChir, PhD, FRCS, FRCS(ED), FEBVS**  
*London, United Kingdom*

**Jos C. van Den Berg, MD, PhD**  
*Lugano, Switzerland*

**Joost van Herwaarden, MD, PhD**  
*Utrecht, The Netherlands*

**Isabelle Van Herzeele, MD, PhD**  
*Ghent, Belgium*

**Marc R.H.M. van Sambeek, MD, PhD**  
*Eindhoven, The Netherlands*

**Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMED (CLINEPI)**  
*Sydney, Australia*

# FACULTY

**Ravi K. Veeraswamy, MD**  
*Charleston, South Carolina*

**Frank J. Veith, MD**  
*Cleveland, Ohio &  
New York, New York*

**Maarit Venermo, MD, PhD**  
*Helsinki, Finland*

**Hence J.M Verhagen, MD, PhD**  
*Rotterdam, The Netherlands*

**Eric L.G. Verhoeven, MD, PhD**  
*Nuremberg, Germany*

**Fabio Verzini, MD, PhD, FEBVS**  
*Turin, Italy*

**Todd R. Vogel, MD, MPH**  
*Columbia, Missouri*

## W

**Jason K. Wagner, MD**  
*Sarasota, Florida*

**Reese A. Wain, MD**  
*Old Westbury, New York*

**Thomas W. Wakefield, MD**  
*Ann Arbor, Michigan*

**Ajay K. Wakhloo, MD, PhD, FAHA**  
*Boston, Massachusetts*

**Ron Waksman, MD**  
*Washington, District of Columbia*

**Craig M. Walker, MD**  
*Houma, Louisiana*

**Grace J. Wang, MD, MSCE**  
*Philadelphia, Pennsylvania*

**Anders Wanhainen, MD, PhD**  
*Uppsala, Sweden*

**Haimanot (Monnie) Wasse, MD,  
MPH, FASN**  
*Chicago, Illinois*

**Fred A. Weaver, MD, MMM**  
*Los Angeles, California*

**Ido Weinberg, MD, MSc**  
*Boston, Massachusetts*

**Mitchell D. Weinberg, MD**  
*Staten Island, New York*

**Paul W. White, MD**  
*Falls Church, Virginia*

**Rodney A. White, MD**  
*Los Angeles, California*

**Mark S. Whiteley, MS, FRCS**  
*Guildford, United Kingdom*

**Michael H. Wholey, MD, MBA**  
*San Antonio, Texas*

**David M. Williams, MD**  
*Ann Arbor, Michigan*

**Willem Wisselink, MD**  
*Amsterdam, The Netherlands*

**Christian Wissgott, MD**  
*Rendsburg, Germany*

**Cees H.A. Wittens, MD, PhD**  
*The Hague, The Netherlands*

**Karen Woo, MD, PhD**  
*Los Angeles, California*

**Mathew D. Wooster, MD, MBA**  
*Charleston, South Carolina*

**I-Hui Wu, MD, PhD**  
*Taipei, Taiwan*

## Y

**Wayne F. Yakes, MD**  
*Englewood, Colorado*

**Kak Khee Yeung, MD, PhD**  
*Amsterdam, The Netherlands*

## Z

**Richard L. Zampolin, MD**  
*New York, New York*

**Christopher K. Zarins, MD**  
*Stanford, California*

**Hany M. Zayed, MD**  
*London, United Kingdom*

**Clark J. Zeebregts, MD, PhD**  
*Groningen, The Netherlands*

**Thomas Zeller, MD**  
*Bad Krozingen, Germany*

**Sara L. Zettervall, MD**  
*Seattle, Washington*

**Wayne W. Zhang, MD**  
*Seattle, Washington*

**Wei Zhou, MD**  
*Tucson, Arizona*

**Robert M. Zwolak, MD, PhD**  
*Lebanon, New Hampshire*

## VEITHSYMPOSIUM ON DEMAND

[www.veithondemand.com](http://www.veithondemand.com)

VIEW THE  
ENTIRE 2022  
VEITHSYMPOSIUM  
ONLINE

VEITHSYMPOSIUM®  
Connecting The Academic Community

Purchase all the Talks, Slides, and Videos - fully synchronized - and all the Panels. This Library or Components thereof can be used as an Educational Resource or Teaching Tool.

**For more information on how to obtain the VEITHSymposium Online Library, please call 800-987-9314 (select option 3).**

# REGISTRATION

Tuesday November 15 - Saturday November 20, 2022  
New York Hilton Midtown

## FULL REGISTRATION (TUESDAY - SATURDAY)

	Tuition
<i>Tuition includes access to any Thursday and Saturday Only Component.</i>	
Registration fee includes breakfast, lunch and breaks	
Physicians (excluding Fellows/Trainees and residents)	\$1399
Physician Combination Rate - VEITHsymposium and AVIDsymposium	\$1899
Physician Combination Rate - VEITHsymposium and AIMsymposium	\$1899
Physician Combination Rate VEITHsymposium, AIMsymposium and AVIDsymposium	\$1899
<b>US 2nd Year</b> Fellows in an RRC-approved 2-Year Vascular Fellowship <b>OR</b> 5th-Year Vascular Resident in an approved Vascular Surgery Residency as of November 2022, <b>AND</b> Canadian Vascular Surgery Fellows in Training ( <b>Tuition is provided through an Educational Grant by W.L. Gore &amp; Associates Inc.</b> ) Letter of verification on official hospital stationery must be obtained prior to registration and emailed to registrar@veithsymposium.org. The letter must include the start and end date of vascular fellowship.	Complimentary
Non-US Fellows and Residents (Trainees) Letter of verification from Chief of Service must be obtained prior to registration and emailed to registrar@veithsymposium.org.	\$699
Physician Assistants (non-physician, clinician), Nurse Practitioners	\$650
Residents, Nurses, Technologists	\$650
Medical Students (Letter of verification from Dean must be obtained prior to registration and emailed to registrar@veithsymposium.org.)	\$500
Allied Health Care Professionals, Venture Capitalists, and All Others	\$950
<b>Venous Venous Venous® Workshop</b> Wednesday, November 16, 2022 from 1:00 p.m. - 6:00 p.m., Americas Hall 2, 3rd Floor <i>Registration is limited to 200 fully paid VEITHsymposium registrants including Industry Personnel. (This is a non-CME Activity.)</i>	\$25

## THURSDAY ONLY - NOVEMBER 17, 2022

<b>Multidisciplinary Acute Stroke Management</b> 8:00 a.m. to 12:15 p.m. Murray Hill Suites, 2nd Floor <i>Tuition includes access to any VEITHsymposium Thursday Sessions.</i>	\$349
---	-------

## FRIDAY ONLY - NOVEMBER 18, 2022

<b>VEITHsymposium Fellows' Career Development Program</b> 8:00 a.m. to 5:00 p.m. Concourse A, Concourse Level (This is a non-CME Activity.)	
<b>Potential Employer/Recruiter</b> (For Employers/Recruiters not registered at VEITHsymposium) <i>Tuition includes access to VEITHsymposium Friday Sessions.</i>	\$500

## SATURDAY ONLY COMPONENTS

<b>Hemodialysis Access (Physicians only)</b> <i>Tuition includes access to any Saturday Only Component.</i>	\$349
<b>VEITHsymposium (Miscellaneous Topics)</b> <i>Tuition includes access to any Saturday Only Component.</i>	\$349
<b>Hemodialysis Access</b> (Non-physician, clinician rate [not available to industry personnel]) <i>Tuition includes access to Hemodialysis Access Only.</i>	\$150

**Cancellation Policy: There is a \$95 cancellation fee if canceled in writing by October 22, 2022. No refunds will be made thereafter.**

**Online:** [www.veithsymposium.org/registration](http://www.veithsymposium.org/registration)

**Phone:** 800-987-9314, (select option 2) with payment information

**Mail:** Please make checks payable to the Cleveland Clinic Educational Foundation and print and mail your receipt to:

The Cleveland Clinic Educational Foundation  
Attn: EGCC083  
P.O. Box 931653  
Cleveland, OH 44193-1082

Please notify registrar@veithsymposium.org if sending by overnight mail or courier service.

**Email:** registrar@veithsymposium.org

Checks must be received by October 22, 2022

**REGISTER ONLINE AT**

**[WWW.VEITHSYMPOSIUM.ORG/REGISTRATION](http://WWW.VEITHSYMPOSIUM.ORG/REGISTRATION)**



**THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION**

PO BOX 931653  
CLEVELAND, OH 44193-1082

**WEDNESDAY, NOVEMBER 16, 2022**

Venous Venous Venous® Workshops at VEITHsymposium

**THURSDAY, NOVEMBER 17, 2022**

Multidisciplinary Acute Stroke Management

**AGAIN THIS YEAR**

- Associate Faculty Global Podium Presentations Program - Wednesday - Thursday, November 16-17, 2022
- The Frank J. Veith International Society Associate Faculty Global Podium Presentations Program at VEITHsymposium - Wednesday - Thursday, November 16-17, 2022
- Fellows Career Development Program - Friday, November 18, 2022

**NEW THIS YEAR**

- Latin American Session at VEITHsymposium - Friday, November 18, 2022
- World Federation of Vascular Surgery at VEITHsymposium - Friday, November 18, 2022
- BEST-CLI Trial: A Review and Discussion of Primary Outcomes - Friday, November 18, 2022

VEITHsymposium is Compliant with the MedTech Europe Code of Ethical Business Practice.



Connecting The **Vascular** Community

[www.veithsymposium.org](http://www.veithsymposium.org)

Tuesday - Saturday  
November 15-19, 2022

Download The VEITHsymposium  
App To Stay Up To Date



Android



Apple